azacitidine has been researched along with Acute Myelogenous Leukemia in 1028 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 48 (4.67) | 18.7374 |
| 1990's | 19 (1.85) | 18.2507 |
| 2000's | 53 (5.16) | 29.6817 |
| 2010's | 543 (52.82) | 24.3611 |
| 2020's | 365 (35.51) | 2.80 |
| Authors | Studies |
|---|---|
| Lane, SW; Straube, J; Vu, T | 1 |
| Alvarado, Y; Daver, NG; DiNardo, CD; Kadia, TM; Kantarjian, HM; Konopleva, MY; Loghavi, S; Maiti, A; Ning, J; Ohanian, M; Qiao, W; Rausch, CR; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Venugopal, S; Yilmaz, M | 1 |
| Bewersdorf, JP; Huntington, SF; Patel, KK; Zeidan, AM | 1 |
| Beach, CL; Bernal, T; Braverman, J; Döhner, H; Dombret, H; Dong, Q; Guo, S; Jang, JH; La Torre, I; Liesveld, J; Martens, UM; Mayer, J; Nehme, SA; Pocock, C; Ravandi, F; Roboz, GJ; Selleslag, D; Shi, L; Skikne, B; Wang, MC; Wei, AH; Yu, P | 1 |
| Goldfinger, M; Saunthararajah, Y; Shastri, A; Verma, AK; Zavras, PD | 1 |
| Abbas, HA; Alaniz, Z; Alfayez, M; Andreeff, M; Cyr, M; Daver, N; Garcia-Manero, G; Issa, GC; Jabbour, E; Konopleva, M; Kornblau, SM; Mackay, S; Matthews, J; Zhou, J | 1 |
| Chai, X; Chen, Y; Deng, B; Fang, Q; Huang, S; Huang, Y; Kang, Q; Li, Y; Liu, M; Ma, D; Ni, M; Wang, J; Wen, S; Zhan, Y; Zhang, F; Zhang, Y; Zhao, M; Zhao, P | 1 |
| Abbott, D; Amaya, M; Cherry, EM; Gutman, JA; Inguva, A; Jordan, CT; McMahon, C; Minhajuddin, M; Pei, S; Pollyea, DA; Rosser, J; Sato, A; Schowinsky, J; Schwartz, M; Smith, C; Stevens, B; Winters, A | 1 |
| Baron, F; Beguin, Y; Berneman, Z; De Becker, A; Deeren, D; Graux, C; Herman, J; Kerre, T; Lewalle, P; Ory, A; Poiré, X; Schoemans, H; Selleslag, D; Zachée, P | 1 |
| Campbell, K; Cashen, AF; DiPersio, JF; Gao, F; Huselton, E; Jacoby, MA; Marcus, S; Pusic, I; Rettig, MP; Romee, R; Schroeder, MA; Uy, GL; Westervelt, P | 1 |
| Amit, O; Avni, B; Pasvolsky, O; Raanani, P; Ram, R; Shargian, L; Shimoni, A; Shimony, S; Shochat, T; Wolach, O; Yerushalmi, R; Yeshurun, M | 1 |
| Alhan, FN; Ataş, Ü; Boduroğlu, A; Doğan, Ö; Iltar, U; Salim, O; Sözel, H; Ündar, L; Vural, E; Yücel, OK | 1 |
| Bazarbachi, A | 1 |
| Abbott, D; Gutman, JA; Jordan, CT; McMahon, C; Pollyea, DA; Rabinovitch, R; Schwartz, M; Smith, CA; Winters, A | 1 |
| Abbas, HA; Al-Atrash, G; Alaniz, Z; Allison, JP; Barrodia, P; Basu, S; Beird, HC; Daver, N; Ding, M; Futreal, A; Garcia-Manero, G; Green, MR; Hao, D; Im, JS; Konopleva, M; Kornblau, SM; Little, L; Lu, W; Marques-Piubelli, ML; Mathews, JT; Ning, J; Parra, ER; Rai, K; Reville, PK; Sharma, P; Solis, LM; Takahashi, K; Tamegnon, A; Tomczak, K; Wang, F; Wang, L; Wang, R; Wang, W; Zhang, J | 1 |
| Bennett, JM; de Botton, S; DiNardo, CD; Döhner, H; Fathi, AT; Frattini, MG; Gong, J; Hasan, M; Kantarjian, HM; Lersch, F; Martin-Regueira, P; Montesinos, P; Schuh, AC; Stein, EM; Vyas, P; Wei, AH; Zeidan, AM | 1 |
| Makowka, P; Serve, H; Stolp, V; Stoschek, K | 1 |
| Al-Abri, M; Chan, SM; Chow, S; Hall, V; Rashedi, I; Tang, K; Tremblay-Lemay, R; Tsui, H | 1 |
| Asada, N; Asou, N; Choi, I; DiNardo, CD; Fukuhara, N; Honda, H; Ishizawa, K; Komatsu, N; Kurokawa, M; Matsumura, I; Miyamoto, T; Miyazaki, Y; Nakashima, Y; Okubo, S; Potluri, J; Pratz, KW; Shinagawa, A; Usuki, K; Yamamoto, K; Yamauchi, T; Yoshida, C; Zha, J; Zhou, Y | 1 |
| Beach, CL; Döhner, H; Garcia-Manero, G; La Torre, I; Santini, V; Skikne, B; Wei, AH | 1 |
| Arbolí, ER; Baldus, CD; Bérard, E; Bergua, J; Bernal, T; Bertoli, S; Bidet, A; Bornhäuser, M; de la Fuente Burguera, A; Delabesse, E; Dumas, PY; Gil, C; Kramer, M; Martínez-Cuadrón, D; Martínez-Sánchez, P; Montesinos, P; Müller-Tidow, C; Pigneux, A; Platzbecker, U; Récher, C; Röllig, C; Serrano, J; Serve, H; Tavitian, S | 1 |
| Boriskina, K; Cavelier, L; Hellström-Lindberg, E; Jädersten, M; Lindholm, C; Mielke, S; Tobiasson, M; Weström, S | 1 |
| Lübbert, M; Ossenkoppele, GJ; Santini, V; Wierzbowska, A | 1 |
| Bao, XB; Hu, XH; Kong, JY; Kong, X; Li, MY; Qiu, HY; Song, BQ; Wu, DP; Wu, XX; Zhang, J; Zong, LH | 1 |
| Bantscheff, M; Baylin, SB; Benowitz, AB; Briand, J; Burt, C; Butlin, RJ; Campobasso, N; Carpenter, C; Chapman, P; Cheng, X; Cockerill, M; Eberl, HC; Fairweather, E; Foley, SW; Fosbenner, DT; Gilmartin, AG; Goldberg, K; Grandi, P; Graves, AP; Groy, A; Handler, JL; Heerding, D; Ho, T; Horton, JR; Jaworski, JP; Jones, PA; Jordan, AM; Jurewicz, AJ; Keenan, K; Kellner, WA; Kershaw, CS; King, BW; Kruger, RG; Li, M; Luengo, JI; McCabe, MT; McHugh, CF; McNulty, DE; Mebrahtu, M; Merrihew, S; Minthorn, E; Mohammad, HP; Muliaditan, M; Ogilvie, D; Pappalardi, MB; Patel, M; Pathuri, S; Prinjha, RK; Raoof, A; Romeril, SP; Rueda, L; Rutkowska, A; Sherk, C; Steidel, M; Stowell, A; Taylor, AN; Waddell, I; Werner, T; Wiseman, AK; Wong, K; Zhang, C; Zhang, X | 1 |
| Alotaibi, AS; Daver, N; Jiang, Y; Kontoyiannis, DP; Spallone, A | 1 |
| Agelopoulos, K; Berdel, WE; Göllner, S; Klosner, J; Müller-Tidow, C; Rohde, C; Schliemann, C | 1 |
| Rowe, JM | 2 |
| Kasner, M; Wilde, L | 1 |
| Chyla, B; Dail, M; DiNardo, CD; Döhner, H; Fracchiolla, NS; Garcia, JS; Illes, A; Jang, JH; Jonas, BA; Ozcan, M; Potluri, J; Pratz, KW; Pullarkat, V; Recher, C; Schuh, AC; Thirman, MJ; Vorobyev, V; Yamamoto, K; Yeh, SP; Zhou, Y | 1 |
| Busija, L; Kenealy, M; McQuilten, ZK; Seymour, JF; Stanworth, S; Weinkove, R; Wood, EM | 1 |
| Beach, CL; Boss, I; Cavenagh, J; Copeland, WB; Fox, BA; Hasle, VE; Hellmann, A; O'Connor, T; Previtali, A; Rose, S; Silverman, LR; Taussig, DC; Thompson, E; Tormo, M; Voso, MT; Zeidan, AM | 1 |
| Chen, X; Liu, F; Rong, D; Tong, X; Wang, H; Xu, L | 1 |
| Beach, CL; Döhner, H; Dombret, H; La Torre, I; Menezes, DL; Ossenkoppele, G; Porkka, K; Ravandi, F; Risueño, A; Roboz, GJ; Schuh, AC; Skikne, B; Thol, F; Voso, MT; Wei, AH; Zhong, J | 1 |
| Bewersdorf, JP; Gowda, L; Prebet, T | 1 |
| Cenfra, N; Cimino, G; Divona, M; La Barbera, EO; Lapietra, G; Mecarocci, S; Perrone, S; Voso, MT | 1 |
| Assis-Mendonça, GR; Bueno, MLP; da Silva, JAF; Duarte, ASS; Ferro, KP; Pericole, FV; Rego, EM; Roversi, FM; Saad, STO; Shiraishi, RN; Torello, CO | 1 |
| Arellano, ML; Chyla, B; Dail, M; DiNardo, CD; Duan, Y; Fiedler, W; Kantarjian, HM; Konopleva, M; Lemoli, RM; Miller, CL; Pigneux, A; Pollyea, DA; Potluri, J; Rizzieri, DA; Shinagawa, A; Smith, BD | 1 |
| Chyla, B; Dail, M; DiNardo, CD; Duan, Y; Garcia, JS; Kantarjian, HM; Konopleva, M; Miller, CL; Potluri, J; Pratz, KW; Pullarkat, V; Recher, C; Thirman, MJ; Wei, AH | 1 |
| Baer, MR; Baylin, SB; Bentzen, SM; Duong, VH; Emadi, A; Kogan, AA; Lapidus, RG; Mi, T; Niyongere, S; O'Connell, CL; Rassool, FV; Youngblood, BA | 1 |
| Al-Ali, HK; Binder, M; Dierks, C; Grimm, J; Jäkel, N; Paschold, L; Schulze, S; Simnica, D; Willscher, E | 1 |
| Fu, JH; Li, JL; Li, Z; Qiu, HY; Qiu, QC; Xue, SL; Zhang, J; Zhou, M | 1 |
| Arnold, C; Bäumer, N; Berdel, WE; Gerß, J; Göllner, S; He, L; Hemmerling, I; Janssen, M; Krämer, S; Leuschner, F; Lipka, DB; Ludwig, AK; Milsom, MD; Müller, JA; Müller-Tidow, C; Niederwieser, C; Niederwieser, D; Pabst, C; Plass, C; Rohde, C; Scheller, M; Schlesner, M; Schönung, M; Serve, H; Stäble, S; Thiede, C; Thiem, U; Trumpp, A; Zaugg, J | 1 |
| Argüello, RJ; Aroua, N; Avet-Loiseau, H; Boet, E; Bosc, C; Bousard, A; Cabon, F; Cognet, G; Farge, T; Fournié, JJ; Fovez, Q; Gadaud, N; Gotanègre, M; Jarrou, L; Joffre, C; Kaoma, T; Kaphan, E; Kluza, J; Larrue, C; Marine, JC; Mazzotti, C; Mouchel, PL; Nicot, N; Picard, M; Poillet-Perez, L; Polley, N; Rambow, F; Récher, C; Sabatier, M; Sahal, A; Saland, E; Sarry, JE; Stuani, L; Su, X; Tamburini, J; Tiong, IS; Tosolini, M; Vergez, F; Wang, Y; Wei, AH | 1 |
| Sato, S; Tamai, Y | 1 |
| Bassan, R; Candoni, A; De Bellis, E; Di Bona, E; Griguolo, D; Imbergamo, S; Lazzarotto, D; Leoncin, M; Liço, A; Lucchini, E; Mauro, E; Mosna, F; Palmieri, C; Poiani, M; Pravato, S; Stulle, M; Tanasi, I; Trentin, L; Zaja, F | 1 |
| Tang, Y; Yan, H; You, Y; Zhou, Z | 1 |
| Abe, H; Hirano, M; Ikegami, M; Inoue, N; Ishihara, Y; Maruyama, D; Mishima, Y; Nishimura, N; Onda, N; Shirouchi, Y; Takeuchi, K; Tamba, M | 1 |
| Chiba, M; Hata, T; Hirooka, S; Iida, H; Ikezoe, T; Imada, K; Ito, Y; Kawashima, I; Kiguchi, T; Kubo, K; Miyazaki, Y; Morimoto, K; Morita, Y; Naoe, T; Nawa, Y; Ohno, R; Uchida, T; Ueda, Y; Yokota, A | 1 |
| Breier, A; Janotka, Ľ; Kavcová, H; Messingerova, L; Šimoničová, K; Sulová, Z | 1 |
| Asatiani, E; Berenson, JR; Bordoni, R; Cook, RJ; Edenfield, WJ; Mohan, S; Savona, MR; Srinivas, N; Zeidan, AM; Zhou, G | 1 |
| Matsuoka, A; Tanibuchi, M; Taoka, T; Yamazaki, I | 1 |
| Bernard, E; Cavelier, L; Dybedal, I; Ebeling, F; Ejerblad, E; Flogegård, M; Garelius, H; Göhring, G; Grønbaek, K; Hellström-Lindberg, E; Jädersten, M; Kittang, AO; Lorenz, F; Marcher, CW; Möllgård, L; Nilsson, L; Nørgaard, JM; Öster Fernström, A; Papaemmanuil, E; Rasmussen, B; Saft, L; Tobiasson, M | 1 |
| Marini, BL; Olivier, T; Prasad, V | 1 |
| de Claro, RA; Gehrke, BJ; Jen, EY; Lee, SL; Leong, R; Li, H; Li, M; Ma, L; McLamore, S; Ni, N; Przepiorka, D; Theoret, MR; Vallejo, J; Wang, X | 1 |
| Basak, GW; Drozd-Sokolowska, J; Feliksbrot-Bratosiewicz, M; Gierej, B; Mądry, K; Paszkowska-Kowalewska, M; Sankowski, B; Siewiorek, K; Sokołowski, J; Stefaniak, A; Stokłosa, T | 1 |
| Dai, H; Gao, X; Li, Y; Wang, W; Xue, Y; Yao, D | 1 |
| Beauvais, D; Chauvet, P; Coiteux, V; Drumez, E; Duhamel, A; Magro, L; Quesnel, B; Srour, M; Wattebled, KJ; Yakoub-Agha, I | 1 |
| Barthélémy, A; Cheok, MH; Gonzales, F; Guilmatre, A; Lapillonne, H; Leverger, G; Petit, A; Pottier, N | 1 |
| Boyadzhiev, H; Ganster, C; Haase, D; Hasenkamp, J; Jung, W; Koch, R; Maulhardt, M; Mazzeo, P; Schmidt, N; Shumilov, E; Wulf, G | 1 |
| Huang, XJ; Jiang, H; Liu, XH; Wu, Y | 1 |
| Ando, J; Delgado, A; Duan, Y; Eto, T; Garbayo Guijarro, B; Imada, K; Ishikawa, Y; Ito, T; Katsuoka, Y; Kawakami, Y; Kiyoi, H; Kizaki, M; Komeno, T; Kondo, T; Llamas, C; Miyamoto, T; Mori, A; Morita, T; Morita, Y; Nakayama, M; Satake, A; Takezako, N; Taneike, I; Uoshima, N; Watanabe, J; Yamamoto, K; Yoshida, C | 1 |
| Niu, T; Wang, J; Wu, Q; Zhu, J | 1 |
| Adès, L; Amé, S; Benramdane, R; Beyne-Rauzy, O; Bordessoule, D; Braun, T; Chermat, F; Chevret, S; Cheze, S; Cluzeau, T; de Botton, S; Dimicoli-Salazar, S; Duployez, N; Fenaux, P; Guerci-Bresler, A; Laribi, K; Marolleau, JP; Nimubona, S; Park, S; Peterlin, P; Preudhomme, C; Quesnel, B; Recher, C; Stamatoullas, A; Thepot, S; Toma, A; Vey, N; Wattel, E; Wickenhauser, S; Zerazhi, H | 1 |
| Alexander, L; Alvarado, Y; Andreeff, M; Borthakur, G; Burger, JA; Daver, N; Dinardo, CD; Estrov, Z; Garcia-Manero, G; Issa, GC; Jabbour, E; Kadia, TM; Konopleva, M; Ma, J; Macaron, W; Masarova, L; Miller, D; Montalban-Bravo, G; Naing, A; Ning, J; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K | 1 |
| Bertani, G; Calado, RT; Daigle, SR; de Botton, S; Döhner, H; Gianolio, DA; Heuser, M; Hui, J; Montesinos, P; Pandya, SS; Recher, C; Schuh, AC; Vives, S; Wang, J; Yeh, SP; Zarzycka, E | 1 |
| Perl, AE; Vyas, P | 1 |
| Arora, S; Bachiashvili, K; Bathini, S; Bhatia, R; Di Stasi, A; Diamond, B; Godby, K; Gupta, U; Jamy, O; Oliver, JD; Rangaraju, S; Salzman, D; Vachhani, P; Worth, S; Zainaldin, C | 1 |
| Breems, D; Chan, G; Ching, K; Gallo Stampino, C; Gyan, E; Joris, M; Kovacsovics, T; Krauter, J; Kudla, A; Ma, WW; Maertens, J; O'Brien, T; Schuster, M; Sekeres, MA; Verma, A; Vyas, P; Wang, ES; Zeidan, AM | 1 |
| Giubellino, A; Nasrollahi, E; Rashidi, A | 1 |
| Azab, M; Bewersdorf, JP; Brandwein, JM; Demeter, J; Döhner, H; Fenaux, P; Gercheva, L; Gobbi, M; Griffiths, EA; Hao, Y; Issa, JJ; Jedrzejczak, WW; Kantarjian, HM; Keer, H; Krauter, J; Mayer, J; Min, YH; Miyazaki, Y; Novák, J; Ojeda-Uribe, M; Robak, T; Roboz, GJ; Thomas, X; Yee, KWL; Yeh, SP; Zeidan, AM | 1 |
| Babushok, DV; Bruno, XJ; Carroll, MP; Frey, NV; Gill, SI; Hexner, EO; Hwang, WT; Loren, AW; Luger, SM; Maillard, IP; Margolis, D; Martin, ME; Matthews, AH; McCurdy, SR; Paralkar, VR; Perl, AE; Porter, DL; Pratz, KW; Stadtmauer, EA | 1 |
| Han, S; Han, Y; Li, X; Pan, T; Qi, J; Wang, H; Xu, X; Yao, Y; Zhou, M | 1 |
| Belli, Ç; Bulan, B; Eşkazan, AE; Yılmaz, U | 1 |
| Arrigo, G; Audisio, E; Cerrano, M; D'Ardìa, S; Frairia, C; Freilone, R; Giai, V; Secreto, C; Urbino, I | 1 |
| Chen, RR; Jin, J; Li, L; Mai, WY; Meng, HT; Qian, JJ; Sun, JN; Tong, HY; Wang, LL; Xie, WZ; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH; Zhu, LX | 1 |
| Chu, HT; Fung, SH; Gill, H; Kwong, YL; Lee, E; Lee, P; Li, J; Liao, JJ; Miu, KK; Tse, E; Wang, Z; Yim, R; Yip, PK; Yung, Y | 1 |
| de Leeuw, DC; Janssen, JJWM; Ossenkoppele, GJ | 1 |
| Bazinet, A; Bhalla, K; Borthakur, G; Curry, JL; Daver, N; Heberton, M; Kadia, T; Khoury, JD; Kim, K; Konopleva, M; Loghavi, S; Miller, D; Pemmaraju, N; Pierce, S; Wilson, NR | 1 |
| Garcia-Horton, A; Raslan, O | 1 |
| Chai, X; Downs, L; Iantuono, E; Ma, E; Montez, M; Nie, X; Pratz, KW; Xie, J; Yin, L | 1 |
| Andreeff, M; Bhalla, KN; Borthakur, G; Daver, NG; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Issa, GC; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, HM; Konopleva, MY; Malla, R; Montalban-Bravo, G; Ohanian, M; Pemmaraju, N; Popat, UR; Quagliato, K; Rausch, CR; Ravandi, F; Reville, PK; Sasaki, K; Short, NJ; Takahashi, K; Wang, X | 1 |
| Betts, KA; Bui, CN; Chai, X; Choi, M; Kapustyan, T; LeBlanc, TW; Ma, E; Montez, M; Song, J; Yin, L | 1 |
| Borthakur, G; Chien, KS; Daver, N; DeLumpa, R; Desikan, SP; Jabbour, EJ; Jain, N; Kadia, TM; Konopleva, M; Kwari, M; Loghavi, S; Macaron, W; Maiti, A; Montalban-Bravo, G; Pemmaraju, N; Ravandi, F; Short, NJ | 1 |
| Ai, J; Arnall, J; Avalos, BR; Boselli, D; Chen, T; Chiad, Z; Chojecki, AL; Copelan, EA; Cruz, A; DiSogra, KY; Grunwald, MR; Karabinos, A; Knight, TG; Patel, R; Ragon, BK; Sanikommu, SR; Shah, NA; Symanowski, J; Verbyla, A | 1 |
| Briceño-Casado, MP; Gil-Sierra, MD; Sierra-Sanchez, JF | 1 |
| Goodman, AM; Mohyuddin, GR; Prasad, V | 1 |
| de Botton, S; Döhner, H; Montesinos, P | 1 |
| Abou Dalle, I; Bazarbachi, A; Brissot, E; El-Cheikh, J; Kreidieh, F; Mohty, M; Moukalled, N | 1 |
| Addo, SN; Boyiadzis, M; Fathi, AT; Hoffman, DM; Ivanov, V; Kang, K; Mayer, J; Mendes, WL; Saini, L; Unal, A; Yeh, SP | 1 |
| Baldus, C; Besenbeck, B; Blank, MF; Bornhäuser, M; Bruch, PM; Dietrich, S; Fabre, M; Göllner, S; Gu, M; Heid, D; Herbst, SA; Janssen, M; Jeremias, I; Knoll, M; Kolb, C; Krijgsveld, J; Ludwig, AK; Müller-Tidow, C; Pabst, C; Platzbecker, U; Przybylla, A; Raffel, S; Renders, S; Rohde, C; Röllig, C; Sauer, T; Schlenk, RF; Schmidt, C; Serve, H; Stölzel, F; Trumpp, A; Vassiliou, G; Vick, B; Vierbaum, L; Waclawiczek, A; Weidenauer, K | 1 |
| Beke, KE; Bryant, AL; Coombs, LA; Deal, AM; Foster, MC; Heiling, HM; Jensen, CE; Richardson, DR | 1 |
| Kantarjian, H; Short, NJ | 1 |
| Aoki, K; Kohno, K; Obara, T; Ogawa, R; Taenaka, R | 1 |
| Cao, J; Chen, Y; Hu, J; Luo, L; Yang, T; Yang, X; Ye, Y; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Abaza, Y; Zeidan, AM | 1 |
| Alonso-Dominguez, JM; Atance-Pasarisas, M; Blas, C; Castaño-Bonilla, T; Cotti-Ferrari, MJ; Franganillo-Suárez, A; Lainez-González, D; Llamas-Sillero, P; Martínez-Díez, Y; Rodríguez-Pinilla, SM; Salgado-Sánchez, R | 1 |
| Abbott, D; Bosma, G; Gutman, JA; Jordan, C; Minhajuddin, M; Pollyea, DA; Winters, AC | 1 |
| Altman, JK; Chou, WC; Esteve, J; Gambacorti-Passerini, C; Gill, SC; Havelange, V; Heuser, M; Hill, JE; Laribi, K; Lee, JH; Liu, S; Minden, MD; Montesinos, P; Naoe, T; Patkowska, E; Philipose, N; Rich, ES; Tiu, RV; Wang, ES; Watson, AM; Wu, R | 1 |
| Boerekamps, A; Hamberg, P; Libourel, EJ | 1 |
| Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H | 1 |
| Beach, CL; Chan, ET; Döhner, H; Dombret, H; Lopes de Menezes, D; Montesinos, P; Porkka, K; Ravandi, F; Risueño, A; Roboz, GJ; Sandhu, I; See, WL; Skikne, B; Thakurta, A; Thol, FR; Ugidos, M; Wei, AH | 1 |
| Cole, R; Daigle, S; Franich, R; Fraser, P; Gruber, E; Hyer, ML; Johnstone, RW; Jones, L; Kats, LM; Lewis, AC; Li, J; Martelotto, LG; Nicolay, B; Rogers, AJ; Shortt, J; So, J; Stanley, K; Thio, N; Trigos, A; Tron, AE; Vidacs, E | 1 |
| Babu, S; Chyla, B; Dail, M; DiNardo, CD; Jonas, BA; Pollyea, DA; Potluri, J; Pratz, KW; Pullarkat, V; Recher, C; Schuh, AC; Sun, Y; Wei, AH | 1 |
| Aubrey, BJ; Brunner, AM | 1 |
| Herold, T; Hiddemann, W; Rausch, C; Spiekermann, K; von Bergwelt-Baildon, M | 1 |
| Bartholdy, BA; Benard, L; Choudhary, G; Cole, S; DeFronzo, S; Heckman, CA; Javarappa, KK; Okoye-Okafor, UC; Pallaud, C; Ramos, PM; Ruiz, S; Saad, J; Shastri, A; Tatiparthy, M; Thiruthuvanathan, VJ; Tsallos, D; Verma, A; Will, B; Yang, D; Zhang, C | 1 |
| DiNardo, C; Duan, Y; Fracchiolla, N; Ishizawa, K; Jang, JH; Jin, J; Jonas, BA; Kantarjian, H; Konopleva, M; Kovacsovics, T; Montesinos, P; Ofran, Y; Potluri, J; Pratz, KW; Pristupa, A; Werner, M | 1 |
| Brackman, D; DiNardo, CD; Duan, Y; Jin, H; Jonas, BA; Kantarjian, H; Konopleva, M; Li, J; Mayer, J; Montez, M; Potluri, J; Pratz, KW; Selleslag, D; Stevens, D; Traina, F; Venditti, A; Werner, M; Yamamoto, K; Zha, J | 1 |
| Pleyer, L; Sekeres, MA | 1 |
| Alvarado, Y; Andreeff, M; Bazinet, A; Chien, K; Colla, S; Darbaniyan, F; Ganan-Gomez, I; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Masarova, L; McCue, D; Mirabella, B; Montalban-Bravo, G; Ohanian, M; Qiao, W; Ravandi, F; Short, N; Takahashi, K; Yilmaz, M | 1 |
| Sekeres, MA; Taylor, J | 1 |
| Fang, M; Hu, W; Jiang, H; Liu, X; Tang, B; Wang, A; Wang, D; Zhang, X; Zhu, X | 1 |
| Aumer, T; Gremmelmaier, CB; Kaiser, S; Pforr, JC; Runtsch, LS; Traube, FR; Yeşiltaç, GN | 1 |
| Chishaki, R; Edahiro, T; Fujino, K; Fukushima, N; Ichinohe, T; Mino, T; Ureshino, H; Yoshida, T | 1 |
| Barankiewicz, J; Basak, GW; Biecek, P; Drozd-Sokołowska, J; Karakulska-Prystupiuk, E; Kobylińska, K; Mądry, K; Rytel, J; Salomon-Perzyński, A; Skwierawska, K; Stokłosa, T | 1 |
| Francis, A; Kuchenbauer, F; Sanford, D; Stubbins, RJ | 1 |
| Ishiguro, C; Kawashiri, A; Kurokawa, T; Maeda, Y; Mochizuki, K; Nakagawa, SI | 1 |
| Ichikawa, M | 2 |
| Morita, Y | 1 |
| Amaya, M; Burke, E; Dale, J; Davis, S; Engel, K; Gasparetto, M; Gillen, A; Goodman, B; Gutman, J; Hull, M; Islam, N; Jordan, C; Larchick, L; McMahon, CM; Pei, S; Reuben, JS; Smith, C; Staggs, S; Stevens, B; Toninato, J; Weller, G; Zane, R | 1 |
| Green, SD; Zeidner, JF | 1 |
| Jia, Y; Li, C; Lin, D; Mi, Y; Wang, H; Wang, J; Wang, Z | 1 |
| Kobayashi, M; Kosugi, N; Suzaki, K; Yasu, T | 1 |
| Gao, Y; Huang, D; Lin, H; Liu, L; Wang, A; Wang, Y | 1 |
| Au, Y; Bui, CN; Chai, X; Guinan, K; Lachaine, J; Mathurin, K; Schuh, AC | 1 |
| Cai, Z; Chen, Y; Ding, B; Dovat, E; Dovat, S; Duan, L; Ge, Z; Han, Q; He, B; Huang, Y; Li, B; Li, J; Liu, Z; Lu, X; Min, F; Qiu, H; Shi, P; Song, C; Sun, N; Sun, Y; SzeKely, L; Tang, H; Wei, Y; Wu, Z; Xia, Y; Xiao, R; Xie, J; Xu, H; Xu, Y; Yang, X; Zhang, Y; Zhao, L; Zhu, W; Zhuang, W; Zi, J | 1 |
| Bajel, A; Borate, U; Brunner, AM; Cheng, WH; Filshie, R; Garcia, JS; Garcia-Manero, G; Harb, JG; Hoffman, D; Krishnadasan, R; Naqvi, K; Odenike, O; Pollyea, DA; Potluri, J; Roncolato, F; Watson, AM; Zeidan, AM; Zha, J; Zhou, Y | 1 |
| Arellano, ML; Baer, MR; Ball, BJ; Blum, W; Borate, U; Boyiadzis, MM; Burd, A; Byrd, JC; Chen, T; Collins, RH; Deininger, M; Druker, BJ; Duong, VH; Foran, JM; Foster, MC; Gana, TJ; Heerema, NA; Kaufmann, SH; Kovacsovics, T; Levine, RL; Lin, TL; Litzow, MR; Marcus, S; Martycz, M; Mims, AS; Odenike, O; Olin, RL; Patel, PA; Peterson, KL; Rosenberg, L; Saliba, AN; Schiller, GJ; Schneider, PA; Shoben, AB; Stefanos, M; Stein, EM; Stock, W; Traer, E; Walker, A; Yocum, AO | 1 |
| Antin, JH; Arihara, Y; Bashey, A; Brunner, AM; Cullen, N; Cutler, C; Davids, MS; DeAngelo, DJ; Flamand, Y; Galinsky, I; Garcia, JS; Ho, V; Jonas, BA; Keng, M; Koller, P; Leonard, R; Luskin, MR; Mendez, LM; Neuberg, D; Penter, L; Pfaff, K; Ritz, J; Robertson, T; Rodig, SJ; Savell, A; Soiffer, RJ; Stone, RM; Streicher, H; Tomlinson, BK; Wadleigh, M; Winer, ES; Wolff, JO; Wu, CJ | 1 |
| Feld, J; Navada, SC; Silverman, LR; Tremblay, D | 1 |
| Arnan, M; Baer, MR; Brevard, J; Cortes, JE; De Botton, S; Dinner, SN; Donnellan, W; Ferrell, PB; Forsyth, S; Guichard, SM; Henrick, P; Jonas, BA; Kelly, P; Lee, S; Marzac, C; Mohamed, H; Montesinos, P; Pigneux, A; Prebet, T; Récher, C; Schiller, GJ; Schwarer, AP; Seiter, KP; Sweeney, J; Wang, ES; Watts, JM; Wei, AH; Yang, J | 1 |
| Anderson, D; Aya-Bonilla, C; Breese, EH; Brown, PA; Cheung, LC; Chiu, SK; Chua, GA; Cruickshank, MN; Faulk, KE; Ferrari, E; Ford, J; Guest, EM; Hesselman, MC; Hughes, AM; Jafari, R; Kees, UR; Kotecha, RS; Kuek, V; Kunold, E; Lock, RB; Loh, ML; Malinge, S; Oommen, J; Post, F; Singh, S | 1 |
| Aida, K; Hatayama, T; Ikezoe, T; Shirahase, T; Usuki, K; Yamauchi, T | 1 |
| Amaro, DMC; Gagelmann, N; Gjærde, LK; Loh, KP; Lombardo, J; Meckstroth, S; Mir, N; Neuendorff, NR; Roy, M; Shih, YY; Singhal, S; Thibaud, V; Zhao, Y | 1 |
| Bewersdorf, JP; Boss, I; de Menezes, DL; Fox, B; Haferlach, T; Halene, S; Hasle, V; Rose, S; Shallis, RM; Thompson, E; Zeidan, AM | 1 |
| Blum, S; Bresser, H; Lübbert, M; Tsilimidos, G | 1 |
| Lu, Y; Pei, R; Yuan, J | 1 |
| Baker, K; Banos, A; Bixby, D; Braun, T; Carulli, J; Cluzeau, T; Cook, RJ; de Botton, S; Eaton, M; Fenaux, P; Fiore, C; Hodgson, G; Jurcic, JG; Kang-Fortner, Q; Kelly, MJ; Liesveld, JL; Madigan, K; McKeown, M; Paul, S; Rizzieri, DA; Roboz, GJ; Roth, DA; Rousselot, P; Savona, MR; Sekeres, MA; Stein, EM; Stephens, K; Vigil, C; Volkert, A | 1 |
| Alharbi, A; Allan, JM; Allsop, D; Altmann, H; Altschuler, SJ; Ariceta, B; Bell, HL; Blair, H; Bornhäuser, M; Bowes, E; Bziuk, Z; Diaz, RA; Dill, C; Elstob, C; Fadly, M; Fitzgibbon, J; Fordham, SE; Haferlach, T; Heidenreich, O; Jackson, GH; Jones, GL; Kunadt, D; Lin, WY; Marr, HJ; Martinez-Lopez, J; Meggendorfer, M; Menne, T; Mohr, B; Montesinos, P; Nandana, D; Onel, K; Park, C; Piddock, R; Prosper, F; Rahman, T; Robinson, A; Röllig, C; Ruhnke, L; Soura, EN; Stölzel, F; Villar, S; Wagenführ, L; Wobus, M; Wu, LF | 1 |
| Han, Y; Jiang, L; Jin, J; Lang, W; Li, K; Lin, P; Liu, X; Lu, C; Luo, Y; Ma, L; Mei, C; Ren, Y; Shen, C; Sun, J; Tong, H; Wang, L; Wang, Y; Xu, G; Yang, H; Yang, W; Ye, L; Ye, X; Zhang, H; Zhang, Q; Zhang, X; Zhou, X; Zhu, S | 1 |
| Belhabri, A; Bertoli, S; Billotey, NC; Bulabois, C; Cartet, E; Dumas, PY; Fornecker, L; Giltat, A; Guepin, GR; Guerineau, E; Houyou, D; Hunault, M; Kaphan, E; Lachenal, F; Laloi, L; Laribi, K; Michallet, AS; Michallet, M; Michel, C; Morisset, S; Paul, F; Pigneux, A; Puisset, F; Récher, C; Rocher, C; Santagostino, A; Simand, C; Simonet, MB; Tabrizi, R; Villate, A | 1 |
| Borate, U; Koenig, KL | 1 |
| Bewersdorf, JP; Goshua, G; Huntington, SF; Patel, KK; Podoltsev, NA; Shallis, RM; Stahl, M; Stein, EM; Zeidan, AM | 1 |
| Takahashi, K | 1 |
| Jiang, L; Jin, J; Lang, W; Lu, C; Luo, Y; Ma, L; Mei, C; Ren, Y; Tong, H; Xu, G; Xu, W; Yang, H; Ye, L; Zhou, X; Zhu, H | 1 |
| Sekeres, MA | 2 |
| Asch, AS; Assouline, S; Cheema, F; Erba, HP; Fang, M; Hay, AE; Jacoby, MA; Kingsbury, LL; Law, LY; Little, RF; Liu, JJ; Maher, T; Michaelis, LC; Moseley, AB; Othus, M; Radich, J; Schroeder, MA; Sweet, KL; Uy, GL; Walter, RB | 1 |
| Arvanitis, M; Bonifant, C; Christodoulou, I; Dalton, WB; DeZern, AE; Esteb, C; Ghiaur, G; Gondek, LP; Jain, T; Jones, RJ; Karantanos, T; Levis, MJ; Paun, BC; Perkins, B; Rajkhowa, T; Teodorescu, P; Varadhan, R; Yegnasubramanian, S | 1 |
| Bang, SY; Cho, BS; Cho, SG; Eom, KS; Kim, HJ; Kim, YJ; Kwag, D; Lee, JH; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Yoon, JH | 1 |
| Bai, LY; Chen, TT; Chou, CH; Ho, MW; Lien, MY; Lin, CC; Wang, ST; Yeh, SP | 1 |
| Hennings, R; Kayser, S; Monecke, A; Ramdohr, F | 1 |
| Al-Ali, HK; Becker, H; Brugger, W; Bug, G; Crysandt, M; De Wit, M; Döhner, H; Döhner, K; Duyster, J; Ganser, A; Giagounidis, A; Götze, KS; Grishina, O; Hackanson, B; Heil, G; Heuser, M; Krauter, J; Kündgen, A; Lübbert, M; May, AM; Müller-Tidow, C; Neubauer, A; Rummelt, C; Salih, HR; Schlenk, RF; Schmoor, C; Scholl, S; Wäsch, R | 1 |
| Madanat, YF; Xie, Z; Zeidan, AM | 1 |
| Dalal, M; Farrelly, E; Kota, V; Kristo, F; Ogbonnaya, A; Raju, A; Schroader, BK | 1 |
| Chang, XL; Guo, YX; Hu, RH; Hui, WH; Lan, XX; Su, L; Sun, WL; Zhang, Y; Zhao, H | 1 |
| Holter-Chakrabarty, J; Keruakous, AR; Khawandanah, MO; Schmidt, SA; Selby, G; Yuen, C | 1 |
| Aiba, M; Miyagishima, T; Shigematsu, A; Suzuki, T | 1 |
| Basilico, CM; Bonuomo, V; Buzzatti, E; Candoni, A; Cattaneo, C; Cerqui, E; Dargenio, M; De Marchi, R; Del Principe, MI; Delia, M; Dragonetti, G; Fanin, R; Fracchiolla, N; Griguolo, D; Lazzarotto, D; Lessi, F; Luppi, M; Mellillo, L; Nadali, G; Olivieri, A; Pagano, L; Papayannidis, C; Pasciolla, C; Piccini, M; Piccioni, AL; Riva, M; Sarlo, C; Sartor, C; Sciumè, M; Spadea, A; Stulle, M; Tisi, MC | 1 |
| Kunisada, K; Matsuoka, A; Taoka, T; Yoshida, S | 1 |
| Beach, CL; Döhner, H; Dombret, H; Jang, JH; Menezes, D; Montesinos, P; Porkka, K; Prebet, T; Ravandi, F; Risueño, A; Roboz, GJ; Sayar, H; See, WL; Selleslag, D; Skikne, B; Ugidos, M; Wei, AH; Zhang, G | 1 |
| Bai, J; Feng, R; Liu, H; Ning, S; Sun, J; Wu, M; Xu, X; Zhang, S | 1 |
| Hou, JX; Hu, YM; Li, SZ; Lin, D; Liu, KQ; Mi, YC; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, GJ; Zhou, CL | 1 |
| Stelmach, P; Trumpp, A | 1 |
| Bonifacio, G; Borate, U; Chen, C; Gaugler, L; Kiendrebeogo, Z; Pollyea, DA; Potluri, R; Prebet, T; Rotter, D; Strocchia, M; Vasconcelos, A; Zeidan, AM | 1 |
| Ambinder, AJ; Dalton, WB; DeZern, AE; Ghiaur, G; Gojo, I; Gondek, LP; Jain, T; Levis, MJ; Newman, M; Prince, GT; Sanber, K; Smith, BD; Tsai, HL; Webster, JA; Ye, K | 1 |
| Adès, L; Bacher, U; Bargetzi, M; Fung, S; Gaidano, G; Gandini, D; Hultberg, A; Johnson, A; Ma, X; Müller, R; Nottage, K; Ochsenbein, AF; Pabst, T; Papayannidis, C; Recher, C; Riether, C; Shah, P; Tryon, J; Vey, N; Xiu, L | 1 |
| Demir, AM; Demirci, U; Iflazoglu, H; Kirkizlar, O; Kirkizlar, TA; Umit, EG; Umut, A | 1 |
| Astolfi, A; Boultwood, J; Casalin, I; Cavo, M; Cocco, L; De Stefano, A; Finelli, C; Follo, MY; Indio, V; Manzoli, L; McCubrey, JA; Mongiorgi, S; Paolini, S; Parisi, S; Pellagatti, A; Pession, A; Ratti, S; Suh, PG | 1 |
| Adams, RH; Beebe, K; Booth, N; Campbell, C; Huschart, E; Miller, H; Mirea, L; Ngwube, A; Salzberg, D; Schwalbach, C | 1 |
| Matsuda, K; Sugimoto, K; Yoshida, T | 1 |
| Hiwase, DK; Kok, CH; Kutyna, MM; Loone, S; Saunders, VA; White, DL | 1 |
| Aribi, A; Ball, B; Marcucci, G; Pullarkat, V; Salhotra, A; Stein, A | 1 |
| Berda-Haddad, Y; Caroline, S; Ciccolini, J; Costello, R; Donnette, M; Fanciullino, R; Farnault, L; Giocanti, M; Osanno, L; Ouafik, L'; Venton, G | 1 |
| Fukuda-Kurahashi, Y; Hoshiko, T; Kamachi, K; Kawasoe, K; Kimura, S; Kurahashi, Y; Ureshino, H; Watanabe, T; Yamamoto, Y; Yoshida-Sakai, N | 1 |
| Al-Kali, A; Alkhateeb, HB; Begna, KH; Gangat, N; Hogan, W; Ilyas, R; Johnson, IM; Litzow, MR; Mangaonkar, A; McCullough, K; Pardanani, A; Patnaik, MM; Shah, M; Tefferi, A | 1 |
| Chen, H; DiNardo, KW; LeBlanc, TW | 1 |
| Betz, B; Donato, E; Grabowski, S; Gryzik, S; Heuser, M; Hundemer, M; Janssen, M; Karpova, D; Leppä, AM; Müller-Tidow, C; Pabst, C; Raffel, S; Renders, S; Reyneri, C; Röllig, C; Sauer, T; Schlenk, RF; Shahswar, R; Stumpf, K; Thiel, V; Trumpp, A; Unglaub, JM; Vierbaum, L; Waclawiczek, A | 1 |
| Beechinor, R; Guglielmo, J; Jonas, BA; Kneen, R; Krackeler, ML; Leija, C; Moskoff, B; Pervitsky, V; Sawicky, D | 1 |
| Beach, CL; Bondarenko, SN; Dohner, H; Dombret, H; Lai, Y; Montesinos, P; Prebet, T; Ravandi, F; Roboz, GJ; Schuh, AC; Selleslag, D; Skikne, B; Wei, AH | 1 |
| Kim, E; Oh, S | 1 |
| Bourke, C; Cummings, NJ; Curtis, DJ; Das, TP; Fleming, SA; Ivey, A; Kliman, DS; North, D; O'Brien, ME; Patil, SS; Spencer, A; Swain, MI; Tan, JLC; Widjaja, JML | 1 |
| Altman, JK; Attar, EC; Fathi, AT; Garcia-Manero, G; Goldberg, AD; Hickman, DK; Kanagal-Shamanna, R; Kantarjian, H; Komrokji, R; Lancet, J; Miller, C; Odenike, O; Roboz, GJ; Sallman, DA; Sweet, K; Wennborg, A; Winer, ES | 1 |
| Beach, CL; Gandhi, A; Khan, R; Lee, JK; Ma, J; Menezes, DL; Prebet, T; Risueño, A; See, WL; Skikne, B; Thakurta, A; Tsai, KT | 1 |
| Gando, Y; Yasu, T | 1 |
| Birsen, R; Bouscary, D; Boussaid, I; Chapuis, N; Deau-Fischer, B; Decroocq, J; Deschamps, P; Franchi, P; Friedrich, C; Johnson, N; Kosmider, O; Miekoutima, E; Mondesir, J; Tamburini, J; Templé, M; Vignon, M; Willems, L | 1 |
| Hu, C; Jin, J; Liu, Y; Lv, Z; Mao, L; Meng, H; Wang, J; You, L; Zhou, Y; Zhu, L | 1 |
| Akazawa, Y; Fujita, J; Fukushima, K; Hino, A; Hosen, N; Kawamura, A; Kusakabe, S; Matsui, T; Miyagawa, S; Sakata, Y; Sudo, T; Ueda, T; Yokota, T | 1 |
| Chung, P; Diorio, C; Niswander, LM; Tasian, SK | 1 |
| Najima, Y | 1 |
| Al-Kali, A; Bogenberger, J; Dueck, AC; Hashmi, S; Hogan, W; Kosiorek, HE; Litzow, MR; Mesa, R; Palmer, J; Sproat, L; Tibes, R | 1 |
| Ge, Z; Hou, Y; Li, J; Long, H; Song, C | 1 |
| Abbott, D; Amaya, M; Brecl, C; Dell-Martin, J; Falco, A; Gutman, JA; Ho, P; Jordan, CT; Kent, A; McMahon, C; Minhajuddin, M; O'Brien, K; Ondracek, O; Pei, S; Pollyea, DA; Schowinsky, J; Smith, C; Sohalski, C; Stevens, B; Taylor, E; Tobin, J; Winters, A; Zhou, K | 1 |
| Giagounidis, A; Hertle, S; Hoef, MV; Ma, F; Santini, V; Sanz, GF; Sekeres, MA; Xiao, Z; Zeidan, AM | 1 |
| Aiman, W; Akerman, MJ; Ali, MA; Anwar, MS; Anwer, F; Basit, MA; Dhanesar, G; Faisal, MS; Hassan, M; Jamil, T; Maroules, M; Omar, Z; Shafique, Z; Suleman, M | 1 |
| Cao, Y; Chen, X; Feng, S; Guo, W; Han, M; He, Y; Jiang, E; Liu, J; Liu, X; Ma, Q; Pang, A; Wang, M; Wei, J; Yang, D; Zhai, W; Zhang, R; Zheng, Y | 1 |
| Ahmadu, C; Armstrong, N; Grimm, S; Howick, J; Joore, M; McDermott, K; Noake, C; Otten, T; Witlox, W; Wolff, R | 1 |
| Ge, L; Jiang, L; Jin, F; Li, J; Qian, W; Tian, W; Xia, L; Yang, M; Zhao, Y | 1 |
| Jin, N; Kong, Y; Liu, Y; Mao, H; Meng, F; Sun, T; Tang, L; Wang, H; Wang, J; You, Y; Zhang, J; Zhu, X; Zou, P | 1 |
| Aoyama, K; Fukuyama, T; Maehiro, Y; Mouri, F; Nagafuji, K; Nakamura, T; Oya, S; Ozawa, H; Takaki, Y; Yamaguchi, M; Yamasaki, Y | 1 |
| Anemona, L; Ardu, NR; Cesini, L; de Fabritiis, P; Fratoni, S; Giovannini, M; Mazzone, C; Niscola, P; Ottone, T; Voso, MT | 1 |
| Bassi, L; Bertelli, S; Ciambella, S; Cippitelli, EE; Crocicchia, A; De Angelis, G; De Gregoris, C; Di Veroli, A; Fuschino, M; Innocenti, V; Isidori, R; Latagliata, R; Lippi, A; Mastini, C; Montanaro, M; Morucci, M; Panichi, V; Pessina, G; Pezzuti, G; Poscente, M; Randi, R; Talucci, R; Tarnani, M; Topini, G; Trapè, G | 1 |
| Cadeddu, RP; Christopeit, M; Drusenheimer, N; Esseling, E; Germing, U; Haas, R; Holtick, U; Jäger, P; Klein, S; Kobbe, G; Kröger, N; Mikesch, JH; Rautenberg, C; Scheid, C; Schroeder, T; Stelljes, M; Trenschel, R | 1 |
| Cahill, K; Chen, C; Fulton, N; Han, D; He, C; Liang, G; Odenike, O; Stock, W; Wang, L; You, Q; Zhang, W | 1 |
| Azab, M; Brandwein, J; Demeter, J; Döhner, H; Döhner, K; Fenaux, P; Gercheva-Kyuchukova, L; Gobbi, M; Griffiths, E; Hao, Y; Issa, JJ; Jedrzejczak, WW; Kantarjian, H; Keer, H; Krauter, J; Kropf, PL; Mayer, J; Min, YH; Miyazaki, Y; Novak, J; Ojeda-Uribe, M; Robak, T; Roboz, GJ; Thomas, X; Yee, K; Yeh, SP | 1 |
| Alsaadi, D; Clesham, K; Low, L; Rowan, F; Zubairu, M | 1 |
| Aladağ Karakulak, E; Büyükaşık, Y; Çınar, OE; Demiroğlu, H; Göker, H; Malkan, ÜY | 1 |
| Anders, NM; Baker, SD; Garrison, DA; Kagan, AB; Rudek, MA; Webster, JA; Yegnasubramanian, S | 1 |
| Imada, K; Ishikawa, T; Kanda, J; Kondo, T; Mizutani, Y; Muranushi, H; Naka, R; Nakabo, Y; Nannya, Y; Nishikubo, M; Ogawa, S; Oka, T; Okada, S; Ueda, Y; Wada, F; Watanabe, M; Yamamoto, S | 1 |
| Blank, MF; Corbacioglu, A; Göllner, S; Heid, D; Janssen, M; Krijgsveld, J; Lotze, M; Müller-Tidow, C; Pabst, C; Pauli, C; Raffel, S; Renders, S; Rohde, C; Sauer, T; Schmidt, C; Trumpp, A; Vierbaum, L; Waclawiczek, A; Weidenauer, K | 1 |
| Bailey, R; Beach, CL; Gaudy, A; Laille, E; Skikne, B; Zhou, S | 1 |
| Fan, J; Wen, X; Yu, J; Zheng, H; Zhu, S | 1 |
| Fujii, F; Kakinoki, Y; Matsuoka, S; Nojima, S | 1 |
| Chu, XX; Deng, XZ; Liu, XD; Ran, XH; Wang, CZ; Wang, L; Wang, LQ; Yang, EQ; Yu, HY; Zhao, CT | 1 |
| Alvarado, Y; Bhalla, KN; Borthakur, G; Burger, J; Daver, N; DiNardo, CD; Fiskus, WC; Garcia-Manero, G; Issa, GC; Jabbour, E; Jain, N; Kadia, T; Khoury, JD; Konopleva, M; Masarova, L; Miller, D; Pemmaraju, N; Pierce, S; Qiao, W; Ravandi, F; Sasaki, K; Senapati, J; Short, NJ; Wilson, NR | 1 |
| Bao, X; Carter, JL; Edwards, H; Ge, Y; Howard, M; Hüttemann, M; Li, J; Qiao, X; Su, Y; Taub, JW; Wang, G; Yang, J; Zhao, J | 1 |
| Chan, G; Cortes, JE; DiRienzo, CG; Dombret, H; Jeyakumar, D; Jou, E; Liu, X; Ma, W; Mayer, J; Merchant, A; Montesinos, P; Novak, J; O'Brien, T; Robak, T; Roh, W; Sekeres, MA; Shaik, N; Taussig, DC; Tomlinson, B; Wang, J | 1 |
| Abedinlou, H; Ghoraeian, P; Hejab, R; Rahimi, H | 1 |
| Alnimer, Y; Boron, J; Bouligny, IM; Doyel, M; Gor, J; Grant, S; Hang, Y; Ho, T; Maher, KR; Murray, G; Patel, T; Tran, V; Venn, C; Wages, NA; Zacholski, K | 1 |
| Ciccolini, J; Correard, F; Donnette, M; Fanciullino, R; Farnault, L; Hamimed, M; Ouafik, L; Sicard, G; Venton, G | 1 |
| Dworzak, MN; Hasle, H; Hoogendijk, R; Huitema, ADR; Janssen, JM; Laille, EJ; Lopez-Yurda, M; Niemeyer, CM; Rubio-San-Simón, A; van den Heuvel-Eibrink, MM; van Eijkelenburg, NKA; van Tinteren, H; Zecca, M; Zwaan, CM | 1 |
| Agarwal, A; Bottomly, D; Chang, BH; Dibb, CA; Druker, BJ; Eide, CA; Huang, A; Joshi, SK; Kaempf, A; Kurtz, SE; Lachowiez, CA; Long, N; McWeeney, SK; Minnier, J; Nechiporuk, T; Saultz, JN; Swords, RT; Taylor, A; Tyner, JW | 1 |
| Asada, S; Chinen, T; Enomoto, Y; Fukagawa, T; Fukuyama, T; Goyama, S; Ishikawa, T; Isobe, T; Kato, K; Kitagawa, D; Kitamura, T; Nakanishi, M; Nannya, Y; Nishiyama, A; Saitoh, K; Sato, N; Satoh, H; Shimura, R; Soga, T; Tanaka, Y; Yabushita, T; Yamamoto, K | 1 |
| Betts, KA; Bui, CN; Dua, A; Lachaine, J; Li, X; Pratz, K; Schuh, AC; Song, J; Suh, HS | 1 |
| Gastaud, L; Mechelfekh, Y | 1 |
| Kühn, MWM; Rausch, J; Ullrich, E | 1 |
| Bouchla, A; Galanopoulos, A; Hatzimichael, E; Kotsianidis, I; Papageorgiou, SG; Pappa, V; Sakellari, I; Symeonidis, A; Thomopoulos, TP; Vyniou, NA; Zikos, P | 1 |
| Benner, A; Bullinger, L; Claus, R; Döhner, K; Mertens, D; Mücke, O; Plass, C; Schlenk, RF; Schmutz, M; Weichenhan, D; Zucknick, M | 1 |
| Narendran, A; Sharma, R; Zhang, C | 1 |
| Montesinos, P; Sossa-Melo, C | 1 |
| Arnan, M; Demirkan, F; Doronin, V; Fogliatto, LM; Guttke, C; Gyan, E; Hamad, N; Herrera, P; Hultberg, A; Jacobs, J; Johnson, AJ; Langlois, A; Ma, X; Martinelli, G; Müller, R; Nottage, K; Ofran, Y; Özcan, M; Pabst, T; Papayannidis, C; Samoilova, O; Tolbert, JA; Trudel, GC; Vey, N; Wei, AH; Xiu, L | 1 |
| Li, Q; Liu, K; Yang, S; Zeng, Q; Zheng, F; Zhou, Z | 1 |
| Petzer, V; Wolf, D | 1 |
| Acharya, L; Dhakal, P; Loeffler, B; Mott, S; Ravindra, A; Sutamtewagul, G | 1 |
| Benedek, S; Bödör, C; Farkas, P; Gaál, L; Horváth, L; Masszi, A; Masszi, T; Nagy, Z; Ruff, E; Svorenj, S; Szita, VR; Szombath, G; Tóth, AD; Varga, G; Várkonyi, J; Wiedemann, Á | 1 |
| Jiang, XS; Liu, KQ; Lu, XX; Wang, X; Yuan, LY; Zhang, JS; Zhang, QQ; Zhao, XL | 1 |
| Aster, JC; Brooks, CL; Christie, AL; Craig, JW; Ghandi, M; Johannessen, CM; Johnson, CA; Jones, KL; Lane, AA; Letai, A; Lindsay, RW; Montero, J; Pastika, T; Pozdnyakova, O; Stephansky, J; Togami, K; Weinstock, DM | 1 |
| Diamantopoulos, PT; Giannakopoulou, N; Hatzidavid, S; Viniou, NA | 1 |
| Hagihara, M; Hua, J; Ide, S; Inoue, M; Ohara, S; Uchida, T | 1 |
| Daher-Reyes, GS; Merchan, BM; Yee, KWL | 1 |
| Bailly, B; Braakman, J; Caekelbergh, K; Chevalier, P; Diels, J; Dierickx, D; Doyle, M; Geers, J; Malfait, B; Meers, S; Van Hoorenbeeck, S; Van Kouwenhove, M; Vande Broek, I | 1 |
| Kong, R; Liu, Q; Qiu, HC; Wang, Y; Wu, DH; Wu, PF; Zhang, XL | 1 |
| Abbott, D; Boggs, C; Chase, S; Ewalt, MD; Gutman, JA; Halsema, K; Jordan, CT; Kaiser, J; Lyle, L; Nakic, M; Pollyea, DA; Purev, E; Rana, V; Rosser, J; Schowinsky, JT; Schuster, S; Siegele, B; Smith, C; Stevens, BM; Tobin, J; Winters, AC | 1 |
| Alajaji, NM; Alhazzani, SA; Alnajjar, FH; Alrajhi, AM; Alshehry, NF; Tailor, IK | 1 |
| Carew, JS; Espitia, C; Jones, TM; Nawrocki, ST; Wang, W | 1 |
| Boerries, M; Dittmann, J; Fulda, S; Haydn, T; Metzger, P; Vogler, M; Ward, GA | 1 |
| Attig, J; Bernard, E; Kassiotis, G; Kazachenka, A; Kordella, C; Kotsianidis, I; Lamprianidou, E; Papaemmanuil, E; Papoutselis, M; Vrachiolias, G; Young, GR; Zoulia, E | 1 |
| Feng, X; Huang, H; Qiu, X; Shen, A; Song, H; Zhang, H; Zhang, Z | 1 |
| Asnafi, V; Bardet, V; Benhamou, M; Bouscary, D; Carmeliet, G; Carvalho, C; Castaigne, S; Cheok, M; de Thé, H; Decroocq, J; Dombret, H; Ginzburg, YZ; Hermine, O; Lieben, L; Maciel, TT; Macintyre, E; Monteiro, RC; Moura, IC; Mupo, A; Paubelle, E; Preudhomme, C; Sujobert, P; Tamburini, J; Vassiliou, GS; Yokoyama, A; Zylbersztejn, F | 1 |
| Aurer, I; Bašić-Kinda, S; Mikulić, M; Vidović Juras, D; Vučićević Boras, V | 1 |
| Amat, P; Calabuig, M; Chaves, FJ; Fuentes, A; García, F; Hernández-Boluda, JC; Martín, I; Navarro, B; Orts, M; Seda, E; Serrano, A; Solano, C; Tormo, M; Villamón, E; Yagüe, N | 1 |
| Al Ali, N; Auberger, P; Calleja, A; Cluzeau, T; Dadone-Montaudie, B; Gastaud, L; Karsenti, JM; Komrokji, R; Mannone, L; Moreilhon, C; Raynaud, S; Robert, G; Sallman, DA; Yun, S | 1 |
| Contieri, B; Duarte, BKL; Lazarini, M | 1 |
| Fang, T; Shu, HE | 1 |
| Buckstein, R; Cheung, MC; Earle, CC; Liu, N; Mittmann, N; Mozessohn, L | 2 |
| Boghaert, ER; Cojocari, D; Jin, S; Leverson, JD; Phillips, DC; Popovic, R; Purkal, JJ; Solomon, LR; Talaty, NN; Xiao, Y | 1 |
| Artz, AS; Cahill, KE; Fulton, N; Godley, LA; Green, M; Jain, N; Kadri, S; Karimi, YH; Karrison, TG; Larson, RA; Le Beau, MM; Liu, H; McNerney, ME; Odenike, O; Segal, J; Stock, W; Thirman, MJ; Weiner, H | 1 |
| Cooper, BW; Craig, MD; Gallogly, MM; Kane, DM; Lazarus, HM; Levis, MJ; Metheny, L; Tomlinson, BK; William, BM | 1 |
| Fan, C; Jiang, H; Jin, J; Li, J; Lou, Y; Lu, Y; Ma, Y; Mao, L; Shao, L | 1 |
| Antunovic, P; Cammenga, J; Deneberg, S; Derolf, ÅR; Eriksson, A; Höglund, M; Juliusson, G; Lazarevic, V; Lehmann, S; Lorenz, F; Möllgård, L; Ölander, E; Österroos, A; Uggla, B; Wennström, L | 1 |
| Kuo, DJ; Severson, E; Wong, V; Woolbright, WC | 1 |
| Abbott, LS; Cada, M; Dror, Y; Johnston, DL; Klaassen, RJ; Leung, EW; Schechter, T; Shabanova, I | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Bengtzén, S; Cordeddu, L; Deneberg, S; Ekwall, K; Lehmann, S; Lennartsson, A; Miliara, S; Mujahed, H; Neddermeyer, A; Nilsson, C | 1 |
| Borchert, NM; Chaturvedi, A; Gabdoulline, R; Ganser, A; Geffers, R; Goparaju, R; Görlich, K; Gupta, C; Haegebarth, A; Heuser, M; Jeffers, M; Kaulfuss, S; Othman, B; Panknin, O; Schottmann, R; Thol, F; Wagner, M; Welzenbach, J | 1 |
| Chen, Q; Li, M; Qiu, H; Sun, A; Wu, D; Wu, X; Zhang, J; Zhou, L | 1 |
| Kanda, T; Kimura, M; Takenaka, S; Teramachi, H; Usami, E; Yoshimura, T | 1 |
| Al Ali, N; Duong, VH; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Sallman, D; Zhang, L | 1 |
| Ding, HK; DU, L; Feng, XQ; Gao, Y; Huang, JX; Lan, FF; Li, TL; Liu, SS; Mao, CX; Meng, FJ; Nie, SM; Qin, DQ; Wang, JC; Yan, XS; Yang, Q; Yao, CZ; Yuan, TL | 1 |
| Kolb, G; Reese, J; Velazquez, GF; Weckenbrock, J | 1 |
| Adès, L; Angeli, E; Bally, C; Calleja, A; Chevallier, P; Cluzeau, T; Fenaux, P; Garnier, A; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Ngo Nloga, AM; Peterlin, P | 1 |
| Greil, R; Leisch, M; Pleyer, L | 1 |
| Bewersdorf, JP; Zeidan, AM | 1 |
| Alvarado, Y; Demakos, EP; Fruchtman, SM; Garcia-Manero, G; John, RB; Maniar, M; Navada, SC; OdchimarReissig, R; Ohanian, MN; Pemmaraju, N; Silverman, LR; Woodman, RC; Zbyszewski, PS | 1 |
| Sallman, DA | 1 |
| Aisa, Y; Akimoto, M; Ito, C; Kamiya, T; Mizuno, K; Nakazato, T; Nishiyama-Fujita, Y; Ogura, S; Sakurai, A; Tanigawa, T | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Caglioti, F; Gianfelici, V; Giugliano, E; Levato, L; Mannella, A; Molica, S; Russo, A | 1 |
| Naoe, T | 1 |
| Abd Elmageed, ZY; Ali, HEA; Buttolph, T; Carraway, HE; Cen, Y; Denvir, J; Fan, J; Fandy, TE; Malkaram, SA; Primerano, DA; Shatnawi, A | 1 |
| Chen, TT; Cheng, FM; Lin, CC; Tien, JZ; Yeh, SP | 1 |
| Ali, N; Andrade, L; Baer, L; Balls, JW; Caimi, P; Cao, S; de Lima, M; Fu, P; Goldstein, SC; Metheny, L; Mori, S; Nelson, M; Patel, RD; Smith, M; Smith, T; Tomlinson, B; Varela, JC | 1 |
| Nakazato, T; Sakurai, A | 1 |
| Franich, RL; Gruber, E; Johnstone, RW; Kats, LM; Shortt, J | 1 |
| Liu, C; Shao, Z; Sun, Y; Wu, C | 1 |
| Beutel, G; Eder, M; Gabdoulline, R; Gohring, G; Heuser, M; Koenecke, C; Krauter, J; Markel, D; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Trummer, A | 1 |
| Kishtagari, A; Sekeres, MA | 1 |
| Baek, DW; Cho, HJ; Kim, J; Moon, JH; Sohn, SK | 1 |
| Franklin, AK; Gore, L; Maloney, KW; Treece, AL; Winters, AC | 1 |
| Abdel-Wahab, O; Alvarez, K; Chung, SS; Gönen, M; Klimek, VM; Mi, X; Paffenholz, SV; Park, JH; Penson, AV; Rampal, RK; Sen, F; Sigler, A; Stein, EM; Tallman, MS; Taylor, J | 1 |
| DiNardo, CD; Döhner, H; Esteve, J; Fenaux, P; Garcia, JS; Hájek, R; Havelange, V; Hong, WJ; Illés, Á; Jang, JH; Jonas, BA; Koller, E; Konopleva, M; Lavie, D; Leber, B; Lemoli, RM; Letai, A; Pejsa, V; Porkka, K; Potluri, J; Pratz, KW; Pullarkat, V; Thirman, MJ; Turgut, M; Wang, J; Wei, AH; Yamamoto, K; Yeh, SP; Yoon, SS; Zhou, Y | 1 |
| Breccia, M; Colafigli, G; Di Prima, A; Diverio, D; Foà, R; Latagliata, R; Mancini, M; Martelli, M; Pepe, S; Scalzulli, E | 1 |
| Killock, D | 1 |
| Anderson, JT; Baker, SD; Buelow, DR; Gibson, AA; Goodwin, EA; Hu, S; Lamba, JK; Pounds, SB; Shi, L; Sparreboom, A | 1 |
| Cheng, XH; Jiang, J; Jiang, M; Li, JH; Tang, MQ; Tian, FQ; Zhang, LS; Zhang, XC | 1 |
| Cazzola, M | 1 |
| Bertoli, S; Bories, P; Cabarrou, B; Cassou, M; De Mas, V; Delabesse, E; Filleron, T; Fornecker, LM; Lagarde, S; Largeaud, L; Luquet, I; Plenecassagnes, J; Prade, N; Recher, C; Sarry, A; Simand, C | 1 |
| Deeg, JH; Guan, F; Li, H; Li, X; Pang, X; Wan, T; Wang, H; Wang, Y; Wu, J; Xie, C | 1 |
| Barrière, S; Gastaud, L | 1 |
| Choe, S; Daigle, S; de Botton, S; DiNardo, CD; Döhner, H; Fan, B; Fathi, AT; Frankfurt, O; Franovic, A; Frattini, MG; Gianolio, DA; Goldwasser, M; Gong, J; Kantarjian, HM; Lersch, F; Martinelli, G; Patel, PA; Raffoux, E; Schuh, AC; Stein, AS; Stein, EM; Stone, RM; Tan, P; Vyas, P; Winkler, T; Wu, B; Zeidan, AM; Zhang, V | 1 |
| Adams, RH; Beebe, K; Campbell, C; Huschart, E; Magee, K; Miller, H; Ngwube, A; Salzberg, D; Schwalbach, C | 1 |
| Alousi, AM; Champlin, RE; de Lima, M; Garcia-Manero, G; Giralt, S; Hosing, C; Lin, R; Oran, B; Popat, U; Rondon, G; Thall, PF; Woodworth, G | 1 |
| Arcaini, L; Boveri, E; Brociner, M; Castagnola, C; Merati, G; Nizzoli, ME; Roncoroni, E; Zappasodi, P | 1 |
| Ajib, S; Bornhäuser, M; Bug, G; Crysandt, M; Dressler, S; Haas, R; Hausmann, A; Heidenreich, D; Hirschbühl, K; Hoepting, M; Jost, E; Kaivers, J; Klein, S; Kobbe, G; Koldehoff, M; Kordelas, L; Kriege, O; Müller, LP; Rautenberg, C; Schaffrath, J; Schmid, C; Schroeder, T; Schuler, E; Wagner-Drouet, EM; Wolff, D | 1 |
| Chitikela, S; Kumar, L; Sahoo, RK | 1 |
| Lucijanic, M | 1 |
| Moore, JW; Pelcovits, A; Reagan, JL | 1 |
| DiNardo, CD; Pratz, KW; Wang, J | 1 |
| Bai, L; Liu, SB; Ma, X; Qian, CS; Sun, AN; Wang, J; Wang, TJ; Wu, DP; Xu, MZ; Xue, SL; Zhou, HX | 1 |
| Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B | 1 |
| Gangat, N; Tefferi, A | 1 |
| Boenisch, O; Bokemeyer, C; Fiedler, W; Ghandili, S; Ittrich, H; Jarczak, D; Karagiannis, P; Kluge, S; Lütgehetmann, M; Modemann, F; Pfefferle, S; Roedl, K; Rohde, H; Schmiedel, S; Sonnemann, P; Weisel, K; Wichmann, D | 1 |
| He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ | 1 |
| Alemdar, MS; Atas, U; Undar, L; Yucel, OK | 1 |
| Bazani, E; Bouchla, A; Diamantopoulos, PT; Foukas, P; Galanopoulos, A; Gkontopoulos, K; Glezou, I; Kontandreopoulou, CN; Kontsioti, F; Kotsianidis, I; Lamprianidou, E; Mpakou, V; Mpamias, A; Papageorgiou, S; Pappa, V; Spathis, A; Symeonidis, A; Thomopoulos, T; Tsakiraki, Z; Viniou, NA; Zafeiropoulou, K | 1 |
| Afanasyev, B; Beach, CL; Beltrami, G; Borin, L; Botelho de Sousa, A; Čermák, J; Döhner, H; Dombret, H; Dong, Q; Frairia, C; Giai, V; Jang, JH; Kizil Çakar, M; Kumar, K; La Torre, I; Montesinos, P; Ofran, Y; Ossenkoppele, GJ; Pocock, C; Porkka, K; Ravandi, F; Roboz, GJ; Rybka, J; Sandhu, I; Sayar, H; Selleslag, D; Skikne, B; Turgut, M; Wei, AH | 1 |
| Abbott, D; Amaya, M; Cherry, E; Gutman, JA; Jordan, CT; McMahon, C; Pollyea, DA; Schowinsky, J; Schwartz, M; Smith, C; Winters, A | 1 |
| Arenillas, L; Bargay, J; Borras, J; Buschbeck, M; Cabezón, M; Coll, R; Escoda, L; Font, LL; Garcia, A; Garrido, A; Hoyos, M; Jiménez, MJ; Malinverni, R; Marcé, S; Rámila, E; Tormo, M; Valcárcel, D; Vall-Llovera, F; Xicoy, B; Zamora, L | 1 |
| Aggarwal, M; Dass, J; Dhawan, R; Kumar Vishwanathan, G; Kumar, P; Mahapatra, M; Senapati, J; Seth, T; Tyagi, S | 1 |
| Romero, D | 1 |
| Adès, L; Bell, J; Campelo, MD; Cerrano, M; Faller, DV; Fram, RJ; Friedlander, S; Graux, C; Liesveld, J; Lopez, PF; Radinoff, A; Sangerman, MA; Sekeres, MA; Selleslag, D; Tzvetkov, N; Watts, J; Zeidner, JF; Zhao, D | 1 |
| Bowen, S; Dai, Y; Faller, DV; Friedlander, S; Haikawa, K; Hua, Z; Kupperman, E; Kuroda, S; Nakai, K; Sedarati, F; Venkatakrishnan, K; Yamamoto, Y; Yuan, Y; Zhou, X | 1 |
| Aisa, Y; Akimoto, M; Ito, C; Nakazato, T; Nishiyama-Fujita, Y; Sakurai, A | 1 |
| Konopleva, M; Zeng, Z | 1 |
| Cho, MK; Heo, JY; Kim, S; Kim, WI; Park, TH; Yoon, SY | 1 |
| Feld, J; Navada, SC; Silverman, LR | 1 |
| Huntington, SF; Patel, KK; Podoltsev, N; Prebet, T; Shallis, RM; Zeidan, AM | 1 |
| DiNardo, CD | 1 |
| Ades, L; Attalah, H; Berthon, C; Bève, B; Carpentier, AF; Chermat, F; Chevret, S; Cluzeau, T; Cuzzubbo, S; Fenaux, P; Komrokji, R; Lehmann-Che, J; Loschi, M; Madelaine, I; Miekoutima, E; Peterlin, P; Quesnel, B; Raffoux, E; Rahmé, R; Rauzy, OB; Recher, C; Sallman, DA; Sebert, M; Stamatoullas, A; Walter-Petrich, A; Willems, L | 1 |
| Foster, MC; Green, SD; Richardson, DR; Zeidner, JF | 1 |
| Albayrak, M; Falay, M; Han, U; Maral, S; Ozturk, HBA; Sahin, O | 1 |
| Banks, J; Filicko-O'Hara, J; Jeurkar, C; Kasner, M; Keiffer, G; Leiby, BE; Palmisiano, N; Wilde, L | 1 |
| Algarra, L; Amador Barciela, ML; Barragán, E; Bergua Burgues, J; Colorado, M; Falantes, JF; Fernández, MÁ; Foncillas, MÁ; García, O; Gascón, A; Gil, C; Herrera, P; Labrador, J; Lavilla, E; López-Lorenzo, JL; Martínez-Cuadrón, D; Martínez-López, J; Martínez-Sánchez, MP; Montesinos, P; Olave, MT; Paiva, B; Pérez-Encinas, MM; Ramos, F; Rodríguez-Veiga, R; Salamero, O; Sanz, MÁ; Sayas, MJ; Serrano, A; Serrano, J; Simiele, A; Tormo, M; Vidriales, B; Vives, S | 1 |
| Dai, H; Kang, L; Li, Z; Ma, Y; Qu, C; Song, Y; Tang, X; Wu, D; Yin, J; Yu, L; Zhu, X | 1 |
| Angelopoulou, MK; Chatzidimitriou, C; Konstantopoulos, K; Korkolopoulou, P; Lafioniatis, S; Lakiotaki, E; Pappa, V; Plata, E; Vassilakopoulos, TP | 1 |
| Ababou, M; Ahchouch, S; Doghmi, K; Hammani, A; Jennane, S; Maaroufi, HE; Mahtat, M; Messaoudi, N; Mikdmae, M | 1 |
| Choi, I; Fukuhara, N; Honda, H; Hong, WJ; Nishimura, Y; Okubo, S; Potluri, J; Salem, AH; Taniguchi, S; Usuki, K; Yamauchi, T | 1 |
| Chen, L; Liu, W; Wang, X; Zhou, Z | 1 |
| Borate, U; Devine, SM; Duléry, R; El Chaer, F; Holtan, SG; Hourigan, CS; Law, AD; Mohty, M; Muffly, L; Nassereddine, S; Shallis, RM; Stringaris, K; Taylor, J | 1 |
| Perl, AE | 1 |
| Byun, SY; Cho, JY; Cho, R; Hong, J; Hur, K; Kim, M; Kim, Y; Koh, Y; Ku, Y; Lee, Y; Lee, YS; Liu, J; Park, HM; Park, JH; Shin, DY; Shum, D; Yoon, SS | 1 |
| Basak, GW; Biecek, P; Bołkun, Ł; Czyż, A; Drozd-Sokołowska, J; Dutka, M; Dwilewicz-Trojaczek, J; Giebel, S; Góra-Tybor, J; Gołos, A; Karakulska-Prystupiuk, E; Kobylińska, K; Kopińska, A; Mądry, K; Piekarska, A; Szwedyk, P; Waszczuk-Gajda, A | 1 |
| H Wei, A; Kipp, D | 1 |
| Chojecki, A | 1 |
| Benitez, LL; Marini, BL; Perissinotti, AJ | 1 |
| Döhner, H; Roboz, GJ; Wei, AH | 1 |
| Avanzino, B; Chopra, VS; DiMartino, JF; Figueroa, ME; MacBeth, KJ; Quek, L; Schwickart, M; See, WL; Tang, L; Zheng, B | 1 |
| Dong, CX; Wang, MF; Yang, LH; Zhai, JH; Zhang, RJ; Zhang, ZJ | 1 |
| Cardamone, L; Paul, E; Rogers, B; Shaw, B; Shepherd, S; Shortt, J; Tey, A | 1 |
| Craddock, C; de Lima, M; Ossenkoppele, G; Platzbecker, U; Roboz, GJ | 1 |
| Alvarado, Y; Andreeff, M; Borthakur, G; Cortes, JE; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Guerra, V; Jabbour, EJ; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, M; Levis, M; Ohanian, M; Pemmaraju, N; Pierce, S; Pinsoy, MR; Ravandi, F; Swaminathan, M; Wierda, WG; Xiao, L | 1 |
| Arrate, MP; Boghaert, ER; Cojocari, D; Gorska, A; Hogdal, LJ; Huska, JD; Phillips, DC; Purkal, JJ; Ramsey, HE; Savona, MR; Smith, BN; Xiao, Y | 1 |
| Bewersdorf, JP; Johnson, A; Lee, J; Schiffer, M; Zeidan, AM; Zhao, J | 1 |
| Bin, Z; Guoliang, H; Hongmei, N; Jiangwei, H; Jianlin, C; Liangding, H; Yao, S; Yuhang, L; Zhuoqing, Q | 1 |
| Azenkot, T; Jonas, BA; Moskoff, BN; Othman, TA; Tenold, ME | 1 |
| Cassinat, B; Diawara, Y; Fenaux, P; Giraudier, S; Maslah, N; Sebert, M | 1 |
| Kamitsuji, Y; Kobayashi, T; Komori, Y; Kuroda, J; Miyashita, A; Mizutani, S; Okamoto, H; Sasaki, N; Shimura, Y; Tsukamoto, T; Tsutsumi, Y; Uoshima, N | 1 |
| Akashi, K; Eto, T; Iwasaki, H; Kato, K; Kuriyama, T; Miyamoto, T; Mori, Y; Obara, T; Odawara, J; Ogawa, R; Ohno, Y; Ueno, T; Yoshida, S; Yoshimoto, G; Yurino, A | 1 |
| Alexander, L; Andreeff, M; Borthakur, G; Bueso-Ramos, C; Cheung, CM; Daver, N; DiNardo, CD; Garcia-Manero, G; Herbrich, SM; Jabbour, E; Kadia, TM; Konopleva, MY; Kornblau, S; Loghavi, S; Pemmaraju, N; Pierce, SA; Ravandi, F; Saxena, K; Tang, G; Wang, SA | 1 |
| Bourgeois, AL; Bris, YL; Ceballos, P; Chevallier, P; François, S; Fronteau, C; Garnier, A; Giltat, A; Guillaume, T; Orvain, C; Peterlin, P; Planche, L; Thépot, S | 1 |
| Chiesa, R; Mishra, AK; Mullanfiroze, K; Vora, A | 1 |
| Dezern, AE; Gojo, I; Jones, RJ; Morrow, J; Prince, GT; Showel, M; Smith, BD; Symons, H; Webster, JA; Yogarajah, M; Zahurak, M | 1 |
| Liu, SB; Qiao, M; Qiu, QC; Shen, XD; Wan, CL; Xue, SL; Yin, J; Zou, JY | 1 |
| Bewersdorf, JP; Stahl, M; Tallman, MS | 1 |
| Kunacheewa, C; Kungwankiattichai, S; Owattanapanich, W; Rungjirajittranon, T | 1 |
| Götze, KS; Hecker, JS; Pachzelt, L | 1 |
| Al-Ammari, M; Albtoosh, BM; Alfayez, M; AlGhamdi, MS; Alnoamani, MS; AlShehry, NF; Altaf, SY; Aoun, SMA; Iqbal, S; Marei, MA; Motabi, IH; Tailor, IK; Zaidi, SZ | 1 |
| Bailey, R; Beach, CL; Chevassut, T; Döhner, H; Dombret, H; Figuera-Alvarez, A; Hiwase, D; La Torre, I; Montesinos, P; Musso, M; Pierdomenico, F; Pocock, C; Ravandi, F; Roboz, GJ; Safah, H; Sayar, H; Selleslag, D; Skikne, B; Sohn, SK; Tse, W; Wei, AH; Zhong, J | 1 |
| Kim, M; Levine, LB; Li, J; Phillips, G; Roddy, JV; Walker, AR | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Bazarbachi, A; Charafeddine, M; El-Cheikh, J; Fares, E; Kharfan-Dabaja, MA; Kreidieh, N; Mahfouz, R; Massoud, R | 1 |
| Alessandrino, EP; Candoni, A; Carella, AM; Cerqui, E; Cortelezzi, A; Criscuolo, M; Fianchi, L; Finelli, C; Leone, G; Masciulli, A; Molteni, A; Parma, M; Piciocchi, A; Poloni, A; Rambaldi, A; Salvi, F; Santarone, S; Sica, S; Spina, F; Voso, MT | 1 |
| Bhalla, K; Boddu, PC; Cortes, JE; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Jain, N; Kadia, TM; Kantarjian, HM; Konopleva, M; Ohanian, M; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Verstovsek, S; Wierda, WG | 1 |
| Anguita, E; Bernal, T; Bulnes, PD; Colado, E; Garay, MCG; Gil, AC; Lopez-Larrea, C; Marin, AM; Márquez-Kisinousky, L; Minguela, A; Mogorron, AV; Raneros, AB; Rodriguez, RM; Suarez-Alvarez, B; Vidal-Castiñeira, JR | 1 |
| Liao, A; Liu, Z; Wang, H; Wang, X | 1 |
| Chen, P; Dong, X; Gu, L; Li, D; Shao, J; Xu, L; Yang, Y; Zhao, H | 1 |
| Guo, H; Li, XX; Lin, J; Ma, JC; Qian, J; Wen, XM; Yan, Y; Yang, L; Zhang, TJ; Zhang, W; Zhou, JD | 1 |
| Al-Kali, A; Begna, K; Elliott, M; Hogan, W; Litzow, M; McCullough, K; Nanah, R; Patnaik, M | 1 |
| He, PF; Lian, XY; Lin, J; Ma, JC; Qian, J; Wen, XM; Xu, ZJ; Yao, DM; Zhang, ZH; Zhou, JD | 1 |
| Borthakur, G; Cortes, J; Daver, N; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, HM; Ohanian, M; Oran, B; Pemmaraju, N; Ragon, BK; Ravandi, F | 1 |
| Liu, P; Zhang, H; Zhou, S | 1 |
| Matsuguma, M; Nakamura, Y; Tanaka, M; Tanaka, Y; Tanizawa, Y; Tokunaga, Y; Yamamoto, K; Yujiri, T | 1 |
| Barwe, SP; Gopalakrishnapillai, A; Kolb, EA; McCahan, SM | 1 |
| Ades, L; Auberger, P; Braun, T; Chomienne, C; Cluzeau, T; Dombret, H; Durand, L; Fenaux, P; Garnier, G; Gastaud, L; Ginet, C; Goursaud, L; Hirsch, P; Karsenti, JM; Luciano, F; Nloga, AM; Padua, RA; Raffoux, E; Robert, G; Rohrlich, P; Vidal, V | 1 |
| Egle, A; Grabmer, C; Greil, R; Jungbauer, C; Leisch, M; Lindlbauer, N; Pleyer, L; Rohde, E; Weiss, L | 1 |
| Acharyya, S; Borbenyi, Z; Breccia, M; Cavenagh, JD; DeAngelo, DJ; Egyed, M; Fenaux, P; Garcia-Manero, G; Gazi, L; Graux, C; Ide, S; Illes, A; Lee, JH; MacWhannell, A; Marker, M; Ottmann, OG; Salman, H; Sekeres, MA; Stauder, R; Valcarcel, D; Yee, K; Zhu, N | 1 |
| Becker, PS; Buckley, SA; Chen, TL; Estey, EH; Halpern, AB; Hendrie, PC; Huebner, EM; Orlowski, KF; Othus, M; Percival, MM; Pogosova-Agadjanyan, EL; Scott, BL; Stirewalt, DL; Walter, RB | 1 |
| Eslin, D; Glade Bender, JL; Glasser, CL; Lee, A; Marks, L; Modak, S | 1 |
| Banos, A; Béné, MC; Bernard, M; Bonmati, C; Bouscary, D; Carré, M; Choufi, B; Couturier, MA; Daguindau, E; Delaunay, J; Dreyfus, F; Fornecker, LM; Hamel, JF; Himberlin, C; Hunault-Berger, M; Ifrah, N; Lissandre, S; Luquet, I; Maillard, N; Marolleau, JP; Ojeda-Uribe, M; Orsini-Piocelle, F; Pigneux, A; Puyade, M; Recher, C; Rouillé, V; Saad, A; Sanhes, L; Schmidt-Tanguy, A; Sutton, L; Tavernier, E | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Baker, K; Deeg, HJ; Festuccia, M; Gooley, TA; Sandmaier, BM; Scott, BL | 1 |
| Delgado, E; López, B; Sampol, A | 1 |
| Goswami, M; Hourigan, CS; Lindblad, KE; Oetjen, KA | 1 |
| Kanagal-Shamanna, R; Quesada, AE | 1 |
| Döhner, H; Dombret, H; Fenaux, P; Pleyer, L; Schuh, AC; Seymour, JF | 1 |
| Carraway, HE; Gore, SD; Keefer, J; Prebet, T; Press, KR; Sakoian, S; Uy, N | 1 |
| Galle, J; Hopp, L; Loeffler, M; Lübbert, M; Przybilla, J | 1 |
| Ai, H; Chen, L; Mi, RH; Song, YP; Wang, P; Wei, XD; Yin, QS; Yuan, FF | 1 |
| Alonso, S; Avila, LF; Bernal, T; Colado, E; Lorenzana, N | 1 |
| Cho, SH; Choi, YS; Chung, JS; Lee, HS; Lee, WS; Lim, SN; Oh, SB; Park, SW; Shin, HJ | 1 |
| Almeida, AM; Bargay, J; Burgstaller, S; Cortesão, E; Falantes, J; Fenaux, P; Foncillas, MÁ; Gardin, C; Greil, R; Itzykson, R; Martínez, MP; Martínez-Robles, V; Maurillo, L; Montesinos, P; Musto, P; Pinto, R; Pleyer, L; Ramos, F; Sanz, MA; Seegers, V; Stauder, R; Thépot, S; Venditti, A | 1 |
| Boddu, P; Borthakur, G; Cortes, J; Daver, N; Garcia-Manero, G; Jabbour, E; Kadia, TM; Kantarjian, H; Pemmaraju, N; Pierce, S; Ravandi, F | 1 |
| Abaza, YM; Alfonso, A; Borthakur, G; Chang, JE; Chong, TH; Chuah, C; Dong, XQ; Durkes, DE; Estrov, Z; Ferrajoli, A; Foudray, MC; Garcia-Manero, G; Goh, BC; Jabbour, EJ; Kadia, TM; Kantarjian, HM; Koh, LP; Konopleva, MY; Wierda, WG | 1 |
| Ferrara, F | 2 |
| Arentsen-Peters, TCJM; Baruchel, A; Danen-van Oorschot, AA; de Haas, V; Fornerod, M; Larmonie, NSD; Obulkasim, A; Pieters, R; Reinhardt, D; Sonneveld, E; Trka, J; Valerio, D; van den Heuvel-Eibrink, MM; Zimmermann, M; Zwaan, CM | 1 |
| Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N | 1 |
| Hori, YS; Kodera, S; Nagai, Y; Suzuki, Y | 1 |
| Alvaro, F; Arceci, RJ; Arndt, C; Barnette, P; Boklan, J; Carpten, J; Cooper, T; Farrar, JE; Gooden, GC; Gore, L; Lee, D; Legendre, C; Liang, WS; Macy, ME; Martin, L; Meshinchi, S; Narendran, A; Pollard, J; Salhia, B; Triche, TJ; Wai, D | 1 |
| Caccetta, T; Harvey, N; Kumarasinghe, SP; Tiwari, SM | 1 |
| Abboud, CN; Ali, AM; Cashen, AF; DiPersio, JF; Fehniger, TA; Gao, F; Ghobadi, A; Jacoby, MA; Oh, ST; Pusic, I; Romee, R; Schroeder, MA; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wartman, LD; Weisel, D; Welch, JS; Westervelt, P | 1 |
| Hao, JX; Li, J; Wu, D; Zhang, M | 1 |
| Beach, CL; Gale, RP; Kambhampati, S; Kew, A; Kumar, R; McCaul, K; Medeiros, BC; Pollyea, DA; Saini, L; Silverman, LR; Vij, R; Wang, X; Zhong, J | 1 |
| Adès, L; Ali, NH; Cluzeau, T; Eclache, V; Fenaux, P; Gyan, E; Hobson, S; Komrokji, RS; List, A; Prebet, T; Sanna, A; Santini, V; Sébert, M; Sekeres, MA | 1 |
| Cai, X; Dai, H; Ke, M; Liu, Z; Luo, H; Yan, M; Zeng, W | 1 |
| Germing, U; Haas, R; Kobbe, G; Rautenberg, C; Schroeder, T | 1 |
| Bornhäuser, M; Bug, G; Germing, U; Geyh, S; Haas, R; Hopfer, O; Klein, S; Kobbe, G; Kondakci, M; Krüger, W; Nachtkamp, K; Platzbecker, U; Rautenberg, C; Schroeder, T; Steinmann, J | 1 |
| Briot, T; Clavreul, A; Lagarce, F; Lautram, N; Roger, E; Verger, A | 1 |
| Schiffer, CA | 1 |
| Dombret, H; Itzykson, R | 1 |
| Al-Ali, HK; Beach, CL; Butrym, A; Candoni, A; Cavenagh, J; Del Castillo, TB; Döhner, H; Dombret, H; Falantes, J; Jang, JH; Kumar, R; Minden, MD; Récher, C; Sandhu, I; Schuh, AC; Selleslag, D; Seymour, JF; Songer, S; Stone, RM; Weaver, J; Wierzbowska, A | 1 |
| Guo, XZ; Huang, YQ; Pan, JX; Wu, SX; Zhang, XY | 1 |
| Müller-Tidow, C; Schlenk, RF | 1 |
| Bittencourt, H; Cooper, TM; Dalla-Pozza, L; Fraser, C; Gaynon, P; Gore, L; Jones, P; Liang, G; Malvar, J; Messinger, Y; Place, AE; Salhia, B; Sposto, R; Sun, W; Triche, T; Wayne, AS; Yang, X | 1 |
| Behrens, YL; Göhring, G; Lentes, J; Rothe, D; Schlegelberger, B; Steinemann, D; Thomay, K; Wittig, V; Wittner, N | 1 |
| Berot, A; Pluchart, C | 1 |
| DU, Y; Jing, Y; Li, PF; Liu, M; Peng, CJ; Sun, JZ; Wang, ZH; Yao, YB; Zhou, HW; Zhou, MH | 1 |
| Allison, J; Boddu, P; Daver, N; Garcia-Manero, G; Kantarjian, H; Sharma, P; Yadav, SS | 1 |
| Adès, L; Ali, A; Ben Abdelali, R; Clappier, E; Dal Bello, R; Dombret, H; Fenaux, P; Hernandez, L; Itzykson, R; Massé, A; Penneroux, J; Pimanda, J; Preudhomme, C; Puissant, A; Quentin, S; Raffoux, E; Renneville, A; Soulier, J; Unnikrishnan, A | 1 |
| Bohl, SR; Bullinger, L; Rücker, FG | 1 |
| Füreder, W; Gleixner, K; Grünberger, B; Hoermann, G; Kornauth, C; Schwarzinger, I; Sperr, WR; Thalhammer, R; Valent, P | 1 |
| Fathi, AT | 1 |
| Berthou, C; Boyer-Perrard, F; Chauveau, A; Couturier, MA; Dagorne, A; Douet-Guilbert, N; Guillerm, G; Houot, R; Hunault, M; Ianotto, JC; Le Calloch, R; Lippert, É; Luycx, O; Malou, M; Mollard, LM; Quintin-Roué, I; Thepot, S; Ugo, V | 1 |
| Hawks, KG; Maples, KT; McCarty, JM; Sabo, RT; Toor, AA | 1 |
| Belickova, M; Cermak, J; Dyr, JE; Hrustincova, A; Jonasova, A; Krejcik, Z; Merkerova, MD; Votavova, H | 1 |
| Imoto, S; Konuma, T; Miyano, S; Shimizu, E; Takahashi, S; Takei, T; Tojo, A; Yamaguchi, R; Yokoyama, K | 1 |
| Bouronikou, E; Diamantopoulos, P; Galanopoulos, AG; Hatzimichael, E; Kontos, CK; Kotsianidis, I; Megalakaki, A; Mparmparousi, D; Panayiotidis, P; Papadaki, H; Papageorgiou, SG; Pappa, V; Poulakidas, E; Symeonidis, A; Vasilatou, D; Vassilakopoulos, TP; Viniou, NA; Zikos, P | 1 |
| Bandeira, SP; Borges, DP; Brilhante, RSN; Cordeiro, RA; Magalhaes, SMM; Pinheiro, RF; Rocha, MFG; Santos, AWA; Sidrim, JJ; Valença Junior, JT | 1 |
| Blanchard, L; Foster, MC; Frank, C; Gallagher, S; Matson, M; Montgomery, N; Muluneh, B; Pepin, K; Vaught, L; Yogarajah, M; Zeidner, JF | 1 |
| Buckstein, R; Cheung, MC; Fallahpour, S; Gill, T; Lau, O; Maloul, A; Mozessohn, L; Zhang, L | 1 |
| Bär, BMAM; Evers, D; Gotthardt, M; van der Velden, WJFM | 1 |
| Arellano, M; Carlisle, JW | 1 |
| Fujiwara, T; Hasegawa, D; Ishida, T; Kishimoto, K; Kosaka, Y; Kozaki, A; Nakamura, S; Nino, N; Saito, A; Tahara, T; Tamura, A; Uemura, S; Yamamoto, N; Yokoi, T | 1 |
| Champlin, RE; Craddock, C; de Lima, M; Giralt, SA; Hetzer, J; Hubbell, B; Laille, E; Oran, B; Papadopoulos, EB; Scott, BL; Skikne, BS; William, BM | 1 |
| Han, Y; Pan, T; Qi, J; Wu, D; Yang, L; You, T; Zhu, L | 1 |
| Chen, RA; Chen, Y; Ji, YR; Li, GH; Liu, C; Liu, L; Qin, WW; Wang, WQ; Zhou, NC | 1 |
| Chen, W; Malli, A; Mumtaz, K; Sobotka, LA | 1 |
| Amraoui, K; Colombat, P; Delain, M; Ertault, M; Ferreira-Maldent, N; Gyan, E; Hérault, O; Jonville-Béra, AP; Ponard, A; Regina, S | 1 |
| Becerra, C; Conkling, P; Dong, Q; Kellerman, A; Kingsley, EC; Kolibaba, K; Laille, E; Morris, JC; Rifkin, RM; Savona, MR; Skikne, BS; Ukrainskyj, SM | 1 |
| Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; Estrov, Z; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Levis, M; Ohanian, M; Patel, K; Pierce, S; Ravandi, F; Richie, MA | 1 |
| Konopleva, M; Letai, A | 1 |
| Advani, AS; Bixby, D; DeAngelo, DJ; Erba, HP; Faderl, S; Fathi, AT; Ho, PA; Jillella, A; Kovacsovics, TJ; Lancet, JE; Levy, MY; O'Meara, MM; Ravandi, F; Stein, AS; Stein, EM; Voellinger, J; Walter, RB | 1 |
| Li, Y; Lv, N; Wang, H; Wang, L; Yu, L | 1 |
| Curtis, SA; Folkers, A; Medoff, E; Mixon, R; Shallis, RM; Xu, ML; Zeidan, AM | 1 |
| Hannig, CV; Harde, J; Harich, HD; Klausmann, M; Losem, C; Müller, J; Niemeier, B; Potthoff, K; Schmitz, S; Tessen, HW; Wehmeyer, J; Zaiss, M | 1 |
| Cao, Y; Cen, JN; Dong, WM; Gu, WY; Lin, Y; Liu, Y; Xiang, LL; Xie, XB | 1 |
| Basak, G; Boguradzki, P; Chmarzyńska-Mróz, E; Drozd-Sokołowska, J; Dwilewicz-Trojaczek, J; Jędrzejczak, W; Karakulska-Prystupiuk, E; Kulikowska, A; Paluszewska, M; Stefaniak, A; Waszczuk-Gajda, A | 1 |
| Al-Ali, HK; Beach, CL; Bullinger, L; Del Castillo, TB; Döhner, H; Dolnik, A; Dombret, H; MacBeth, KJ; Minden, MD; Santini, V; Seymour, JF; Skikne, BS; Songer, S; Stone, RM; Tang, L; Tu, N; Vyas, P | 1 |
| Appelbaum, FR; Erba, HP; Estey, E; Garcia-Manero, G; Nand, S; Othus, M; Sekeres, MA | 1 |
| Deng, ZQ; He, PF; Li, XX; Lian, XY; Lin, J; Ma, JC; Qian, J; Wu, DH; Yan, Y; Zhang, TJ; Zhang, ZH; Zhou, JD | 1 |
| Das, M | 1 |
| Abbott, D; Culp-Hill, R; D'Alessandro, A; Gillen, AE; Gutman, JA; Hesselberth, JR; Jones, CL; Jordan, CT; Minhajuddin, M; Pei, S; Pollyea, DA; Purev, E; Riemondy, KA; Schatz, D; Smith, C; Stevens, BM; Winters, A | 1 |
| Adane, B; Culp-Hill, R; D'Alessandro, A; DeGregori, J; Jones, CL; Jordan, CT; Khan, N; Krug, A; Nemkov, T; Pei, S; Pollyea, DA; Reinhold, D; Reisz, JA; Smith, C; Stevens, BM; Ye, H | 1 |
| Ramos, F | 1 |
| Baldus, CD; Bochtler, T; Borkmann, C; Bornhäuser, M; Bug, G; Dührsen, U; Ehninger, G; Fransecky, L; Götze, KS; Groth, C; Hänel, M; Herbst, R; Krämer, A; Kramer, M; Kubasch, AS; Mende, M; Middeke, JM; Mütherig, A; Noppeney, R; Oelschlägel, U; Platzbecker, U; Röllig, C; Schetelig, J; Schubert, A; Serve, H; Sockel, K; Stelljes, M; Stölzel, F; Thiede, C; von Bonin, M; Wolf, D | 1 |
| Al Yacoub, R; Cronin, TL; Griffiths, EA; Miller, A; Ontiveros, EP; Thompson, JE; Vachhani, P; Wang, ES; Zhang, F | 1 |
| Alvarez, MC; Cury, NM; Dos Santos, GP; Duarte, ADSS; Favaro, P; Ferro, KP; Giardini Rosa, R; Longhini, AL; Lopes, MR; Machado-Neto, JA; Pericole, FV; Roversi, FM; Saad, STO; Yunes, JA | 1 |
| Aldoss, I; Marcucci, G; Mei, M; Pullarkat, V | 1 |
| Cairoli, R; Cassin, R; Cortelezzi, A; Fattizzo, B; Freyrie, A; Giannarelli, D; Molteni, A; Pennisi, M; Reda, G; Riva, M | 1 |
| Cashen, AF | 1 |
| DiMartino, J; Escoubet, L; Leung, KK; MacBeth, KJ; Nguyen, A; Ni, X; Shi, T; Tang, L; Wells, JA | 1 |
| Michaelis, LC | 1 |
| Nakada, D | 1 |
| Armatys, A; Boral, K; Chromik, K; Dworaczek, M; Helbig, G; Koclęga, A; Kopińska, AJ; Markiewicz, M; Panz-Klapuch, M; Woźniczka, K | 1 |
| Biemond, BJ; Breems, D; Chitu, DA; de Weerdt, O; Deeren, D; Graux, C; Havelange, V; Hodossy, B; Huls, G; Jongen-Lavrencic, M; Klein, S; Kooy, RVM; Kuball, J; Löwenberg, B; Ossenkoppele, GJ; Sinnige, H; Terpstra, W; van de Loosdrecht, AA; Vekemans, MC; Vellenga, E | 1 |
| Brock, K; Cavenagh, J; Craddock, C; De Santo, C; Dennis, M; Ferguson, P; Hodgkinson, A; Ingram, W; Malladi, R; Mussai, F; Siddique, S; Slade, D; Wheat, R; Yap, C | 1 |
| Cook, JR; Nomani, L; Rogers, HJ | 1 |
| Boasman, K; Graham, C; Rinaldi, CR; Saunthararajah, Y; Simmonds, MJ | 1 |
| Benner, A; Bernhard, H; Derigs, HG; Döhner, H; Döhner, K; Gaidzik, V; Ganser, A; Girschikofsky, M; Göhring, G; Grießhammer, M; Haase, D; Herr, W; Hertenstein, B; Heuser, M; Koller, E; Krauter, J; Kremers, S; Kuendgen, A; Lange, E; Martens, UM; Paschka, P; Ringhoffer, M; Salih, HR; Schlenk, RF; Teleanu, V; Thol, F; Wattad, M; Weber, D; Westermann, J; Wolf, D; Wulf, G | 1 |
| Abaza, Y; Arellano, M; Atallah, E; Garcia-Manero, G; Ghalie, R; Giorgino, R; Karamlou, K; Khaled, SK; Maness-Harris, L; Medeiros, BC; Odenike, O; Patel, P; Patnaik, M; Sayar, H; Stuart, R; Takahashi, K; Traer, E; Tummala, M; Yacoub, A | 1 |
| Auberger, P; Robert, G | 1 |
| Anastasiadou, E; Avigan, D; Cole, L; Ephraim, A; Ghiasuddin, H; Jain, S; Kufe, D; Leaf, RK; Liegel, J; McMasters, M; Molldrem, JJ; Nahas, MR; Orr, S; Pyzer, AR; Rahimian, M; Rosenblatt, J; Sergeeva, A; Slack, F; Stroopinsky, D; Washington, A; Weinstock, M | 1 |
| Wei, AH | 1 |
| Huls, G; Kicinski, M; Lübbert, M; Suciu, S; Wijermans, P | 1 |
| Angelopoulou, M; Dagla, K; Gkirkas, K; Gkodopoulos, K; Grigoriou, E; Kapsimalli, V; Karagiannidou, A; Konsta, E; Lowdell, M; Pappa, V; Stamouli, M; Stavroulaki, G; Tsirigotis, P; Tsirogianni, M | 1 |
| Abbasi, T; Abbott, D; Cogle, CR; Drusbosky, L; Fullerton, A; Gutman, JA; Hammes, A; Hemenway, G; Jordan, CT; Miltgen, N; Pollyea, DA; Schatz, D; Singh, NK; Smith, C; Stevens, B; Vali, S; Wei, Q; Winters, A | 1 |
| Hale, G; Oshrine, BR; Petrovic, A; Shyr, D | 1 |
| Duchmann, M; Itzykson, R | 1 |
| Aziz, M; Bandyopathyay, D; Chung, H; Claiborne, J; Clark, W; Hawks, K; McCarty, J; Roberts, C; Simmons, G; Toor, A; Wiedl, C | 1 |
| Cook, RJ; Kearney, M; Lachowiez, C; Maziarz, RT; Meyers, G | 1 |
| Borel, C; Chevallier, P; Garnier, A; Gaugler, B; Guillaume, T; Huynh, A; Labopin, M; Magro, L; Malard, F; Milpied, N; Mohty, M; Moreau, P; Peterlin, P; Rubio, MT; Tabrizi, R; Vigouroux, S; Yakoub-Agha, I | 1 |
| Abedin, SM; Platanias, LC | 1 |
| Flaishon, L; Rowe, JM; Stone, A; Yakar, RB; Zukerman, T | 1 |
| Ossenkoppele, GJ; Santini, V | 1 |
| Amit, O; Avivi, I; Bar-On, Y; Gurion, R; Raanani, P; Ram, R; Wolach, O; Zuckerman, T | 1 |
| Blanco, ML; Brunet, S; Bussaglia, E; Carricondo, M; Esquirol, A; García-Cadenas, I; Garrido, A; Gich, I; Hoyos, M; Martino, R; Nomdedéu, JF; Pratcorona, M; Santaliestra, M; Sierra, J | 1 |
| Kunacheewa, C; Owattanapanich, W; Thongthang, P; Ungprasert, P; Utchariyaprasit, E | 1 |
| Bewersdorf, JP; Stahl, M; Zeidan, AM | 1 |
| Cortes, JE; Graef, T; Jonas, BA; Luan, Y; Stein, AS | 1 |
| Agarwal, S; Friedel, A; Gopalakrishnan, S; Hayslip, J; Kirschbrown, W; Menon, R; Mensing, S; Potluri, J; Salem, AH | 1 |
| Coleman, E; Cowper, S; Gore, S; Leventhal, J; Panse, G; Prebet, T | 1 |
| Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Nakamura, R; O'Donnell, M; Pillai, R; Pullarkat, V; Salhotra, A; Sanchez, JF; Sandhu, K; Snyder, D; Stein, AS; Sun, W; Yang, D | 1 |
| Estey, EH; Percival, MM | 1 |
| Azab, M; Chung, W; Fung, H; Issa, JJ; Jelinek, J; Kantarjian, HM; Kelly, AD; Kropf, P; Roboz, GJ; Su, XY | 1 |
| Bouchla, A; Bouronikou, E; Diamantopoulos, P; Galanopoulos, A; Hatzimichael, E; Karousi, P; Kontos, CK; Kotsianidis, I; Mparmparousi, D; Panayiotidis, P; Papadaki, H; Papageorgiou, SG; Pappa, V; Poulakidas, E; Repousis, P; Symeonidis, A; Vassilakopoulos, TP; Viniou, NA; Zikos, P | 1 |
| Kubasch, AS; Platzbecker, U | 1 |
| Angenendt, L; Bohnenberger, H; Buzovetsky, O; Cinatl, J; Comoglio, F; Ferreirós, N; Geisslinger, G; Hartmann, W; Kaderali, L; Keppler, OT; Knecht, KM; Michaelis, M; Mohr, S; Oellerich, T; Rothenburger, T; Scheich, S; Schliemann, C; Schneider, C; Serve, H; Ströbel, P; Thomas, D; Wardelmann, E; Wilke, A; Xiong, Y | 1 |
| Absalon, M; Blum, W; Broun, R; Davies, SM; Garzon, R; Marcucci, G; McMasters, R; Mo, J; Moscow, JA; O'Brien, M; Perentesis, JP; Phillips, CL; Schwind, S; Smolarek, T | 1 |
| Seiter, K | 1 |
| Gore, SD; Suarez, L | 2 |
| Cai, LL; Chang, C; Fan, H; Guo, B; Han, WD; Li, SX; Lin, J; Liu, Y; Lu, XC; Ran, HH; Wang, Y; Yang, B; Yang, Y; Zhai, B; Zhang, F; Zhang, L; Zhu, HL | 1 |
| Han, XP; Huang, WR; Jiang, MM; Jing, Y; Mei, JH; Wang, QS; Wang, SH; Yang, H; Yu, L; Zhang, SS; Zhu, HY | 1 |
| Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Garzon, R; Hoellerbauer, P; Huang, X; Klisovic, R; Lee, LJ; Lee, RJ; Marcucci, G; Mims, A; Muthusamy, N; Perrotti, D; Santhanam, R; Schwind, S; Walker, AR; Wang, H; Yu, B | 1 |
| Adès, L; Bally, C; Dartigeas, C; de Botton, S; de Renzis, B; Dreyfus, F; Fadlallah, J; Fenaux, P; Itzykson, R; Quesnel, B; Thépot, S; Turlure, P; Vey, N | 1 |
| Alimena, G; Breccia, M; Salaroli, A; Serrao, A | 1 |
| Bug, G; Cadeddu, RP; Czibere, A; Dienst, A; Fenk, R; Fröbel, J; Germing, U; Haas, R; Kobbe, G; Kröger, N; Platzbecker, U; Schroeder, T; Uharek, L | 1 |
| Estey, E; Kantarjian, H; Ravandi, F; Wilson, W | 1 |
| Bargetzi, M; Blum, S; Brauchli, P; Chalandon, Y; Gregor, M; Heim, D; Leoncini, L; Li, Q; Meyer-Monard, S; Pabst, T; Passweg, JR; Stussi, G | 1 |
| Curran, MP | 1 |
| Daenen, SM; Huls, G; Mulder, AB; Scheepers, ER; van den Berg, E; van der Helm, LH; Veeger, NJ; Vellenga, E | 1 |
| Li, JY; Qian, SX; Zhu, Y | 1 |
| Alattar, ML; Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; Dellasala, S; Faderl, S; Garcia-Manero, G; Grunwald, MR; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Pierce, S; Rajkhowa, T; Ravandi, F; Richie, MA; Rudek, MA | 1 |
| Chantepie, SP; Charbonnier, A; Gruson, B; Harrivel, V; Ivanoff, S; Lemasle, E; Marolleau, JP; Merlusca, L; Royer, B; Votte, P | 1 |
| Jing, Y; Sun, L; Yang, L; Yuan, L | 1 |
| Angermann, H; Burgstaller, S; Egle, A; Girschikofsky, M; Greil, R; Krippl, P; Lang, A; Linkesch, W; Melchardt, T; Mitrovic, M; Pfeilstocker, M; Pleyer, L; Schreder, M; Sliwa, T; Stauder, R; Steinkirchner, S; Tinchon, C; Voskova, D | 1 |
| Germing, U; Platzbecker, U | 1 |
| Beijnen, JH; Derissen, EJ; Schellens, JH | 1 |
| Ichikawa, M; Iizuka, H; Kurokawa, M; Masuda, A; Nannya, Y; Yamamoto, G; Yatomi, Y; Yoshimi, A | 1 |
| Hayashi, K; Ohashi, A; Okuyama, R | 1 |
| Abáigar, M; Aguilar, C; Alonso, JM; Benito, R; de las Heras, N; del Cañizo, MC; Díez-Campelo, M; Fuertes, M; Hermosín, L; Hernández-Rivas, JM; Megido, M; Ramos, F; Recio, I; Rodríguez, JN; Sánchez-del-Real, J | 1 |
| Estey, EH | 1 |
| Auberger, P; Cassuto, JP; Cluzeau, T; Gabriel Fuzibet, J; Garnier, G; Gastaud, L; Gutnecht, J; Karsenti, JM; Legros, L; Montagne, N; Mounier, N; Raynaud, S; Re, D; Richez, V | 1 |
| Gore, SD; Komrokji, RS; Zeidan, AM | 1 |
| Guinea de Castro, JM; Moreno de Gusmão, B; Oiartzabal, I; Perez-Persona, E | 1 |
| Abhyankar, S; Aljitawi, O; Bhalla, KN; Dutreix, C; Fiskus, W; Fleming, A; Ganguly, S; Kambhampati, S; McGuirk, JP; Reyes, R; Wick, J; Williams, CB | 1 |
| Sekeres, MA; Steensma, DP | 2 |
| Hals, PA; Hascher, A; Hummel-Eisenbeiss, J; Lyko, F; Müller-Tidow, C; Rius, M; Sandvold, ML | 1 |
| Dou, LP; Jing, Y; Mei, JH; Wang, QS; Yu, L | 1 |
| Chen, SN; Gao, S; Han, Y; He, GS; Hu, XH; Jin, ZM; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y | 1 |
| Ornstein, DL; Preis, M | 1 |
| Alkhaeir, S; Callens, C; Damaj, G; Dussiot, M; Gorin, NC; Hermine, O; Isnard, F; Marolleau, JP; Monteiro, RC; Moura, IC; Paubelle, E; Rubio, MT; Suarez, F; Zylbersztejn, F | 1 |
| Dong, W; Jian, N; Jian, P; Jian, W; Jun, L; Li, P; Na, W; Pei-Fang, X; Wen-Li, Z; Xing, F; Yan-Fang, T | 1 |
| de Fabritiis, P; Fratoni, S; Giovannini, M; Niscola, P; Palombi, M; Perrotti, A; Scaramucci, L; Tendas, A; Trawinska, MM | 1 |
| Gao, X; Jiang, M; Ning, Q; Wang, J; Wang, L; Yao, Y; Yu, L; Zhou, J | 1 |
| Blum, W; Byrd, JC; Devine, SM; Garzon, R; Grever, MR; Humphries, K; Klisovic, RB; Marcucci, G; Schaaf, LJ; Walker, AR | 1 |
| Gao, L; Gao, X; Jiang, M; Li, J; Li, Y; Luo, X; Wang, L; Yao, Y; Yu, L; Zhou, J; Zhou, M | 1 |
| Belz, K; Fulda, S; Steinhart, L | 1 |
| Appelbaum, FR; Coutre, SE; Erba, HP; Godwin, JE; Howard, DS; Nand, S; Norwood, TH; Othus, M; Willman, CL | 1 |
| Borthakur, G; Cortes, J; DiNardo, CD; Faderl, S; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, M; Luthra, R; Patel, KP; Pemmaraju, N; Pierce, S; Ravandi, F | 1 |
| Bechelli, J; Becker, MW; Chen, R; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Minhajuddin, M; Mulford, D; O'Dwyer, K; Phillips, GL; Rosell, K; Walker, A | 1 |
| Estey, EH; Gallegos, L; Gardner, KM; Hendrie, PC; Medeiros, BC; Orlowski, KF; Scott, BL; Walter, RB | 1 |
| Baer, MR; Bhatnagar, B; Chen, C; Duong, VH; Emadi, A; Gourdin, TS; Ning, Y; Sausville, EA; Tidwell, ML | 1 |
| Berenzon, D; Dralle, S; Ellis, LR; Isom, S; Klepin, HD; Lawrence, J; Lyerly, S; Manuel, M; Pardee, T; Powell, BL; Sliesoraitis, S; Tawfik, B | 1 |
| Fernández-Sojo, J; Oliveras Vilà, T; Ribera, JM; Vives, S | 1 |
| Aguilar-Guisado, M; Calderón, C; Espigado, I; Falantes, JF; González, J; Márquez-Malaver, FJ; Martín-Peña, A; Martino, ML; Montero, I; Parody, R; Pérez-Simón, JA | 1 |
| Arthur, C; Berrak, E; Delaunay, J; Jones, M; Kantarjian, HM; Thomas, XG | 1 |
| Cai, LL; Chi, XH; Li, SW; Lu, XC; Ran, HH; Wang, HT; Yang, B; Yang, Y; Yu, RL; Zhao, Y; Zhu, HL | 1 |
| Bueso-Ramos, C; Cortes, J; Davanlou, M; DiNardo, C; Estecio, MR; Fang, Z; Garcia-Manero, G; Geng, QR; Kantarjian, H; Nguyen, M; Parmar, S; Pierce, S; Wei, Y; Yang, H | 1 |
| Govindaraj, C; Plebanski, M; Spencer, A; Tan, P; Walker, P; Wei, A | 1 |
| Buchi, F; Gozzini, A; Masala, E; Rossi, A; Sanna, A; Santini, V; Spinelli, E; Valencia, A | 1 |
| Akasaka, T; Honjo, G; Izumi, K; Kishimori, C; Maesako, Y; Ohno, H; Okamori, S; Okumura, A; Takeoka, K | 1 |
| Dell'Aringa, J; Frankel, SR; Gudgeon, CJ; Harrington, KH; Kischel, R; Laszlo, GS; Means, GD; Newhall, KJ; Sinclair, AM; Walter, RB | 1 |
| Ades, L; Banos, A; Beve, B; Chait, Y; Chaury, MP; Cheze, S; Cluzeau, T; Dartigeas, C; Delaunay, J; Dombret, H; Dreyfus, F; Fenaux, P; Gardin, C; Guerci, A; Ifrah, N; Isnard, F; Itzykson, R; Marfaing Koka, A; Marolleau, JP; Morel, P; Pautas, C; Plantier, I; Quesnel, B; Raffoux, E; Recher, C; Seegers, V; Stamatoullas, A; Taksin, AL; Thépot, S; Thomas, X; Vey, N | 1 |
| Lübbert, M; Navada, SC; Silverman, LR; Steinmann, J | 1 |
| Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E | 1 |
| Ahmann, G; Azorsa, DO; Bogenberger, JM; Braggio, E; Camoriano, J; Cardone, M; Choudhary, A; Chow, D; Coombes, KR; Fauble, V; Gonzales, IM; Kornblau, SM; Lena, R; Mantei, J; Mesa, RA; Pierceall, WE; Qiu, YH; Shi, CX; Stewart, AK; Tibes, R; Tiedemann, RE; Valdez, R; Yin, H | 1 |
| Alhan, C; Buchi, F; Eeltink, C; Huls, G; Ossenkoppele, GJ; Santini, V; van de Loosdrecht, AA; van der Helm, LH; Westers, TM; Witte, BI | 1 |
| Al-Ali, HK; Jaekel, N; Niederwieser, D | 1 |
| Driscoll, H; Duarte, C; Peterson, S; Sathyanarayana, P; Ufkin, ML; Yang, X | 1 |
| Robak, T; Wierzbowska, A | 1 |
| Kearns, P; Leonard, SM; Perry, T; Woodman, CB | 1 |
| Tohyama, K | 1 |
| Arthur, C; Berrak, E; Delaunay, J; Jones, M; Kantarjian, HM; Li, Y; Mayer, J; Mazur, G; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Andreeff, M; Bogenberger, JM; Carter, BZ; Coombes, KR; Jacamo, RO; Kornblau, SM; Mak, DH; Mak, PY; McQueen, T; Mu, H; Qiu, Y; Shi, Y; Tibes, R; Yao, H | 1 |
| Almazmi, A; Benjamin, D; Enright, H; Evans, P; Frankova, H; Hameed, A; McHale, C; McHugh, J; Murphy, P; O'Connell, N; O'Gorman, P; O'Reilly, MA; Quinn, J; Sargent, J; Thornton, P; Verburgh, E | 1 |
| Bochtler, T; Dietrich, S; Dreger, P; Ho, AD; Krämer, A; Luft, T; Radujkovic, A; Schöning, T | 1 |
| Czader, M; Erba, HP; Figueroa, ME; Gabrilove, J; Gore, SD; Greenberg, PL; Herman, J; Juckett, M; Ketterling, R; Litzow, M; Malick, L; Melnick, A; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS | 1 |
| Cabrera, JR; de Laiglesia, A; de Pablo, R; Dorado, N; Forés, R; García-Marco, JA; Lario, A; Piris, M; Regidor, C; Vilches, C | 1 |
| Santini, V | 1 |
| Bauça, JM; López Andrade, B; Morell-García, D | 1 |
| Daskalakis, M; Hackanson, B | 1 |
| Florek, M; Müller, AM | 1 |
| Govindaraj, C; Kong, YY; Madondo, M; Plebanski, M; Tan, P; Wei, A | 1 |
| Fulp, WJ; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Rodriguez, Y; Tinsley, S; Yu, D | 1 |
| Andreu, R; Badiella, L; Bailén, A; Bargay, J; Brunet, S; Casaño, J; de Miguel, D; Falantes, JF; Figueredo, A; García-Delgado, R; González, JR; Jurado, AF; Medina, A; Ramos, F; Sanz, G; Tormo, M | 1 |
| Cuneo, A; Rigolin, GM | 1 |
| Adès, L; Bally, C; de The, H; Eclache, V; Fenaux, P; Lehmann-Che, J; Mozziconacci, MJ; Preudhomme, C; Renneville, A; Sebert, M | 1 |
| Schleiffenbaum, BE | 1 |
| Boku, S; Hosoda, T; Kagoo, T; Ohashi, K; Ueno, H; Yamamoto, R; Yano, T; Yokoyama, A; Yoneda, M | 1 |
| Schlenk, RF; Thol, F | 1 |
| Aparicio, S; Bullinger, L; Chaturvedi, A; Damm, F; Döhner, K; Ganser, A; Geffers, R; Heuser, M; Humphries, RK; Jyotsana, N; Lübbert, M; Schwarzer, A; Yap, D; Yun, H | 1 |
| Desjonqueres, A; Eveillard, M | 1 |
| Burgstaller, S; Eckmüllner, O; Geissler, D; Girschikofsky, M; Greil, R; Krippl, P; Lang, A; Linkesch, W; Machherndl-Spandl, S; Pfeilstocker, M; Pleyer, L; Schlick, K; Schreder, M; Sliwa, T; Sperr, WR; Stauder, R; Thaler, J; Theiler, G; Tinchon, C; Voskova, D | 1 |
| Blaser, R; Germing, U; Götze, K; Haferlach, T; Huberle, C; Kremer, M; Müller-Thomas, C; Peschel, C; Platzbecker, U; Rondak, IC; Rudelius, M; Schanz, J; Schmidt, B | 1 |
| Chen, Y; Duan, Y; Gu, X; Hao, J; Li, L; Liu, J; Liu, Z; Shen, Z; Wang, L; Wang, Y; Zhao, W | 1 |
| Cai, L; Chi, X; Li, S; Lu, X; Tuo, S; Wang, H; Wang, X; Wu, X; Yang, B; Yang, Y; Yu, R; Zhang, F; Zhu, H | 1 |
| Erba, HP; Gabrilove, J; Gore, SD; Greenberg, P; Juckett, M; Katterling, RP; Lee, JW; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS; Zeidan, AM | 1 |
| Honda, H; Inaba, T; Nagamachi, A | 1 |
| Bredeson, C; Eid, JE; Frankel, P; Gojo, I; Goldberg, SL; Issa, JP; Kirschbaum, M; Kujawski, LA; Lubiniecki, GM; Marks, P; Sun, X; Tosolini, A; Yang, A | 1 |
| Wiernik, PH | 1 |
| Dear, AE; Liu, HB; Spencer, A; Tan, P; Urbanavicius, D | 1 |
| Kanashima, H; Nakao, T; Sugiyama, H; Ueda, H; Yamane, T; Yoshida, M | 1 |
| Benjamin, HL; Fazal, S; Hilton, C; Khan, C; Lister, J; Rossetti, JM; Sadashiv, SK; Sahovic, E; Shadduck, RK | 1 |
| Cupelli, L; de Fabritiis, P; Del Poeta, G; Dentamaro, T; Giovannini, M; Niscola, P; Piccioni, D; Scaramucci, L; Tendas, A | 1 |
| Milne, TA | 1 |
| Bérard, E; Bertoli, S; Beyne-Rauzy, O; Bories, P; Delabesse, E; Duchayne, E; Huguet, F; Laurent, J; Récher, C; Sarry, A | 1 |
| Du, Y; Ji, C; Ji, M; Li, P; Lu, F; Ma, D; Ye, J | 1 |
| Collamat-Lai, G; Griffiths, EA; James, SR; Karbach, J; Karpf, AR; Matsuzaki, J; Nemeth, MJ; Paluch, BE; Srivastava, P; Taverna, P | 1 |
| Haferlach, T; Herr, W; Klobuch, S; Rehli, M; Reichle, A; Schelker, R; Thomas, S; Troppmann, M; Zaiss, S | 1 |
| Baer, MR; Bhatnagar, B; Chen, Q; Duong, VH; Tidwell, ML; Vannorsdall, EJ; Zandberg, DP | 1 |
| Adams, PD; Clark, W; Cole, JJ; Copland, M; Edwards, JR; Lund, K; McBryan, T; Pchelintsev, NA; VanderKraats, ND | 1 |
| Guryanova, OA; Levine, RL | 1 |
| Glasmacher, A; Meers, S; Mineur, P; Potier, H; Selleslag, D; Voelter, V | 1 |
| Kuendgen, A; Lübbert, M | 1 |
| Borthakur, G; Brandt, M; Cortes, J; Garcia-Manero, G; Huang, X; Issa, JP; Jabbour, E; Kantarjian, HM; Pierce, S; Ravandi, F | 1 |
| Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY | 2 |
| Fu, ZZ; Wang, J; Zheng, HF; Zhou, J | 1 |
| Li, HM; Zhang, R | 1 |
| Chen, S; Fu, Z; Gao, S; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D | 1 |
| Beguin, Y; Bries, G; Deeren, D; Graux, C; Meers, S; Mineur, P; Noens, L; Potier, H; Ravoet, C; Selleslag, D; Theunissen, K; Trullemans, F; Voelter, V; Vrelust, I | 1 |
| Adès, L; Beyne-Rauzy, O; Boehrer, S; Chermat, F; Delaunay, J; Fenaux, P; Hunault, M; Jourdan, E; Kroemer, G; Prebet, T; Raffoux, E; Sebert, M; Seegers, V; Thepot, S; Wattel, E | 1 |
| Calderón, C; Espigado, I; Falantes, JF; Gómez, M; González, J; Márquez-Malaver, FJ; Martín-Antonio, B; Martino, ML; Millán, A; Montero, I; Parody, R; Pérez-Simón, JA; Piruat, JI; Trujillo, P; Urbano-Ispizua, A | 1 |
| Berdel, WE; Edemir, B; Füller, M; Göllner, S; Klein, M; Müller-Tidow, C; Qianli, J; Rohde, C; Schmidt, E; Schulze, I; Tschanter, P | 1 |
| Löwenberg, B; Ossenkoppele, G | 1 |
| Abdel-Wahab, O; Ahn, J; Armstrong, SA; Chiosis, G; Chung, YR; Dogan, A; Hricik, T; Intlekofer, A; Levine, RL; Lipson, D; Manshouri, T; McKenney, AS; Miller, VA; Nahas, M; Otto, GA; Pandey, S; Park, CY; Rampal, R; Rapaport, F; Stephens, PJ; van den Brink, MR; Verstovsek, S; Wang, K; Yelensky, R | 1 |
| Aoki, J; Doki, N; Kakihana, K; Kobayashi, T; Najima, Y; Ohashi, K; Oshikawa, G; Saito, M; Sakamaki, H | 1 |
| Adès, L; Berthon, C; Bouscary, D; Caillot, D; Cluzeau, T; Dartigeas, C; Delaunay, J; Devidas, A; Dombret, H; Fenaux, P; Gardin, C; Guièze, R; Ifrah, N; Itzykson, R; Marolleau, JP; Plantier, I; Prébet, T; Recher, C; Stamatoullas, A; Taksin, AL; Thépot, S; Turlure, P; Vey, N | 1 |
| Andreeff, M; Borthakur, G; Cortes, J; Daver, N; Durand, M; Estrov, Z; Garcia-Manero, G; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Rajkhowa, T; Ravandi, F; Strati, P | 1 |
| Bhatt, VR | 1 |
| Beelen, DW; Bornhäuser, M; Bug, G; Czibere, A; Dienst, A; Fenk, R; Germing, U; Haas, R; Klein, S; Kobbe, G; Kondakci, M; Kröger, N; Luft, T; Nachtkamp, K; Platzbecker, U; Rachlis, E; Ringhoffer, M; Schroeder, T; Stadler, M; Steckel, NK; Stelljes, M; Uharek, L; Wolf, D | 1 |
| Ho, A; Lao, Z; Wong, GC; Yiu, R | 1 |
| Greil, R; Pleyer, L | 1 |
| Erba, HP | 1 |
| Cao, L; Fang, Q; Gao, R; Lu, T; Ma, D; Wang, J; Wang, P; Wu, W | 1 |
| Bargay, J; Burgstaller, S; Debén, G; Fenaux, P; Gaidano, G; Gardin, C; Greil, R; Itzykson, R; Martínez-Robles, V; Maurillo, L; Musto, P; Pleyer, L; Ramos, F; Récher, C; Sánchez-Guijo, F; Seegers, V; Stauder, R; Thépot, S; Venditti, A | 1 |
| Bohannan, Z; Borthakur, G; Bueso-Ramos, C; Chang, KS; DiNardo, CD; Estécio, MR; Fang, Z; Garcia-Manero, G; Kantarjian, H; Kondo, K; Maddipoti, S; Pierce, SA; Stevenson, W; Wei, Y; Yang, H | 1 |
| Baczyńska, D; Butrym, A; Kuliczkowski, K; Mazur, G; Rybka, J; Tukiendorf, A | 1 |
| Avery, S; Fleming, S; Govindaraj, C; McManus, J; Patil, S; Perruzza, S; Plebanski, M; Spencer, A; Stevenson, W; Tan, P; Wei, A | 1 |
| Carter-Cooper, B; Emadi, A; Etemadi, A; Faramand, R; Ford, LA; Griffiths, EA; Lapidus, RG; Tolu, S; Wang, ES; Wetzler, M | 1 |
| Mukherjee, S; Ornstein, MC; Sekeres, MA | 1 |
| Björkholm, M; de Jonge, N; Li, B; Xu, D; Zhang, X | 1 |
| Brandwein, J; Brian, L; Chen, EX; Degelder, T; Egorin, MJ; Espinoza-Delgado, I; Gupta, V; Haines, P; Holleran, JL; How, J; McGill, S; Minden, MD; Piekarz, R; Schimmer, AD; Schuh, AC; Siu, LL; Stayner, LA; Wang, L; Webster, S; Wong, T; Yee, KW | 1 |
| Bhatnagar, B; Blum, W; Devine, S; Garzon, R; Hofstetter, J; Kauffman, M; Klisovic, R; Marcucci, G; Phelps, MA; Ranganathan, P; Santhanam, R; Shacham, S; Vasu, S; Walker, A; Walsh, K; Yu, X | 1 |
| Chen, Y; Ding, J; Duan, L; Gu, J; Hong, M; Li, J; Li, Y; Liu, P; Lu, H; Pan, L; Qian, S; Qiu, H; Shi, J; Wang, J; Wu, H; Xu, J; Xu, Y; Yu, K; Zhang, R; Zhang, S; Zhou, J; Zhou, S; Zhu, H; Zhu, Y | 1 |
| Bertz, H; Bogatyreva, L; Finke, J; Lübbert, M; Marks, R; Steinmann, J; Wäsch, R; Zeiser, R | 1 |
| Cooper, BW; Craig, MD; Creger, RJ; Hamadani, M; Kindwall-Keller, TL; Lazarus, HM; Tse, WW | 1 |
| Ford, LA; Gandhi, S; Griffiths, EA; Gupta, N; Miller, A; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, TM; Kantarjian, H; Konopleva, M; Pierce, S; Ravandi, F; Wang, X | 1 |
| Akria, L; Arad, A; Aviv, A; Braester, A; Dally, N; Filanovsky, K; Gafter-Gvili, A; Gatt, ME; Hellmann, I; Herishanu, Y; Herzog-Tzarfati, K; Leiba, R; Merkel, D; Mittelman, M; Nagler, A; Nemets, A; Ofran, Y; Ronson, A; Rouvio, O; Silbershatz, I; Tadmor, T; Vidal, L; Yeganeh, S | 2 |
| Choi, WW; Chow, HC; Gill, H; Ip, AH; Kwong, YL; Leung, AY; Man, CH | 1 |
| Friis, LS; Grønbæk, K; Hokland, M; Holm, MS; Skovbo, A; Treppendahl, MB; Ørskov, AD | 1 |
| Chen, XH; Gao, L; Kong, PY; Liu, J; Liu, Y; Zhang, C; Zhang, X | 1 |
| Bohannan, Z; Cabrero, M; Garcia-Manero, G; Jabbour, E; Kantarjian, HM; Pierce, S; Ravandi, F | 1 |
| Berda, Y; Ciccolini, J; Costello, R; Fanciullino, R; Fina, F; Lacarelle, B; Mercier, C; Ouafik, L; Serdjebi, C | 1 |
| Arthur, C; Delaunay, J; Dmoszynska, A; Kadia, TM; Kantarjian, H; Minden, M; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Chevassut, T; Cho, IH; Choudhury, SR; Chowdhury, B; Cooper, B; Cui, Y; Irudayaraj, J; Lossie, AC; McGovern, A | 1 |
| Amigo, ML; Ardanaz, MT; Bargay, J; Benlloch, L; Bernal, T; Brunet, S; de Paz, R; del Cañizo, C; Luño, E; Martínez-Camblor, P; Nomdedeu, B; Pedro, C; Sánchez-García, J; Sanz, G; Tormo, M; Valcárcel, D; Xicoy, B | 1 |
| Chan, TS; Chau, D; Cheng, YY; Fong, B; Kwong, YL; Ng, K; Tam, S; Tse, E | 1 |
| Al-Ali, HK; Beach, CL; Bernal del Castillo, T; Butrym, A; Candoni, A; Cavenagh, J; Döhner, H; Dombret, H; Falantes, J; Jang, JH; Kumar, R; Lucy, LM; Martinelli, G; McIntyre, H; Minden, MD; Noppeney, R; Récher, C; Sandhu, I; Schuh, AC; Selleslag, D; Seymour, JF; Songer, S; Stone, RM; Wierzbowska, A | 1 |
| Cieslik, C; Döhner, K; Grishina, O; Hackanson, B; Lübbert, M; Lubrich, B; May, AM; Müller, MJ; Schmoor, C | 1 |
| Breier, A; Imrichova, D; Kavcova, H; Messingerova, L; Sulova, Z; Turakova, K | 1 |
| Aloe-Spiriti, MA; Breccia, M; Buccisano, F; Criscuolo, M; Fenu, S; Fianchi, L; Filardi, N; Fragasso, A; Latagliata, R; Mansueto, G; Maurillo, L; Musto, P; Niscola, P; Pagano, L; Piccioni, AL; Piciocchi, A; Tendas, A; Venditti, A; Voso, MT; Zini, G | 1 |
| Abboud, CN; Cashen, AF; Choi, J; DiPersio, JF; Fiala, MA; Gao, F; Holt, M; Jacoby, MA; Pusic, I; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Westervelt, P | 1 |
| Fu, C; Han, Y; Jin, Z; Liu, H; Ma, L; Miao, M; Qiu, H; Tang, X; Wang, J; Wang, P; Wu, D; Yan, S; Zheng, H; Zhou, J | 1 |
| De Castro, CM; Griffin, PT; Komrokji, RS; Lancet, JE; List, AF; Melchert, M; Rizzieri, DA | 1 |
| Laufer, CB; Roberts, O | 1 |
| Berthon, C; Delaunay, J; Dreyfus, F; Esterni, B; Fenaux, P; Itzykson, R; Kulasekararaj, A; Micol, JB; Mufti, G; Prebet, T; Recher, C; Roux, C; Sebert, M; Thepot, S; Vey, N; Wanquet, A | 1 |
| Huls, G | 1 |
| Deng, ZQ; Guo, H; Lin, J; Ma, JC; Qian, J; Wen, XM; Yang, J; Yang, L; Yin, JY; Zhang, M; Zhang, YY; Zhu, XW | 1 |
| Angelucci, E; Barraqueddu, F; Contini, S; Corda, G; Dore, F; Fozza, C; Galleu, A; Isoni, A; Longinotti, M; Virdis, P | 1 |
| Bazani, E; Bouchla, A; Dimitriadis, G; Foukas, P; Ioannidou, ED; Kefala, M; Kontos, CK; Papageorgiou, SG; Pappa, V; Vasilatou, D | 1 |
| Bakarakos, P; Diamantopoulos, P; Dimitrakopoulou, A; Galanopoulos, A; Giannakopoulou, N; Iliakis, T; Kalala, F; Papadopoulou, V; Rougala, N; Variami, E; Viniou, NA; Zervakis, K | 1 |
| Costa, S; Javier, KP; Linares, M; Orero, M; Ortiz, S; Pérez, PL; Roig, M; Villegas, C | 1 |
| Kobbe, G; Schroeder, T | 1 |
| Braulke, F; Ganster, C; Haase, D; Platzbecker, U; Salinas-Riester, G; Schanz, J; Shirneshan, K | 1 |
| Auboeuf, D; Balsat, M; Campos, L; Cheok, M; Cros, E; Dumontet, C; El-Hamri, M; Flandrin-Gresta, P; Guyotat, D; Koering, C; Michallet, M; Mohamed, AM; Mortada, H; Mortreux, F; Nibourel, O; Nicolini, F; Payen-Gay, L; Pinatel, C; Preudhomme, C; Solly, F; Thenoz, M; Thomas, X; Wattel, E | 1 |
| Garcia-Manero, G | 1 |
| Cogle, CR; Garcia-Manero, G; Gore, SD; Hetzer, J; Kumar, K; Laille, E; MacBeth, KJ; Shi, T; Skikne, B | 1 |
| Azab, M; Chung, W; Daver, N; Griffiths, EA; Hao, Y; Issa, JJ; Jabbour, E; Kantarjian, H; Lowder, JN; Naim, S; O'Connell, C; Oganesian, A; Rizzieri, D; Roboz, G; Stock, W; Taverna, P; Tibes, R; Walsh, K; Yee, K | 1 |
| Kharfan-Dabaja, MA | 1 |
| Ford, LA; Freyer, CW; Griffiths, EA; Muppidi, MR; Portwood, S; Thompson, JE; Wang, ES; Wetzler, M | 1 |
| Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL | 1 |
| Fujii, S; Fujita, M; Iyama, S; Jomen, W; Kanari, Y; Kato, J; Kuroda, H; Maeda, M; Sato, M; Shimoyama, S; Usami, M; Yamada, M; Yoshida, M | 1 |
| Ocqueteau Tachini, M; Pilcante, J; Ramírez Villanueva, P; Sarmiento Maldonado, M | 1 |
| Buka, R; Byrne, J; Craddock, C; Crawley, C; Dennis, M; Ferguson, P; Goodyear, O; Hazlewood, P; Jilani, N; Khan, J; Malladi, R; Nagra, S; Russell, N; Siddique, S; Snowden, J; Tholouli, E; Vyas, P; Ward, J; Yap, C | 1 |
| Borthakur, G; Cortes, J; Daver, N; Diaz-Pines-Mateo, M; Dinardo, C; Estey, E; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Pemmaraju, N; Pierce, S; Ravandi, F; Verstovsek, S; Wang, X | 1 |
| De Porre, P; Diels, J; Güntert, A; Lange, A; Tapprich, C; Thilakarathne, P; Tomeczkowski, J; Xiu, L | 1 |
| Advani, AS; Beausoleil, SA; Carew, JS; Carraway, HE; Espitia, CM; Han, Y; Kelly, KR; Maciejewski, JP; Nawrocki, ST; Nazha, A; Possemato, A; Sekeres, MA; Visconte, V | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Berube, C; Cardone, MH; Coutre, S; Doykan, C; Garcia, JS; Gotlib, J; Greenberg, P; Hewitt, R; Liedtke, M; McMillan, A; Medeiros, BC; Narayan, R; Percival, ME; Regan, K; Williamson, C | 1 |
| Tan, H; Wang, C; Xie, B; Xu, J; Yu, B; Zheng, R | 1 |
| Carter, BZ; Dai, M; Ding, B; Jiang, L; Jiang, X; Liang, S; Liu, Q; Meng, F; Wang, Z; Ye, J; Yin, C; Yu, G; Zhang, Y; Zhao, Q; Zhong, Q | 1 |
| Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y | 1 |
| Benz, R; Gemuenden, C; Gerber, B; Goede, JS; Manz, MG; Senn, O | 1 |
| Boyd, T; Cogle, CR; Garcia-Manero, G; Scott, BL | 1 |
| Chandra, S; Dahl, NA; McMasters, RL; Michaels, ST; O'Brien, MM | 1 |
| Baldus, CD; Berdel, WE; Brümmendorf, TH; Butterfaß-Bahloul, T; Dugas, M; Ehninger, G; Eveslage, M; Frickhofen, N; Gerss, J; Giagounidis, A; Görner, M; Götze, K; Hänel, M; Herr, W; Kaiser, U; Kaufmann, M; Kiani, A; Kiehl, M; Koschmieder, A; Koschmieder, S; Krause, SW; Krug, U; Kunzmann, V; Link, H; Müller-Tidow, C; Naumann, R; Neubauer, A; Noppeney, R; Peceny, R; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schmitz, N; Serve, H; Steffen, B; Stelljes, M; Thiede, C; Thiem, U; Tschanter, P; Wagner, R | 1 |
| Issa, JP; Lowder, JN; Taverna, P | 1 |
| Al-Jamal, HA; Hassan, R; Johan, MF; Mat Jusoh, SA | 1 |
| Becker, PS; Dean, C; Deeg, HJ; Estey, E; Hendrie, P; Mawad, R; Myint, H; Pagel, JM; Sandhu, V; Scott, B; Singer, JW; Walter, R; Wang, L; Wood, BL | 1 |
| Czader, M; Erba, HP; Figueroa, M; Gabrilove, J; Gore, SD; Greenberg, P; Herman, J; Juckett, M; Ketterling, RP; Litzow, M; Malick, L; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS; Zeidan, A | 1 |
| Ades, L; Bemba, M; Berthon, C; Desoutter, J; Duhamel, A; Fenaux, P; Fernandes, J; Figeac, M; Frimat, C; Gay, J; Geffroy, S; Gruson, B; Helevaut, N; Labreuche, J; Marceau, A; Nibourel, O; Plantier, I; Preudhomme, C; Quesnel, B; Renneville, A; Roumier, C; Stalnikiewicz, L | 1 |
| Dai, Y; He, HS; Huang, DP; Huang, LQ; Jiang, YZ; Su, GP; Sun, ZM | 1 |
| Chang, E; Ganguly, S; Gocke, CD; Konig, H; Levis, M; Rajkhowa, T | 1 |
| Borthakur, G; Bueso-Ramos, C; Cortes, JE; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, M; Patel, KP; Pemmaraju, N; Pierce, S; Ravandi, F; Wierda, W; Yang, H | 1 |
| Adamopoulos, PG; Galanopoulos, AG; Garypidou, V; Hatjiharissi, E; Kontos, CK; Kotsianidis, I; Lamprianidou, E; Miltiades, P; Nakou, E; Papadaki, HA; Papageorgiou, SG; Papaioannou, M; Pappa, V; Scorilas, A; Spanoudakis, E; Tsatalas, C; Vakalopoulou, S; Vassilakopoulos, TP | 1 |
| Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z | 1 |
| Al-Kali, A; Baidoun, F; Elliott, M; Hashmi, S; Hogan, W; Hreh, M; Litzow, M; Patnaik, M; Subari, S | 1 |
| Almeida, A; Falantes, J; Garcia-Manero, G; Jang, JH; Kantarjian, H; Marlton, P; Mohan, S; Montesinos, P; Porkka, K; Ravandi, F; Roboz, GJ; Sayar, H; Selleslag, D; Skikne, B; Voso, MT; Wei, A | 1 |
| Achille, NJ; Appelbaum, FR; Cooper, K; Erba, HP; Godwin, JE; Nand, S; Othus, M; Phelan, K; Radich, JP; Zeleznik-Le, NJ; Zhang, S | 1 |
| Deng, M; Li, R; Li, Z; Xiao, X; Yang, J; Zhang, G | 1 |
| Fu, JX; Ju, SG; Li, J; Sun, Y; Wang, ZY; Yuan, YQ; Zhang, LY; Zhou, DM | 1 |
| Arceci, RJ; Elmoneim, AA; Heuston, E; Triche, T; Wai, DH | 1 |
| Bernardi, M; Borin, L; Cairoli, R; Caramazza, D; Della Porta, M; Freyrie, A; Gigli, F; Greco, R; Guarco, S; Mariotti, J; Molteni, A; Morra, E; Nichelatti, M; Pelizzari, AM; Quaresmini, G; Ravano, E; Riva, M; Ubezio, M | 1 |
| Bär, B; Blijlevens, NNM; Bremmers, MEJ; Cruijsen, M; Dolstra, H; Falkenburg, JHF; Hobo, W; Huls, G; Jansen, J; Kester, M; Schaap, NPM; van der Velden, WJFM; Woestenenk, R | 1 |
| Bainschab, A; Greinix, HT; Krause, R; Quehenberger, F; Sill, H; Wölfler, A; Zebisch, A | 1 |
| Al Ali, NH; Bart-Smith, E; Craig, BM; Epling-Burnette, PK; Komrokji, RS; Kordasti, S; Kulasekararaj, A; Lancet, JE; List, AF; Mufti, GJ; Padron, E; Pinilla-Ibarz, J; Zhang, L | 1 |
| Blagitko-Dorfs, N; Collamat-Lai, G; Ford, LA; Griffiths, EA; James, SR; Karpf, AR; Lübbert, M; Matsuzaki, J; Naqash, R; Nemeth, MJ; Paluch, BE; Srivastava, P | 1 |
| Dreger, P; Ho, AD; Luft, T; Radujkovic, A; Schnitzler, P | 1 |
| He, L; Liu, FZ; Wang, JS; Zhang, S; Zhu, HQ | 1 |
| Gojo, I; Malla, M; Newman, M | 1 |
| Leitch, HA; Tsang, E | 1 |
| Deng, C; Du, X; Geng, S; Huang, X; Li, M; Lu, Z; Tong, J; Weng, J; Wu, P; Yao, H | 1 |
| Adam, PJ; Blum, W; Borges, E; Bucci, D; Caligiuri, MA; Cheney, C; Gopalakrishnan, B; Groh, V; He, S; Heider, KH; Konopitzky, R; Kössl, C; Lozanski, G; Lucas, DM; Mani, R; Marcucci, G; Mo, X; Muthusamy, N; Rueter, B; Vasu, S; Whitman, SP; Yu, J | 1 |
| Arnan, M; Duarte, RF; Pomares, H; Sánchez-Ortega, I; Sureda, A | 1 |
| Blaise, D; Bourhis, JH; Chevallier, P; Craddock, C; Finke, J; Hallek, M; Kröger, N; Labopin, M; Luft, T; Mohty, M; Nagler, A; Robin, M; Sengelov, H; Yakoub-Agha, I | 1 |
| Béhanzin, E; Bowen, D; Demolis, P; Flores, B; Gisselbrecht, C; Hudson, I; Moreau, A; Nieto, M; Pignatti, F; Salmonson, T; Stemplewski, H | 1 |
| Akay, OM; Akdeniz, A; Berber, İ; Doğu, MH; Erkurt, MA; Fıratlı Tuğlular, T; Gören Şahin, D; Gürkan, E; Kaynar, L; Kis, C; Mehtap, Ö; Merter, M; Nevruz, O; Özcan, M; Özcan, MA; Şahin, F; Salim, O; Sarı, İ; Solmaz, ŞM; Sungur, MA; Tarkun, P; Tiftik, EN; Tombak, A; Uçar, MA; Uysal, A; Yavaşoğlu, İ; Yıldırım, M; Yıldırım, R; Yıldızhan, E | 1 |
| Atagunduz, IK; Avsar, E; Deveci, B; Ferhanoglu, B; Geduk, A; Kara, O; Kurtoglu, E; Mehtap, O; Ozturk, E; Salim, O; Tiftik, EN; Tombak, A; Toptas, T; Tuglular, TF; Undar, L; Yucel, OK | 1 |
| Dong, W; Gu, W; Hua, X; Li, H; Lin, Y; Ling, Y; Wu, W; Xiang, L; Xie, X; Yan, F | 1 |
| Scott, LJ | 1 |
| Alam, M; Avigan, D; Bouillez, A; Gali, R; Kharbanda, S; Kufe, D; Rajabi, H; Stone, R; Stroopinsky, D; Tagde, A | 1 |
| Cowan, L; Filshie, R; Hertzberg, M; Ho, SJ; Kenealy, M; Link, E; Mills, T; Nicol, A; Patton, N; Prosser, I; Seymour, JF; Zannino, D | 1 |
| Abraham, I; Fernandez-Zapico, ME; Patnaik, MM; Robertson, KD; Vincelette, ND; Yun, S | 1 |
| Hu, W; Jiang, Q; Kong, X; Li, Y; Lv, C; Yang, L; Zhang, Y | 1 |
| Cermak, J; Hajkova, H; Jonasova, A; Klema, J; Merkerova, MD; Monika Belickova, M; Pejsova, B; Valka, J; Vesela, J; Votavova, H | 1 |
| Alvarez, M; Duarte, AD; Lazarini, M; Machado-Neto, JA; Niemann, FS; Pericole, FV; Saad, ST; Traina, F; Vieira, KP | 1 |
| Dasanu, CA; Keating, M | 1 |
| Basak, GW; Drozd-Sokołowska, J; Dutka, M; Dwilewicz-Trojaczek, J; Gil, L; Karakulska-Prystupiuk, E; Mądry, K; Piekarska, A; Waszczuk-Gajda, A | 1 |
| Abboud, C; Cashen, A; Choi, J; DiPersio, J; Eissenberg, LG; Fiala, MA; Fletcher, T; Ghobadi, A; Jacoby, M; Liu, J; Pusic, I; Schroeder, MA; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P | 1 |
| Altman, J; Dinner, S; Frankfurt, O; Gao, J; Helenowski, I; McMahon, BJ; Stein, BL; Waisbren, J | 1 |
| Liu, H; Sun, Z; Tang, B; Tong, J; Zhang, L; Zhang, X; Zheng, C; Zhou, H; Zhu, X | 1 |
| Baer, MR; Bloomfield, CD; Blum, W; DeAngelo, DJ; Geyer, S; Hoke, E; Klisovic, R; Kohlschmidt, J; Kolitz, JE; Larson, RA; Marcucci, G; Mrózek, K; Powell, BL; Sanford, BL; Stock, W; Stone, RM; Uy, G; Wang, ES | 1 |
| Aoyama, K; Choi, K; Hasegawa, N; Iseki, T; Isshiki, Y; Iwama, A; Kawajiri-Manako, C; Koide, S; Mimura, N; Muto, T; Nagao, Y; Nakaseko, C; Ohwada, C; Sakai, S; Sakaida, E; Shimizu, R; Starczynowski, DT; Takeda, Y; Takeuchi, M; Togasaki, E; Tsukamoto, S; Yokote, K | 1 |
| Beach, CL; Döhner, H; Dombret, H; Dougherty, D; Gambini, D; Minden, MD; Seymour, JF; Stone, R; Weaver, J | 1 |
| Cooper, C; Hoyle, MW; Mujica Mota, RE; Rudin, CE; Snowsill, TM; Tikhonova, IA; Varley-Campbell, JL | 1 |
| Alvares, C; Chakraborty, M; Conner, C; Gosrani, D; Mahdi, AJ; Rayment, R; Rees, A; Wilson, K | 1 |
| Lu, SY; Wang, C; Wang, Z; Zhao, XH; Zhou, ZH | 1 |
| Deeg, HJ; Fang, M; Mielcarek, M; Scott, BL; Storer, B; Woo, J; Yeung, C | 1 |
| Gornicec, M; Sill, H; Stanzel, S; Wölfler, A; Zebisch, A | 1 |
| Marconi, G; Martinelli, G; Ottaviani, E; Paolini, S; Papayannidis, C; Parisi, S; Sartor, C; Simonetti, G; Tenti, E; Testoni, N | 1 |
| Cheong, JW; Chung, H; Jang, J; Kim, JS; Kim, SJ; Kim, Y; Lee, J; Min, YH; Park, H | 1 |
| Adès, L; Auberger, P; Campos, L; Cornillon, J; Fenaux, P; Flandrin-Gresta, P; Guyotat, D; Koering, C; Kosmider, O; Maucort-Boulch, D; Mohamed, AM; Mortreux, F; Robert, G; Solly, F; Tavernier-Tardy, E; Wattel, E | 1 |
| Dienst, A; Germing, U; Haas, R; Heyn, C; Kobbe, G; Kondakci, M; Nachtkamp, K; Rautenberg, C; Schmidt, PV; Schroeder, T | 1 |
| Becker, H; Bissé, E; Bogatyreva, L; Claus, R; Ihorst, G; Lübbert, M; Sander, PN; Suciu, S; Wijermans, PW | 1 |
| Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Kusaba, K; Nishioka, A; Sano, H; Shindo, T; Ureshino, H | 1 |
| Chua, N; Saini, L | 1 |
| Abboud, CN; Baty, JD; Cashen, AF; DiPersio, JF; Duncavage, EJ; Fehniger, TA; Fronick, CC; Fulton, RS; Ghobadi, A; Graubert, TA; Hantel, A; Heath, SE; Jacoby, MA; Janke, MR; Khan, N; Knoebel, RW; Lee, YS; Ley, TJ; Link, DC; Luber, K; Miller, CA; O'Laughlin, M; Oh, ST; Petti, AA; Pusic, I; Romee, R; Schroeder, MA; Stock, W; Stockerl-Goldstein, KE; Sukhanova, MJ; Tandon, B; Tomasson, MH; Uy, GL; Vij, R; Walter, MJ; Wartman, LD; Welch, JS; Westervelt, P; Wilson, RK | 1 |
| Abu-Arja, R; Abusin, G; Cabral, L; Ding, H; Hashem, H; Lazarus, HM; Rangarajan, H | 1 |
| Chang, CK; Guo, J; He, Q; Li, X; Song, LX; Su, JY; Wu, D; Wu, LY; Xiao, C; Xu, F; Zhang, Z; Zhao, YS | 1 |
| Hagihara, M; Hua, J; Inoue, M; Uchida, T | 1 |
| Choi, DR; Choi, Y; Chung, YJ; Goo, BK; Hur, EH; Jung, SH; Lee, JH; Moon, J | 1 |
| Avivi, I; Gatt, M; Helman, I; Inbar, T; Merkel, D; Nagler, A; Ofran, Y; Ram, R | 1 |
| Abdelkarim, M; Blagitko-Dorfs, N; Bullinger, L; Döhner, K; Duyster, J; Gaidzik, VI; Hackanson, B; Hiller, JK; Lübbert, M; Schmidt-Salzmann, C; Schmoor, C; Yalcin, A | 1 |
| Huang, P; Jarpe, MB; Jones, SS; Min, C; Moore, N; Quayle, SN; Shearstone, JR; van Duzer, JH; Yang, M | 1 |
| Cashen, AF; DiPersio, JF; Duncavage, EJ; Fronick, CC; Fulton, RS; Gao, F; Jacoby, MA; Lee, YS; Ley, TJ; Link, DC; Miller, CA; O'Laughlin, M; Petti, AA; Tandon, B; Uy, GL; Walter, MJ; Wartman, LD; Welch, JS; Westervelt, P; Wilson, RK | 1 |
| Annereau, M; Auger, N; Bermudez, E; Chahine, C; Danu, A; de Botton, S; Desmaris, RP; El Halabi, L; Ghez, D; Lazarovici, J; Leary, A; Lemare, F; Micol, JB; Pistilli, B; Saada, V; Solary, E; Willekens, C | 1 |
| Akın Belli, A; Dere, Y; Kara, A; Karakuş, V; Kurtoğlu, E | 1 |
| Chen, Y; Huang, J; Li, J; Li, Y; Lian, Y; Qian, S; Wu, Y; Xie, Y; Zhang, X; Zhao, H; Zhu, Y | 1 |
| Stahl, M; Zeidan, AM | 1 |
| Garrett-Bakelman, FE; Glass, J; Gliser, C; Intlekofer, AM; Knapp, K; Levine, RL; Mason, CE; Melnick, A; Meydan, C; Nazir, A; Shank, K; Shih, AH; Stein, EM; Straley, K; Thompson, CB; Travins, J; Ward, PS; Yen, K | 1 |
| Blaise, D; Charbonnier, A; D'Incan, E; Mohty, B; Rey, J; Sid, S; Vey, N | 1 |
| Deeg, HJ; Fang, M; Howard, NP; Scott, BL; Storer, BE; Woo, J; Yeung, CC | 1 |
| Andel, J; Autzinger, EM; Beach, CL; Burgstaller, S; Döhner, H; Dombret, H; Geissler, K; Girschikofsky, M; Greil, R; Halter, B; Hojas, S; Lang, A; Machherndl Spandl, S; Pfeilstöcker, M; Pichler, A; Pleyer, L; Rogulj, IM; Schlick, K; Schuh, AC; Seymour, JF; Sill, H; Sperr, WR; Stauder, R; Swern, AS; Thaler, J; Voskova, D; Zebisch, A | 1 |
| Dickinson, M; Seymour, JF; Slavin, MA; Spelman, T; Thursky, KA; Trubiano, JA; Worth, LJ | 1 |
| Artz, A; Churpek, JE; Godley, LA; Hantel, A; Khan, N; King, D; Knoebel, RW; Larson, RA; Liu, H; Odenike, O; Stock, W; Thirman, MJ | 1 |
| Bohl, SR; Bullinger, L; Claus, R; Döhner, H; Döhner, K; Dolnik, A; Gaidzik, VI; Hackanson, B; Jensen, T; Knudsen, S; Lang, KM; Lübbert, M; Paschka, P | 1 |
| Dombret, H; Gardin, C | 1 |
| Garcia-Manero, G; Kantarjian, H; Sharma, S; Stoltz, ML; Ward, MR | 1 |
| Adès, L; Boehrer, S; de Botton, S; Fabre, C; Fenaux, P; Grosjean, J; Kroemer, G; Perfettini, JL; Tailler, M | 1 |
| Atadja, P; Bhalla, K; Chen, J; Eaton, K; Fernandez, P; Fiskus, W; Herger, B; Joshi, R; Kolhe, R; Lee, P; Mandawat, A; Peiper, S; Rao, R; Wang, Y; Yang, Y | 1 |
| Estey, E | 1 |
| Götze, KS; Müller-Thomas, C; Peschel, C; Schuster, T | 1 |
| Büsche, G; Dobbelstein, C; Fenner, M; Ganser, A; Hasemeier, B; Krauter, J; Kreipe, H; Lehmann, U; Metzig, K; Römermann, D; Steinemann, D | 1 |
| Ali, F; Galili, N; Lascher, S; Mehdi, M; Mumtaz, M; Raza, A | 1 |
| DeRemer, DL; Farrow, S; Jillella, A; Kalla, A; Ustun, C | 1 |
| Baer, MR; James, SR; Jones, DA; Karpf, AR; Link, PA | 1 |
| Alkan, S; Barton, K; Germano, E; Godwin, J; Michaelis, L; Nand, S; Rychlik, K; Smith, S; Stiff, P; Veerappan, R | 1 |
| Batz, C; Claus, R; Flotho, C; Ihde, S; Lübbert, M; Niemeyer, CM; Plass, C; Sandrock, I; Schneider, M | 1 |
| Gore, SD | 1 |
| Karp, J | 1 |
| Rao, Q; Wang, J; Wang, L; Wang, M; Wang, Y; Xu, Z; Zhao, X | 1 |
| Atadja, P; Balusu, R; Bhalla, KN; Buckley, K; Chen, J; Fiskus, W; Joshi, A; Joshi, R; Koul, S; Mandawat, A; Rao, R; Upadhyay, S; Wang, Y; Yang, Y | 1 |
| Bertz, H; Claus, R; Finke, J; Lübbert, M; Marks, R; Rüter, B; Wäsch, R | 2 |
| Barragán, E; Bolufer, P; Cervera, J; Moscardó, F; Román-Gómez, J; Sanz, GF; Sanz, MA; Such, E; Valencia, A | 1 |
| Chowdhury, S; Marks, PW; Seropian, S | 1 |
| Carraway, H; Fandy, TE; Fernandez, H; Figueroa, ME; Gore, SD; Greally, JM; Jiemjit, A; Li, Y; Licht, JD; Melnick, A; Paietta, E; Skrabanek, L; Tallman, MS | 1 |
| Abramowtiz, M; Alencar, C; Braunshweig, I; Jacobson, M; Parekh, S; Silverman, L; Verma, A | 1 |
| Bandzuchova, E; Demitrovicova, L; Mistrik, M; Polakova, K; Russ, G; Sabty, FA | 1 |
| Dey, BR; Hasserjian, RP; Spitzer, TR | 1 |
| Bornhäuser, M; Ehninger, G; Kiani, A; Platzbecker, U; Thiede, C; Wermke, M | 1 |
| Borthakur, G; Cortes, J; Faderl, S; Garcia-Manero, G; Issa, JP; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Shan, J; Verstovsek, S | 1 |
| Baccarani, M; Bosi, C; Chiarini, F; Clissa, C; Cocco, L; Finelli, C; Follo, MY; Manzoli, L; Martelli, AM; Martinelli, G; Mongiorgi, S; Ramazzotti, G; Testoni, N | 1 |
| Bruns, I; Czibere, A; Fenk, R; Germing, U; Gräf, T; Haas, R; Kobbe, G; Kröger, N; Lind, J; Platzbecker, U; Schröder, T; Zohren, F | 1 |
| Dirks, WG; Drexler, HG; Marschalek, R; Meyer, C; Quentmeier, H; Röhrs, S; Scherr, M; Slany, R; Wallace, A | 1 |
| DeCoteau, JF; Geyer, CR; Lakshmikuttyamma, A; Scott, SA | 1 |
| Keating, GM | 2 |
| Berry, D; Borthakur, G; Faderl, S; Ferrajoli, A; Huang, X; Issa, JP; Kantarjian, H; Morris, G; Ravandi, F; Torma, R | 1 |
| Cashen, AF; DiPersio, JF; O'Donnell, MR; Schiller, GJ | 1 |
| Backstrom, J; Beach, CL; Dombret, H; Fenaux, P; Gattermann, N; Germing, U; Gore, S; Hellström-Lindberg, E; List, AF; McKenzie, D; Mufti, GJ; Santini, V; Sanz, G; Seymour, JF; Silverman, LR; Zimmerman, L | 1 |
| Büchner, T; Krug, U; Lübbert, M | 1 |
| Blagitko-Dorfs, N; Daskalakis, M; Hackanson, B | 1 |
| Anders, V; Bolaños-Meade, J; Villela, L | 1 |
| Becker, H; Bloomfield, CD; Blum, W; Byrd, JC; Chan, KK; Croce, CM; Devine, H; Devine, SM; Garzon, R; Geyer, S; Grever, MR; Havelange, V; Heerema, NA; Kefauver, C; Klisovic, RB; Liu, S; Marcucci, G; Mickle, J; Schaaf, L; Schwind, S; Villalona-Calero, M; Walker, A | 1 |
| Almstedt, M; Blagitko-Dorfs, N; Duque-Afonso, J; Jäger, E; Karbach, J; Lübbert, M; Pfeifer, D | 1 |
| Rogers, BB | 1 |
| Aggerholm, A; Antunovic, P; Astermark, J; Bernell, P; Engström, LM; Grövdal, M; Hellström-Lindberg, E; Hokland, P; Holm, MS; Jacobsen, SE; Karimi, M; Khan, R; Kjeldsen, L; Linder, O; Nilsson, L; Oberg, G; Olsson, A; Porwit, A; Tangen, JM; Wallvik, J | 1 |
| Connock, M; Edlin, R; Fry-Smith, A; Greenheld, W; Hyde, C; Round, J; Tubeuf, S | 1 |
| Batty, GN; Cortés, JE; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; McCue, D; O'Brien, S; Pierce, S; Ravandi, F; Santos, FP | 1 |
| Adès, L; Chait, Y; Cluzeau, T; Dartigeas, C; Delaunay, J; Dreyfus, F; Eclache, V; Fenaux, P; Harel, S; Itzykson, R; Kiladjian, JJ; Quesnel, B; Raffoux, E; Salanoubat, C; Sanhes, L; Seegers, V; Sorin, L; Thepot, S; Turlure, P | 1 |
| Braun, TM; Champlin, R; de Lima, M; de Padua Silva, L; Garcia-Manero, G; Giralt, S; Jones, RB; Komanduri, K; Nguyen, HQ; Thall, PF | 1 |
| Li, C; Li, M; Peng, F; Ruan, L; Tan, T; Tang, C; Xiao, Y; Xiao, Z; Yi, H; Zhang, P | 1 |
| Hofmann, WK; Nolte, F | 1 |
| Garcia-Manero, G; Martin-Santos, T; Vigil, CE | 1 |
| Criscuolo, M; D'alo', F; Fabiani, E; Giachelia, M; Greco, M; Guidi, F; Hohaus, S; Leone, G; Rutella, S; Voso, MT | 1 |
| Bauer, F; Bilgrami, S; Boruchov, A; Mulay, S | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Calin, GA; Fang, Z; Garcia-Manero, G; Hu, Y; Kantarjian, HM; Wei, Y; Yang, H | 1 |
| Ferrara, F; Musto, P | 2 |
| Boëlle, PY; Chevret, S; Chomienne, C; Cras, A; Daniel, MT; de Labarthe, A; Degos, L; Dombret, H; Fenaux, P; Gardin, C; Maarek, O; Malfuson, JV; Marolleau, JP; Maury, S; Raffoux, E; Recher, C; Reman, O; Rousselot, P; Turlure, P; Victor, M | 1 |
| Fleurence, R; Kim, E; Knopf, K; Linnehan, JE; Pan, F; Peng, S | 1 |
| Ar, C; Atesoglu, EB; Bekoz, H; Cetiner, M; Ferhanoglu, B; Ozbalak, M; Salihoglu, A; Tuzuner, N | 1 |
| Baer, MR; Gojo, I | 1 |
| Gao, L; Gao, XN; Kang, HY; Li, YH; Lin, J; Wang, LL; Wang, W; Wang, XR; Yan, GT; Yu, L | 1 |
| Bayraktar, UD; Domingo, GC; Pereira, D; Schmit, J | 1 |
| Sanchez, JF | 1 |
| Font, P | 1 |
| de Marcos, NS; Font, P; Molina, CA; Rodríguez, MJ | 1 |
| Adès, L; Beyne-Rauzy, O; Cluzeau, T; Dreyfus, F; Fenaux, P; Fontenay, M; Gelsi-Boyer, V; Itzykson, R; Kosmider, O; Mansat-De Mas, V; Preudhomme, C; Quesnel, B; Raynaud, S; Vey, N | 1 |
| Bryan, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H | 1 |
| Chim, CS; Chung, LP; Jin, DY; Lam, WW; Li, GK; Liang, R; Loong, F; So, CC; Wong, KY | 1 |
| Ikezoe, T; Nishioka, C; Udaka, K; Yang, J; Yokoyama, A | 1 |
| George, E; Holden, J; Miller, W; Stein, K | 1 |
| Adès, L; Auberger, P; Baran-Marszak, F; Boehrer, S; Cluzeau, T; de Botton, S; Eclache, V; Fenaux, P; Galluzzi, L; Gardin, C; Kroemer, G; Lainey, E; Leroy, C; Roudot, H; Sébert, M; Tailler, M; Thépot, S | 1 |
| Advani, A; Copelan, E; Ebrahem, Q; Gu, X; Hu, Z; Kalaycio, M; Link, KA; Maciejewski, J; Mahfouz, RZ; Mulloy, JC; Negrotto, S; Ng, KP; Radivoyevitch, T; Saunthararajah, Y; Sekeres, M; Sobecks, R | 1 |
| Fang, GA; Li, YW; Liu, XG; Qiu, L; Wang, YK; Yang, XC; Zhou, JH; Zhou, SQ | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Bornhäuser, M; Ehninger, G; Kiani, A; Platzbecker, U; Radke, J; Schaich, M; Sockel, K; Thiede, C; Wermke, M | 1 |
| Buccisano, F; D'Arco, AM; Di Renzo, N; Ferrero, D; Gaidano, G; Levis, A; Lunghi, M; Maurillo, L; Musto, P; Oliva, E; Pastore, D; Pavone, V; Santagostino, A; Spagnoli, A; Venditti, A | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Gao, F; Hassan, A; Klco, JM; Procknow, E; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Bodo, J; Gopalan, B; Guinta, K; Hsi, E; Jankowska, AM; Maciejewski, J; Mulloy, JC; Negrotto, S; Ng, KP; Saunthararajah, Y | 1 |
| Brissot, E; Clavert, A; Delaunay, J; Frikeche, J; Gaugler, B; Grégoire, M; Mohty, M | 1 |
| Bornhäuser, M; Ehninger, G; Graehlert, X; Kiani, A; Klut, IM; Knoth, H; Mohr, B; Oelschlaegel, U; Platzbecker, U; Radke, J; Röllig, C; Schetelig, J; Seltmann, F; Thiede, C; Wermke, M | 1 |
| Atanackovic, D; Bartels, K; Bokemeyer, C; Cao, Y; Fuchs, G; Hegewisch-Becker, S; Hildebrandt, Y; Kloth, B; Kobbe, G; Kröger, N; Lajmi, N; Luetkens, T; Meyer, S; Platzbecker, U; Reinhard, H; Schilling, G; Schroeder, T | 1 |
| Chow, KU | 1 |
| Alhan, C; Beeker, A; Biemond, BJ; Brouwer, RE; Croon-de Boer, F; de Weerdt, O; Eefting, M; Hoogendoorn, M; Huls, G; Jie, KS; Koedam, J; Libourel, WJ; Luykx-de Bakker, SA; Minnema, MC; Schaafsma, R; van de Loosdrecht, AA; van der Helm, LH; van Marwijk Kooy, M; van Rees, BP; Veeger, NJ; Vellenga, E; Wegman, J; Wijermans, PW | 1 |
| Gorin, NC; Isnard, F; Malak, S; Perot, C; Rubio, MT; Scherman, E | 1 |
| Abdel-Wahab, O; Berube, C; Bhattacharya, S; Coutre, S; Figueroa, ME; Gallegos, L; Gotlib, JR; Kohrt, HE; Levine, R; Liedtke, M; Medeiros, BC; Melnick, A; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B | 1 |
| Brugger, W; Claus, R; Deschler, B; Döhner, H; Döhner, K; Galm, O; Ganser, A; Germing, U; Hackanson, B; Hagemeijer, A; Heil, G; Kuendgen, A; Lübbert, M; Platzbecker, U; Rethwisch, V; Rüter, BH; Schmid, M; Schmoor, C; Wijermans, PW | 1 |
| Akpek, G; Cao, Q; Gojo, I; Rapoport, AP; Singh, SN | 1 |
| Bloomfield, CD; Blum, W; Garzon, R; Geyer, S; Klisovic, RB; Marcucci, G; Metzeler, KH; Walker, A | 1 |
| Dervenoulas, I; Dimitriadis, G; Economopoulos, T; Girkas, K; Karvounis, K; Pagageorgiou, S; Pappa, V; Sambani, C; Stathopoulou, E; Tsirigiotis, P | 1 |
| Bosi, A; Buchi, F; Ferrari, G; Gozzini, A; Masala, E; Sanna, A; Santini, V; Spinelli, E | 1 |
| Cook, G; Cook, M; Craddock, CF; Crawley, C; Dennis, M; Goodyear, OC; Griffiths, M; Jilani, NY; Khanum, R; Loke, J; Malladi, R; Moss, P; Nunnick, J; Raghavan, M; Russell, N; Ryan, G; Siddique, S; Snowden, JA; Vyas, P; Yin, J | 1 |
| Borthakur, G; Burger, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, M; Ravandi, F; Wang, X | 1 |
| Marks, PW | 1 |
| Beyne Rauzy, O; Dreyfus, F; Esterni, B; Fenaux, P; Gardin, C; Gore, SD; Prébet, T; Quesnel, B; Thépot, S; Vey, N | 1 |
| Ballestar, E; Blanco, B; Caballero-Velazquez, T; Calderón, C; Cañizo, C; Carrancio, S; Ciudad, L; de la Rica, L; Gutierrez-Cosío, S; Herrero-Sánchez, C; Pérez-Simón, JA; San Miguel, JF; Sánchez-Abarca, LI; Santamaría, C | 1 |
| Armstrong, RN; Baird, DM; Colyer, HA; Jones, RE; Mills, KI; Pettigrew, KA; Rea, IM; Zhang, SD | 1 |
| Aimiuwu, J; Blum, W; Chan, KK; Chen, P; Klisovic, R; Liu, S; Marcucci, G; Mims, A; Wang, H; Wang, J; Xie, Z | 1 |
| Cesano, A; Cohen, A; Cordeiro, JA; Hawtin, RE; Hogge, D; Lacayo, N; Rosen, DB | 1 |
| Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Curfman, JP; Devine, SM; Eisfeld, AK; Garr, C; Garzon, R; Geyer, S; Grever, MR; Jacob, S; Kefauver, C; Klisovic, R; Marcucci, G; Perrotti, D; Santhanam, R; Schwind, S; Tarighat, SS; Walker, A; Wang, H; Whitman, S | 1 |
| Auberger, P; Cassuto, JP; Cluzeau, T; Dufies, M; Jacquel, A; Karsenti, JM; Luciano, F; Mounier, N; Preudhomme, C; Puissant, A; Raynaud, S; Renneville, A; Robert, G | 1 |
| Adès, L; Beelen, D; Bornhäuser, M; Deeg, HJ; Ehninger, G; Fenaux, P; Finke, J; Germing, U; Itzykson, R; Kobbe, G; Platzbecker, U; Schaefer-Eckart, K; Schetelig, J; Scott, BL; Trenschel, R | 1 |
| Autry, J; Borthakur, G; Boumber, Y; Castoro, R; Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Issa, JP; Jabbour, E; Jorgensen, J; Kantarjian, H; Ravandi, F; Wen, S | 1 |
| Arthur, C; Buckstein, R; Cermak, J; Chou, WC; Delaunay, J; Dmoszynska, A; Faderl, S; Gau, JP; Kantarjian, HM; Kuo, CY; Lysák, D; Mayer, J; Mazur, G; Minden, M; Oriol, A; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Chen, WF; Huang, F; Zha, J | 1 |
| Audureau, E; Bardet, V; Benet, B; Clozel, T; Dreyfus, F; Ettou, S; Fontenay, M; Humbrecht, C; Jammes, H; Lacombe, C; Mayeux, P; Solary, E | 1 |
| Cutler, C | 1 |
| Bloomfield, CD; Blum, W; Bundschuh, R; Byrd, JC; Caligiuri, MA; Curfman, J; Frankhouser, D; Garzon, R; Geyer, S; Grever, MR; Jacob, S; Klisovic, R; Marcucci, G; Metzeler, K; Murphy, M; Rodriguez, B; Tam, HH; Trimarchi, M; Walker, A; Whitman, SP; Wu, YZ; Yan, P | 1 |
| Ritchie, EK | 1 |
| Abboud, CN; Bernabe, N; Cashen, AF; DiPersio, JF; Monahan, R; Ramsingh, G; Stockerl-Goldstein, K; Uy, GL; Vij, R; Westervelt, P | 1 |
| Aloe Spiriti, A; Breccia, M; Criscuolo, M; D'Alò, F; Fianchi, L; Finelli, C; Gaidano, G; Hohaus, S; Leone, G; Leoni, P; Levis, A; Lunghi, M; Musto, P; Oliva, EN; Pagano, L; Santini, V; Voso, MT | 1 |
| Blum, S; Duchosal, MA; Gavillet, M; Lambert, JF; Noetzli, J; Spertini, O | 1 |
| Andreeff, M; Antony, A; Coombes, KR; Kojima, K; Konoplev, S; Konopleva, M; Kornblau, S; Lu, H; Qiu, YH; Ruvolo, V; Shi, Y; Tsao, T; Zhang, N | 1 |
| Chang, CK; He, Q; Li, X; Song, LX; Wu, LY; Xu, L; Zhang, QX; Zhang, Y | 1 |
| Brower, V | 1 |
| Chen, C; Huang, T; Jia, J; Li, B; Wang, L; Zeng, J; Zhang, X; Zhang, Y; Zhou, M | 1 |
| Bertoli, S; Delabesse, E; Demur, C; Fialin, C; Larrue, C; Manenti, S; Mansat-De Mas, V; Payrastre, B; Récher, C; Roche, S; Sarry, JE; Vergez, F | 1 |
| Castro, CC; Germano, RT; Magalhaes, SM; Pinheiro, RF; Sousa, JC | 1 |
| Cupelli, L; de Fabritiis, P; Fratoni, S; Giovannini, M; Morino, L; Neri, B; Niscola, P; Scaramucci, L; Tendas, A | 1 |
| Roboz, GJ | 1 |
| Camós, M; Colomer, D; Díaz, T; Díaz-Beyá, M; Esteve, J; Ferrer, G; Gel, B; Monzo, M; Navarro, A; Pratcorona, M; Rozman, M; Torrebadell, M | 1 |
| Botrugno, OA; Di Croce, L; Frigè, G; Gutierrez, A; Minucci, S; Pallavicini, I; Pelicci, P; Romanenghi, M; Santoro, F; Soncini, M | 1 |
| Deng, AC; Magro, CM; Sagransky, MJ | 1 |
| Fujiki, A; Hirashima, Y; Hosoi, H; Imamura, T; Kawashima, S; Miyachi, M; Nakatani, T; Sakamoto, K; Sugita, K; Yagyu, S; Yoshida, H | 1 |
| Bouteloup, C; De Botton, S; Enot, D; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Marie, N; Micol, JB; Scoazec, M; Wolfromm, A | 1 |
| Blaise, D; Charbonnier, A; Gelsi-Boyer, V; Mozziconacci, MJ; Prebet, T; Vey, N | 1 |
| Abhyankar, S; Aljitawi, OS; Amin, M; Divine, C; Ganguly, S; McGuirk, JP | 1 |
| Ganetsky, A | 1 |
| Bertz, H; Finke, J; Lübbert, M; Müller, MJ | 1 |
| Almstedt, M; Claus, R; Hackanson, B; Lübbert, M; Pfeifer, D; Plass, C; Zucknick, M | 1 |
| Alberich-Jordà, M; Amabile, G; Avellino, R; Balastik, M; Delwel, R; Di Ruscio, A; DiRuscio, A; Ebralidze, AK; Figueroa, ME; Lowers, I; Melnick, A; Radomska, HS; Shapiro-Koss, C; Tenen, DG; Valk, PJ; Wouters, B; Ye, M; Zhang, H; Zhang, J | 1 |
| Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Chen, CS; Dorrance, AM; Garzon, R; Hoellerbauer, P; Huang, X; Jacob, S; James Lee, L; Klisovic, RB; Marcucci, G; Mims, A; Mrózek, K; Perrotti, D; Santhanam, R; Schwind, S; Sun, J; Tarighat, SS; Walker, AR; Walker, C; Wang, H | 1 |
| Aimiuwu, J; Blum, W; Byrd, JC; Chan, KK; Chen, P; Garzon, R; Grever, MR; Klisovic, R; Liu, Z; Marcucci, G; Mims, A; Santhanam, R; Saradhi, UV; Schwind, S; Villalona-Calero, MA; Walker, A; Wang, H; Wang, J | 1 |
| Arrazi, J; Aztberger, A; Brookes, C; Burnett, A; Cavenagh, J; Craddock, C; Davies, B; Freeman, S; Goardon, N; Griffiths, M; Grimwade, D; Hills, R; Ivey, A; Knapper, S; Majeti, R; McSkeane, T; Price, A; Quek, L; Raghavan, M; Schuh, A; Siddique, S; Virgo, P; Vyas, P; Wall, K; Weissman, I | 1 |
| Cortes, JE; Faderl, S; Fullmer, A; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Wierda, W | 1 |
| Carlson, K; Christos, PJ; Feldman, EJ; Ippoliti, C; Lagassa, CB; Ritchie, EK; Roboz, GJ; Rohan, SD; Scandura, JM | 1 |
| Chan, K; Covey, J; Ebrahem, Q; Engelke, KJ; Gu, X; Jankowska, A; Ling, Y; Maciejewski, J; Mahfouz, RZ; Radivoyevitch, T; Saunthararajah, Y; Sekeres, MA; Tabarroki, A; Terse, P; Tiu, R; Visconte, V | 1 |
| Antar, A; Aractingi, S; Bazarbachi, A; Kharfan-Dabaja, M; Mohty, M; Otrock, ZK; Salem, Z | 1 |
| Mitrovic, M; Pleyer, L; Stauder, R; Steurer, M; Valentiny, C; Willenbacher, W | 1 |
| Erdmann-Gilmore, P; Hundal, J; Klco, JM; Lamprecht, TL; Ley, TJ; Lichti, CF; Magrini, V; Mardis, ER; Meyer, MR; Sarkaria, SM; Spencer, DH; Townsend, RR; Varghese, N; Walker, J; Wilson, RK; Wylie, T | 1 |
| Czepulkowski, B; Gäken, J; Ireland, R; Krishnamurthy, P; Kulasekararaj, AG; Lea, NC; Marsh, JC; Mian, SA; Mohamedali, AM; Mufti, GJ; Pennaneach, C; Pomplun, S; Smith, AE | 1 |
| Ishigatsubo, Y; Kanamori, H; Maruta, A; Matsumoto, K; Ogusa, E; Tachibana, T; Yamamoto, W | 1 |
| Berdel, WE; Brandts, CH; Büchner, T; Bug, G; Dührsen, U; Ehninger, G; Gerss, J; Koschmieder, A; Koschmieder, S; Krug, U; Müller-Tidow, C; Noppeney, R; Röllig, C; Schaich, M; Schwammbach, D; Serve, H; Steffen, B; Stelljes, M; Thiede, C; Tidow, N | 1 |
| Bruns, I; Bug, G; Czibere, A; Fenk, R; Germing, U; Giagounidis, A; Haas, R; Kobbe, G; Kröger, N; Luft, T; Platzbecker, U; Rieger, K; Schroeder, T; Uharek, L; Wolschke, C; Zohren, F | 1 |
| Allen, PB; Baer, MR; Kleinberg, ME; Koka, R | 1 |
| Denman, CJ; Kopp, LM; Lee, DA; Ray, A; Senyukov, VS; Somanchi, SS; Zhu, S | 1 |
| Bornhäuser, M; Braulke, F; Bug, G; Ehninger, G; Germing, U; Giagounidis, A; Götze, K; Haase, D; Hofmann, WK; Kündgen, A; Naumann, R; Neesen, J; Platzbecker, U; Röllig, C; Schönefeldt, C; Shirneshan, K; Wermke, M | 1 |
| El-Osta, A | 1 |
| Hirschfeld, S; Ho, PT; Pazdur, R; Smith, M | 1 |
| Bies, J; Garin, MT; Koller, R; Liao, W; Malumbres, M; Perella, C; Powell, D; Tessarollo, L; Wolff, L | 1 |
| Dörken, B; Schmelz, K; Tamm, I; Wagner, M | 1 |
| Furukawa, Y; Ishii, H; Nishimura, M; Saito, Y; Sutheesophon, K; Wada, T | 1 |
| Decoteau, JF; Dong, WF; Geyer, CR; Hirsch, C; Ichinohasama, R; Sanche, SE; Scott, SA; Sheridan, D | 1 |
| Schmelz, K; Tamm, I; Wagner, M | 1 |
| Broekhuizen, AJ; Creutzig, U; Gibson, BE; Hubeek, I; Kaspers, GJ; Peters, GJ; Sargent, J | 1 |
| Rosenfeld, CS | 1 |
| Almstedt, M; Claus, R; Lübbert, M | 1 |
| Gozzini, A; Santini, V | 1 |
| Issa, JP | 1 |
| Chun, K; Costa, R; Haghighi, F; McMinn, J; Minden, M; Tycko, B; White, S; Yuan, E | 1 |
| Choi, SW; Doshi, KD; Estecio, MR; Garcia-Manero, G; Gharybian, V; Issa, JP; Kantarjian, HM; Luna, R; Mannari, RK; Mason, JB; Rashid, A; Shen, L; Yang, AS | 1 |
| Cashen, AF; Devine, H; DiPersio, J | 1 |
| Bueso-Ramos, C; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Fiorentino, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; Koller, C; O'brien, S; Ravandi, F; Rosner, G; Rytting, M; Sanchez-Gonzalez, B; Verstovsek, S; Wierda, WG; Xiao, L; Yang, H | 1 |
| Balaian, L; Ball, ED | 1 |
| Agrawal, S; Berdel, WE; Ehrich, M; Hofmann, WK; Koschmieder, S; Müller-Tidow, C; Serve, H; Tidow, N; van den Boom, D | 1 |
| Bueso-Ramos, CE; Cortes, J; Davisson, J; Garcia-Manero, G; Huang, X; Issa, JP; Kantarjian, HM; O'Brien, S; Ravandi, F; Shan, J | 1 |
| Desmond, JC; Haferlach, T; Hofmann, WK; Koeffler, HP; Raynaud, S; Tung, E | 1 |
| Cashen, AF; DiPersio, J; Fisher, N; Shah, AK; Todt, L | 1 |
| Cortes, J; Estey, EH; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Issa, JP; Kantarjian, HM; Ouzounian, S; Pierce, S; Quezada, A; Ravandi, F; Soriano, AO; Wierda, WG; Yang, H | 1 |
| Blum, W; Byrd, JC; Chan, KK; Devine, H; Devine, SM; Grever, MR; Hackanson, B; Heerema, NA; Huynh, L; Kefauver, C; Klisovic, RB; Liu, S; Liu, Z; Lozanski, G; Marcucci, G; Murgo, A; Plass, C; Vukosavljevic, T | 1 |
| Aventín, A; Brunet, S; Carnicer, MJ; Lasa, A; Nomdedéu, JF; Orantes, V; Pena, J; Serrano, E; Sierra, J | 1 |
| Craig, CM; Schiller, GJ | 1 |
| Bernstein, ML; Chabot, GG; Hurtubise, A; Lemaire, M; Momparler, LF; Momparler, RL; Raynal, NJ | 1 |
| Cadman, E; Grant, S | 1 |
| Land, V; Nitschke, R; Ragab, AH; Steuber, CP | 1 |
| Cabanillas, F | 1 |
| Cadman, E; Grant, S; Margolin, J; Rauscher, F | 1 |
| DeBellis, R; Kasdorf, H; Schiffer, CA; Wiernik, PH | 1 |
| Schmidt, AM; Williams, D | 1 |
| Christman, JK; Herzog, D; Mendelsohn, N; Schneiderman, N | 1 |
| Baum, ES; Gaynon, PS | 1 |
| Boccia, R; Champlin, R; Elashoff, R; Foon, K; Gale, RP; Jacobs, A; Zighelboim, J | 1 |
| Go, B; Gordon, DS; Meyer, L; Raney, MR; Vogler, WR; Winton, EF | 1 |
| Bouchard, J; Momparler, RL; Onetto, N; Rivard, GE | 1 |
| Curtis, JE; McCulloch, EA; Motoji, T; Smith, LJ | 1 |
| Robak, T | 1 |
| Attadia, V; Di Fiore, PP; Ferrara, F; Fusco, A; Pinto, A; Spada, OA | 1 |
| Attadia, V; Cimino, R; Maio, M; Pinto, A; Zappacosta, S | 1 |
| Bhalla, K; Gleyzer, M; Grant, S | 2 |
| Hagemeijer, A; Hoebee, B; Honders, MW; Landegent, JE; Stegmann, AP; Willemze, R | 1 |
| Bartolucci, AA; Moore, JO; Omura, GA; Stagg, M; Volger, WR; Weiner, RS | 1 |
| De Gregoris, C; Fazi, P; Gattei, V; Latagliata, R; Mandelli, F; Merola, MC; Monfardini, S; Petti, MC; Pinto, A; Zagonel, V | 1 |
| Bennett, J; Browman, G; Bryant, J; Goldberg, J; Grunwald, H; Gryn, J; Larson, R; Preisler, H; Raza, A; Vogler, R | 1 |
| Camitta, B; Holbrook, T; Krischer, J; Land, V; Mahoney, D; Sexauer, C; Steuber, CP; Weinstein, H | 1 |
| Archimbaud, E; Berneman, Z; Dardenne, M; Dohner, H; Jaksic, B; Jehn, U; Labar, B; Louwagie, EA; Muus, P; Stryckmans, P; Suciu, S; Tjean, M; Wijermans, P; Willemze, R; Zittoun, R | 1 |
| Di Leone, L; Fernandes, MS; Gerhardt, LM; Kalakun, L; Loitzembauer, B; Moschen, M; Schaan, MD; Schwartsmann, G | 1 |
| Champlin, R; Davis, M; de Vos, D; Giralt, S; Kantarjian, H; O'Brien, S; van Besien, K | 1 |
| Beran, M; de Vos, D; Estey, E; Giralt, S; Kantarjian, HM; Keating, M; O'Brien, SM; Rios, MB; Talpaz, M | 1 |
| Cihák, A; Veselý, J | 2 |
| Chabner, BA; Coleman, CN; Drake, JC; Stoller, RG | 1 |
| Muggia, FM; Slavik, M; Von Hoff, DD | 1 |
| Keller, JW; Miller, DS; Vogler, WR | 1 |
| Bear, RA; Garvey, MB; Ho, M | 1 |
| Slavik, M; von Hoff, DD | 1 |
| Preisler, HD; Renick, J; Rustum, YM; Walczak, I | 1 |
| Lichtenfeld, KM; Van Echo, DA; Wiernik, PH | 1 |
| Costanzi, JJ; Hewlett, JS; Hoogstraten, B; McCredie, KB; Morrison, FS; Saiki, JH; Stuckey, WJ; Vietti, TJ; Whitecar, J | 1 |
| Bartolucci, A; Neely, CL; Omura, GA; Silberman, H; Vogler, WR | 1 |
| Greenberg, MS | 1 |
| Cassileth, PA; Cooper, RA; Katz, ME; Petrillo, MH | 1 |
| Belt, J; Brenner, MK; Crom, W; Hurwitz, CA; Krance, R; Mahmoud, H; Ribeirio, R; Roberts, WM; Santana, VM; Schell, MJ | 1 |
| Camitta, BP; Clavell, LA; Gelber, RD; Grier, HE; Link, MP; Weistein, HJ | 1 |
| Gray, RG; Rees, JK | 1 |
| Fiere, D; Haanen, C; Jehn, U; Löwenberg, B; Peetermans, M; Solbu, G; Stryckmans, P; Suciu, S; Willemze, R; Zittoun, R | 1 |
| Buckley, JD; Hammond, GD; Lampkin, BC; Woods, WG | 1 |
| Heinemann, V; Jehn, U | 1 |
| Champlin, R; Gajewski, J; Ho, W; Landaw, E; Nimer, S; Schiller, G; Vollset, S; Winston, D | 1 |
| Gallagher, R; Hogge, DE; Lee, EJ; Schiffer, CA | 1 |
| Hassan, HT; Maurer, HR; Veit, A | 1 |
| Camitta, B; Holbrook, T; Krischer, J; Land, VJ; Sexauer, C; Steuber, CP | 1 |
| Bouchard, J; Momparler, RL; Samson, J | 1 |
| Hall, RE; Leftwich, JA | 1 |
| Chen, E; Frost, JP; Ginder, GD; Gonwa, TA; Karr, RW | 1 |
| McCulloch, EA; Wang, C | 1 |
| Burnison, M; Champlin, R; Decker, R; Gale, RP; Greenberg, P; Ho, W; Holly, FE; Winston, D | 1 |
| Gyger, M; Momparler, LF; Momparler, RL; Onetto, N | 1 |
| Catovsky, D; Chessells, JM; Galton, DA; Goldman, JM; Hann, IM; Hoffbrand, AV; Marcus, RE; Newland, AC; Prentice, HG; Stevens, RF | 1 |
| Gray, R; Hayhoe, FG; Rees, JK | 1 |
| Leyva, A; Pinedo, HM; Schwartsmann, G | 1 |
| Curtis, JE; McCulloch, EA; Senn, JS; Tritchler, DL; Wang, C | 1 |
| Baehner, RL; Buckley, JD; Chard, RL; Hammond, GD; Lampkin, BC; Nesbit, ME; Woods, WG | 1 |
| Attadia, V; Bullian, PL; Carbone, A; Colombatti, A; Gattei, V; Monfardini, S; Pinto, A; Zagonel, V | 1 |
| Colly, LP; Richel, DJ; Willemze, R | 1 |
| Hoang, T; McCulloch, EA; Motoji, T; Tritchler, D | 1 |
| Jehn, U; Zittoun, R | 1 |
| Finklestein, JZ; Karon, M; Leimbrock, S; Nesbit, ME; Sieger, L; Swaney, JJ | 1 |
| Grignani, F; Martelli, M; Tonato, M | 1 |
131 review(s) available for azacitidine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Aged; Azacitidine; Decitabine; Genetic Therapy; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2021 |
Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myeloproliferative Disorders; Randomized Controlled Trials as Topic | 2022 |
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Remission Induction | 2022 |
Changing trends in the therapy of acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Remission Induction; Sulfonamides | 2021 |
Azacitidine maintenance in AML post induction and posttransplant.
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Remission Induction | 2022 |
Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Topics: Aged; Azacitidine; Decitabine; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
Efficacy of azacitidine in preventing relapse after hematopoietic stem cell transplantation for advanced myeloid malignancies: a systematic review and meta-analysis.
Topics: Azacitidine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local | 2022 |
Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review.
Topics: Azacitidine; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors | 2022 |
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Topics: Aged; Aniline Compounds; Azacitidine; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment.
Topics: Aged; Azacitidine; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors | 2022 |
Azacitidine and its role in the upfront treatment of acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2022 |
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Network Meta-Analysis; Quality of Life; Sulfonamides | 2022 |
Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment.
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Transplantation, Homologous | 2022 |
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cell Division; Clinical Trials, Phase III as Topic; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Sulfonamides | 2022 |
Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions.
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Azacitidine; Humans; Immune Checkpoint Inhibitors; Immunologic Factors; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration | 2022 |
SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes.
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life | 2022 |
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Erythropoietin; Female; Hematinics; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Prognosis; Thrombocytopenia | 2022 |
Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology.
Topics: Aged; Azacitidine; General Practitioners; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute | 2022 |
[Treatment stratification by fitness for chemotherapy in acute myeloid leukemia].
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; United States | 2022 |
Hypomethylating agent-based therapies in older adults with acute myeloid leukemia - A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Decitabine; Humans; Leukemia, Myeloid, Acute; Quality of Life | 2023 |
Role of Bcl-2 inhibition in myelodysplastic syndromes.
Topics: Aged; Azacitidine; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2 | 2023 |
Improving clinical trials in higher-risk myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Patient Selection | 2022 |
Advances in myelodysplastic syndromes: promising novel agents and combination strategies.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Risk | 2023 |
Leukemic stem cells and therapy resistance in acute myeloid leukemia.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Sulfonamides | 2023 |
Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelodysplastic syndrome in randomized controlled trials: a systematic review and network meta-analysis.
Topics: Aged; Azacitidine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Network Meta-Analysis; Randomized Controlled Trials as Topic; Systematic Reviews as Topic; Treatment Outcome | 2023 |
Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS.
Topics: Azacitidine; Chronic Disease; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Recurrence; Transplantation, Homologous | 2023 |
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 2023 |
Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.
Topics: Azacitidine; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Mutation | 2023 |
Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adult; Azacitidine; Cost-Benefit Analysis; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Technology Assessment, Biomedical | 2023 |
DNA methyltransferase inhibitor exposure-response: Challenges and opportunities.
Topics: Azacitidine; Decitabine; DNA; DNA Methylation; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Methyltransferases | 2023 |
Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes Theorem; Cytarabine; Humans; Leukemia, Myeloid, Acute; Network Meta-Analysis; Treatment Outcome | 2023 |
Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy.
Topics: Azacitidine; Epigenesis, Genetic; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Treatment Outcome | 2023 |
Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Topics: Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drugs, Investigational; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Survival Rate; Time Factors | 2019 |
GINGIVAL ULCERATIONS IN A PATIENT WITH ACUTE MYELOID LEUKEMIA: A case report and literature review.
Topics: Adult; Azacitidine; Fatal Outcome; Female; Gingival Diseases; Humans; Leukemia, Myeloid, Acute | 2019 |
Updates on DNA methylation modifiers in acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Meta-Analysis as Topic; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Sulfonamides; Treatment Outcome | 2020 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Decitabine; DNA Methylation; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Postoperative Care; Transplantation, Homologous; Treatment Outcome | 2020 |
[Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sarcoma, Myeloid; Sulfonamides | 2020 |
Myelodysplastic Syndromes.
Topics: Azacitidine; Decitabine; Enzyme Inhibitors; Erythrocyte Transfusion; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation, Homologous; Watchful Waiting | 2020 |
PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation.
Topics: Azacitidine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Recurrence; Transplantation, Homologous | 2021 |
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Decitabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Sulfonamides | 2020 |
Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Cell Line, Tumor; Clinical Trials as Topic; Cytarabine; Drug Approval; Drug Evaluation, Preclinical; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mice; Phenylurea Compounds; Signal Transduction; Smoothened Receptor; United States | 2021 |
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Topics: Animals; Antineoplastic Agents; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Prognosis; Sulfonamides | 2021 |
Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Disease Management; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Odds Ratio; Prognosis; Treatment Outcome | 2021 |
Perspectives on current survival and new developments in AML.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Survival Rate | 2021 |
Which novel agents will have a clinically meaningful impact in AML at diagnosis?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2021 |
Hypomethylating agents for elderly patients with acute myeloid leukemia: a PRISMA systematic review and meta-analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic | 2021 |
AML and the art of remission maintenance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Remission Induction; Survival Analysis | 2021 |
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept.
Topics: Antineoplastic Agents; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Randomized Controlled Trials as Topic | 2021 |
Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Male | 2017 |
Immunological effects of hypomethylating agents.
Topics: Animals; Antineoplastic Agents; Azacitidine; Biomarkers; Decitabine; Dendritic Cells; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation; Humans; Immunomodulation; Killer Cells, Natural; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; T-Lymphocytes | 2017 |
Azacitidine in adult patients with acute myeloid leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2017 |
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin | 2017 |
Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.
Topics: Allografts; Azacitidine; Decitabine; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Salvage Therapy; Secondary Prevention; Stem Cell Transplantation | 2018 |
How and when to decide between epigenetic therapy and chemotherapy in patients with AML.
Topics: Azacitidine; Chromosome Aberrations; Decision Making; Decitabine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute | 2017 |
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle Checkpoints; DNA Methylation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2018 |
Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2018 |
How I treat older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous | 2018 |
Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studie
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Decitabine; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Treatment Outcome | 2018 |
BCL-2 inhibition in AML: an unexpected bonus?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2018 |
Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
Topics: Azacitidine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests | 2018 |
Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.
Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Arthritis, Rheumatoid; Azacitidine; Blood Transfusion; Breast Neoplasms; Female; Humans; Hydroxyurea; Isocitrate Dehydrogenase; Jehovah's Witnesses; Leukemia, Myeloid, Acute; Male; Myeloproliferative Disorders; Neoplasms, Second Primary; Treatment Refusal | 2018 |
Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Decitabine; Drug Administration Schedule; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Practice Guidelines as Topic; Remission Induction; Sulfonamides; Survival Analysis; Treatment Outcome | 2019 |
Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Primary Myelofibrosis; Retrospective Studies; Treatment Outcome | 2018 |
Clinical update on hypomethylating agents.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Drug Administration Schedule; Drug Combinations; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Uridine | 2019 |
Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 2019 |
Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use.
Topics: Azacitidine; Decitabine; DNA Methylation; Humans; Leukemia, Myeloid, Acute | 2019 |
A systematic review and meta
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Female; Hematologic Diseases; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2019 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Comorbidity; Consolidation Chemotherapy; Decitabine; DNA Methylation; DNA-Cytosine Methylases; DNA, Neoplasm; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Treatment Outcome | 2014 |
Decitabine: a review of its use in older patients with acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Drug Administration Schedule; Europe; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 2013 |
Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2013 |
Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Treatment Outcome | 2013 |
The euphoria of hypomethylating agents in MDS and AML: is it justified?
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; DNA Methylation; Endpoint Determination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
Clinical development of demethylating agents in hematology.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Mutation, Missense; Myelodysplastic Syndromes | 2014 |
The role of hypomethylating agents in the treatment of elderly patients with AML.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle; Clinical Trials as Topic; Decitabine; DNA Methylation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2014 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Decitabine.
Topics: Animals; Antineoplastic Agents; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
5-Azacytidine/5-Azacitidine.
Topics: Animals; Antineoplastic Agents; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
Decitabine. Acute myeloid leukaemia: no progress.
Topics: Age Factors; Aged; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Patient Selection; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Gemtuzumab ozogamicin in acute myeloid leukemia revisited.
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gemtuzumab; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Recurrence; Treatment Failure | 2014 |
-7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Decitabine; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myeloid Cells; Prognosis | 2015 |
Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Prognosis; Remission Induction; Treatment Outcome | 2014 |
[Research progress of epigenetic drug decitabine in AML].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute | 2014 |
How I treat the older patient with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cytogenetic Analysis; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Precision Medicine; Prognosis; Survival Analysis; Treatment Outcome | 2015 |
Digging deep into "dirty" drugs - modulation of the methylation machinery.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Code; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transcription, Genetic | 2015 |
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Critical Care; Cytarabine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Organophosphates; Quinazolines; Quinolones | 2015 |
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat | 2015 |
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Disease Management; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Thalidomide; Transplantation, Homologous | 2015 |
D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Young Adult | 2016 |
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Topics: Administration, Oral; Azacitidine; Clinical Trials as Topic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2015 |
Effect of Decitabine Combined with Unrelated Cord Blood Transplantation in an Adult Patient with -7/EVI1+ Acute Myeloid Leukemia: a Case Report and Literature Review.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Decitabine; DNA-Binding Proteins; Fetal Blood; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; MDS1 and EVI1 Complex Locus Protein; Proto-Oncogenes; Transcription Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2015 |
Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; DNA Methylation; Humans; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2016 |
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2016 |
Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Cost-Benefit Analysis; Humans; Leukemia, Myeloid, Acute; Models, Economic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Rate; Technology Assessment, Biomedical | 2017 |
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Treatment Outcome | 2016 |
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 5; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Translocation, Genetic | 2017 |
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 5; Disease Progression; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2017 |
Hypomethylating Agents as a Therapy for AML.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute | 2017 |
New drugs in acute myeloid leukemia.
Topics: Adenine Nucleotides; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Decitabine; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Leukemia, Myeloid, Acute | 2008 |
Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Bone Marrow Cells; Chromosome Inversion; Combined Modality Therapy; Erythrocyte Transfusion; Erythroid Precursor Cells; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome | 2009 |
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
Topics: Azacitidine; Benzenesulfonates; Decitabine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Prenylation; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Staurosporine | 2010 |
Decitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Stem Cell Transplantation; Transplantation, Homologous | 2010 |
Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cost-Benefit Analysis; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Models, Economic; Myelodysplastic Syndromes; Quality of Life; Quality-Adjusted Life Years; Survival; United Kingdom | 2010 |
[Current treatment options for myelodysplastic syndromes].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Bone Marrow Transplantation; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Iron Overload; Lenalidomide; Leukemia, Myeloid, Acute; Long-Term Care; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Thalidomide | 2010 |
Safety and efficacy of azacitidine in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Survival | 2010 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Treatment of myelodysplastic syndromes in elderly patients.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Agents; Azacitidine; Blood Component Transfusion; Case Management; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Contraindications; Hematinics; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunomodulation; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Thalidomide | 2011 |
Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Clinical Trials, Phase III as Topic; Contraindications; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Lymphocyte Activation; Myelodysplastic Syndromes; Neutropenia; Practice Guidelines as Topic; Prognosis; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2011 |
Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Topics: Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2005 |
Pharmacokinetic evaluation of decitabine for the treatment of leukemia.
Topics: Age Factors; Aged; Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2011 |
Decitabine for acute myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Methyltransferases; Middle Aged; Pharmacovigilance; Remission Induction; Risk Adjustment; Treatment Outcome | 2012 |
Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Humans; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2012 |
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Cytarabine; Disease Progression; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality of Life; Risk Assessment; Sickness Impact Profile | 2012 |
Current treatment of acute myeloid leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Consolidation Chemotherapy; Cytarabine; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Precision Medicine; Stem Cell Transplantation | 2012 |
Primary cutaneous langerhans cell sarcoma: a report of four cases and review of the literature.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Humans; Immunophenotyping; Langerhans Cell Sarcoma; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Multiple Primary; Skin Neoplasms | 2013 |
The role of decitabine for the treatment of acute myeloid leukemia.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute | 2012 |
Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.
Topics: Antineoplastic Agents; Azacitidine; Child; Child, Preschool; Drug Approval; Humans; Leukemia, Myeloid, Acute; Methotrexate; Neuroblastoma; Osteosarcoma; Pediatrics; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Teniposide; United States; United States Food and Drug Administration; Vindesine | 2003 |
Clinical development of decitabine as a prototype for an epigenetic drug program.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Adducts; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Remission Induction; Time Factors; Treatment Outcome | 2005 |
Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Silencing; Hematologic Neoplasms; Herpesvirus 4, Human; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Models, Genetic; Neoplasms; Time Factors; Tumor Suppressor Proteins | 2005 |
Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Patient Selection; Treatment Outcome | 2005 |
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.
Topics: Animals; Azacitidine; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemistry; Europe; Female; Humans; Kinetics; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukopenia; Liver; Nausea; Neoplasms, Experimental; Neuromuscular Diseases; RNA, Messenger; United States; Vomiting | 1976 |
5-azacytidine--a new anticancer drug with significant activity in acute myeloblastic leukemia.
Topics: Abortifacient Agents; Animals; Antineoplastic Agents; Azacitidine; Bacteria; Chemical Phenomena; Chemistry; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Leukopenia; Mutagens; Neoplasms; Species Specificity | 1977 |
[Possibilities for the clinical use of 5-azacytidine].
Topics: Adult; Animals; Azacitidine; Biopharmaceutics; Chemical Phenomena; Chemistry; Child; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; Humans; In Vitro Techniques; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mice; Mice, Inbred AKR; Molecular Conformation | 1977 |
205 trial(s) available for azacitidine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.
Topics: Azacitidine; Fatigue; Humans; Leukemia, Myeloid, Acute; Quality of Life; Remission Induction; Treatment Outcome | 2021 |
Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.
Topics: Antineoplastic Agents; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2021 |
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Chemokine CXCL12; DNA Methylation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Heparin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Receptors, CXCR4; Survival Rate | 2021 |
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
Topics: Aged; Aminopyridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Mutation; Progression-Free Survival; Random Allocation; Treatment Outcome; Triazines | 2021 |
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Japan; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis; Remission Induction; Sulfonamides | 2022 |
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute | 2022 |
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Topics: Antimetabolites; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis; Recurrence; Remission Induction | 2022 |
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA; Humans; Leukemia, Myeloid, Acute; Methyltransferases; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; T-Lymphocytes | 2022 |
A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Humans; Japan; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2022 |
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
Topics: Acetonitriles; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hematologic Neoplasms; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Pyrimidines; Pyrroles | 2022 |
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
Topics: Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction | 2022 |
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Idarubicin; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Treatment Outcome; Valproic Acid | 2022 |
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cohort Studies; Gemtuzumab; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Ivosidenib and Azacitidine in
Topics: Antineoplastic Agents; Azacitidine; Febrile Neutropenia; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Leukopenia; Pyridines; Recurrence | 2022 |
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzimidazoles; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Phenylurea Compounds; Risk Assessment; Treatment Outcome | 2022 |
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Humans; Insurance, Health, Reimbursement; Leukemia, Myeloid, Acute; Quality-Adjusted Life Years; Sulfonamides; United States | 2022 |
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2022 |
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase Kinases; Mutation; Pyridones; Pyrimidinones; Sulfonamides | 2022 |
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Pyrazines | 2022 |
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Topics: Azacitidine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Prognosis; Protein-Tyrosine Kinases; Recurrence; Remission Induction | 2022 |
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2022 |
High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2022 |
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Sulfonamides; Treatment Outcome | 2023 |
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Topics: Aged; Azacitidine; Cyclopentanes; Humans; Leukemia, Myeloid, Acute; Pyrimidines; Tumor Suppressor Protein p53 | 2023 |
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Febrile Neutropenia; Female; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Thrombocytopenia | 2023 |
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Nivolumab | 2023 |
Activity of decitabine combined with all-
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Tretinoin | 2023 |
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute | 2023 |
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute | 2023 |
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2023 |
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Protein p53 | 2023 |
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Treatment Outcome | 2023 |
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual | 2023 |
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
Topics: Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2023 |
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Nausea | 2023 |
Azacitidine (Vidaza
Topics: Adult; Azacitidine; Child; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile; Myelodysplastic Syndromes; Remission Induction | 2023 |
Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2023 |
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction | 2023 |
[Efficacy and Safety of Decitabine Combined with Half-Course Pre-excitation for the Treatment of Elderly Patients with Acute Myeloid Leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Treatment Outcome | 2019 |
Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine.
Topics: Aged; Aged, 80 and over; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Cyclin-Dependent Kinase Inhibitor p15; Disease-Free Survival; DNA Methylation; DNA, Neoplasm; Female; GTPase-Activating Proteins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Nucleophosmin; Promoter Regions, Genetic; Survival Rate; Tumor Suppressor Proteins | 2020 |
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.
Topics: Aged; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Nucleophosmin; Remission Induction | 2020 |
A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Staurosporine | 2020 |
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.
Topics: Azacitidine; Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2020 |
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Glycine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Sulfones | 2020 |
Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Sulfonamides; Young Adult | 2020 |
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Patient Safety; Prognosis; Survival Rate; Triazoles | 2020 |
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Double-Blind Method; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukopenia; Male; Middle Aged; Pneumonia; Recurrence; Remission Induction; Sulfonamides; Thrombocytopenia | 2020 |
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Apoptosis; Azacitidine; Drug Therapy, Combination; Enzyme Inhibitors; Female; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyridines | 2021 |
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients.
Topics: Adolescent; Adult; Aged; Azacitidine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Young Adult | 2020 |
[Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prospective Studies; Treatment Outcome | 2020 |
Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML.
Topics: Aniline Compounds; Azacitidine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines | 2021 |
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Nausea; Quality of Life; Remission Induction; Survival Analysis | 2020 |
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cyclopentanes; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Pyrimidines | 2021 |
Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Azacitidine; Cyclopentanes; Drugs, Investigational; Global Burden of Disease; Humans; Incidence; International Cooperation; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Maximum Tolerated Dose; Myelodysplastic Syndromes; Pharmacology, Clinical; Pyrimidines; Translational Research, Biomedical; Ubiquitin-Activating Enzymes; United States | 2021 |
Eprenetapopt Plus Azacitidine in
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Myelodysplastic Syndromes; Quinuclidines; Tumor Suppressor Protein p53 | 2021 |
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome; Vidarabine | 2021 |
Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Japan; Leukemia, Myeloid, Acute; Male; Remission Induction; Sulfonamides; Survival Analysis; Treatment Outcome | 2021 |
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Azacitidine; Benzothiazoles; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Myelodysplastic Syndromes; Phenylurea Compounds | 2021 |
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Azacitidine; B7-H1 Antigen; Humans; Leukemia, Myeloid, Acute; Middle Aged; Young Adult | 2021 |
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic synd
Topics: Azacitidine; Bone Marrow; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence | 2021 |
Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Topics: Adolescent; Adult; Azacitidine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2021 |
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; Female; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Placebo Effect; Remission Induction; Thrombocytopenia | 2021 |
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Risk Factors; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Decitabine; Disease-Free Survival; Epigenesis, Genetic; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Translocation, Genetic; Vidarabine | 2017 |
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Female; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Panobinostat; Treatment Outcome | 2017 |
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; Decitabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Recurrence; Treatment Outcome; Young Adult | 2017 |
Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.
Topics: Aged; Aged, 80 and over; Azacitidine; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Survival Rate; Thalidomide | 2017 |
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Azacitidine; Benzimidazoles; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Invasiveness; Neoplasm Staging; Patient Safety; Risk Assessment; Sex Factors; Survival Analysis; Treatment Outcome | 2017 |
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Topics: Adolescent; Azacitidine; Child; Child, Preschool; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Epigenesis, Genetic; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Promoter Regions, Genetic; Treatment Outcome | 2017 |
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Proportional Hazards Models; Treatment Outcome | 2018 |
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2017 |
A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Decitabine; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male | 2018 |
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.
Topics: Adult; Aged; Allografts; Azacitidine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate | 2018 |
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Fatigue; Female; Food; Food-Drug Interactions; Gastric Acidity Determination; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Proton Pump Inhibitors | 2018 |
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Remission Induction; Salvage Therapy; Sorafenib; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2018 |
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzodiazepines; Decitabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Pyrroles; Sialic Acid Binding Ig-like Lectin 3; Survival Rate | 2018 |
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Drug Administration Schedule; Female; Germany; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Nucleophosmin; Progression-Free Survival; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Time Factors | 2018 |
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Remission Induction | 2019 |
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Recurrence; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Failure; United Kingdom; Young Adult | 2019 |
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Etoposide; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Nucleophosmin; Prospective Studies; Young Adult | 2019 |
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Female; Humans; Leukemia, Myeloid, Acute; Male; Survival Analysis; Treatment Outcome | 2019 |
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Computational Biology; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Predictive Value of Tests; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2019 |
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Allografts; Azacitidine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Risk Factors; Survival Rate; Unrelated Donors | 2019 |
Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Non-Randomized Controlled Trials as Topic; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Survival Rate | 2019 |
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; DNA Methylation; Female; Genomics; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome; Young Adult | 2019 |
Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Protocols; Azacitidine; Cohort Studies; Female; France; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Radiation Injuries; Societies, Medical; Young Adult | 2013 |
Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Frail Elderly; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2014 |
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib; Survival Rate; Tandem Repeat Sequences; Young Adult | 2013 |
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Austria; Azacitidine; Cohort Studies; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Registries; Treatment Outcome | 2013 |
Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cohort Studies; Decitabine; Drug Synergism; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Recurrence; Staurosporine | 2013 |
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2014 |
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease-Free Survival; Female; Gemtuzumab; Humans; Hydroxyurea; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Risk; Survival Analysis | 2013 |
A phase I study of decitabine and rapamycin in relapsed/refractory AML.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Recurrence; Sirolimus | 2013 |
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
Topics: Age Factors; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Gemtuzumab; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Vorinostat | 2014 |
A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Treatment Outcome | 2014 |
Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Panobinostat; Receptors, Tumor Necrosis Factor, Type II; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory | 2014 |
Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytogenetic Analysis; Decitabine; Female; Humans; Internationality; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Risk Factors; Treatment Outcome | 2014 |
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pyridines; Survival Analysis; Treatment Outcome | 2014 |
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Drug Therapy, Combination; Gene Expression; Humans; Immunologic Factors; Interferon-gamma; Interleukin-2; Lenalidomide; Leukemia, Myeloid, Acute; Receptors, Tumor Necrosis Factor, Type II; Recurrence; Remission Induction; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide | 2014 |
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Azacitidine; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2014 |
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Austria; Azacitidine; Cohort Studies; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Registries; Retrospective Studies; Survival Rate; Treatment Outcome; World Health Organization | 2014 |
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Vorinostat; Young Adult | 2014 |
Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2014 |
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes Theorem; Decitabine; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Valproic Acid | 2015 |
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2014 |
Azacitidine for the treatment of relapsed and refractory AML in older patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Risk Factors; Survival Rate | 2015 |
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Staurosporine; Young Adult | 2015 |
Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
Topics: Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Retrospective Studies; Survival Rate | 2015 |
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Nucleophosmin; Thalidomide; Treatment Outcome | 2015 |
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Retreatment; Treatment Outcome; Vorinostat | 2015 |
Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia.
Topics: Aclarubicin; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Staurosporine; Treatment Outcome | 2015 |
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Remission Induction; Treatment Outcome | 2015 |
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Withholding Treatment | 2015 |
Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2015 |
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Female; Follow-Up Studies; Humans; International Agencies; Leukemia, Myeloid, Acute; Male; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate | 2015 |
DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute mye
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Protocols; Decitabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Tretinoin; Valproic Acid | 2015 |
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Topics: Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Young Adult | 2015 |
A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Induction Chemotherapy; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Pilot Projects; Remission Induction; Survival Analysis; Thrombocytopenia | 2015 |
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Azacitidine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Epigenesis, Genetic; Half-Life; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis | 2015 |
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis | 2015 |
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Sialic Acid Binding Ig-like Lectin 3 | 2016 |
Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML).
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Proportional Hazards Models; Statistics as Topic; Survival Rate; United States | 2015 |
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; BH3 Interacting Domain Death Agonist Protein; Biomarkers; Bone Marrow; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retreatment; Thalidomide; Treatment Outcome | 2016 |
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis | 2016 |
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Treatment Outcome | 2016 |
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyridines; Treatment Outcome | 2016 |
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Methylation; Enzyme-Linked Immunosorbent Assay; Female; Gemtuzumab; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Risk Factors; Transcriptome; Treatment Outcome | 2016 |
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Neoplasm Staging; Quality of Health Care; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
Topics: Adult; Aged; Azacitidine; Drug Administration Schedule; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2016 |
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).
Topics: Adolescent; Adult; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Remission Induction; Survival Rate; Young Adult | 2017 |
Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Survival Rate | 2017 |
Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
Topics: Adult; Allografts; Azacitidine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Salvage Therapy; Sorafenib; Survival Rate | 2017 |
Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Decitabine; Disease-Free Survival; DNA Methylation; Female; Fetal Hemoglobin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis | 2017 |
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: 5-Methylcytosine; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Bone Marrow; Decitabine; Exome; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prospective Studies; Risk Factors; Survival Rate; Tumor Suppressor Protein p53 | 2016 |
Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Epigenesis, Genetic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Survival Rate; Treatment Outcome | 2017 |
Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.
Topics: Azacitidine; Blood Cells; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes; Neoplasm Proteins | 2017 |
A pilot pharmacokinetic study of oral azacitidine.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Pharmacokinetics; Pilot Projects | 2008 |
Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug-Related Side Effects and Adverse Reactions; Gemtuzumab; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Remission Induction; Risk Assessment; Survival Analysis | 2008 |
Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate; Transplantation Conditioning | 2009 |
Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Salvage Therapy; Treatment Outcome | 2009 |
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Topics: Antigens, CD34; Azacitidine; Bone Marrow Cells; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leukemia, Myeloid, Acute; Male; MAP Kinase Signaling System; Myelodysplastic Syndromes; Neoplasms, Second Primary; Promoter Regions, Genetic; Time Factors; Wnt Proteins | 2009 |
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2010 |
Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2010 |
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Bone Marrow Cells; Female; Follow-Up Studies; Humans; International Agencies; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2010 |
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Decitabine; Disease-Free Survival; DNA Methylation; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Remission Induction; Treatment Outcome | 2010 |
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; DNA, Neoplasm; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Polymerase Chain Reaction; Promoter Regions, Genetic; Remission Induction; Thrombocytopenia; Treatment Outcome | 2010 |
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; France; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Philadelphia Chromosome; Prognosis; Treatment Outcome | 2010 |
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
Topics: Adult; Aged; Azacitidine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation, Homologous | 2010 |
Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; MicroRNAs; Myelodysplastic Syndromes; Treatment Outcome; Tretinoin; Valproic Acid | 2011 |
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Methylation; DNA, Neoplasm; Epigenomics; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Polymerase Chain Reaction; Survival Rate; Treatment Outcome; Tretinoin; Valproic Acid | 2010 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Azacitidine; Bone Marrow; Bone Marrow Cells; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Young Adult | 2011 |
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chimerism; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Recurrence; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2012 |
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named p
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Platelets; Cohort Studies; Compassionate Use Trials; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Netherlands; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Cytokines; DNA Methylation; Female; Gene Expression Profiling; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Thalidomide; Treatment Outcome | 2012 |
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Comorbidity; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prevalence; Treatment Outcome | 2012 |
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; CD8-Positive T-Lymphocytes; Cytokines; Epitopes; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Count; Lysosomal-Associated Membrane Protein 1; Male; Middle Aged; T-Lymphocytes, Regulatory; Transplantation, Homologous | 2012 |
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Consolidation Chemotherapy; Cytarabine; Decitabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2012 |
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.
Topics: Azacitidine; DNA, Neoplasm; Enzyme Inhibitors; Female; Humans; K562 Cells; Leukemia, Myeloid, Acute; Male; Ribonucleoside Diphosphate Reductase; RNA Stability; RNA, Messenger; RNA, Neoplasm; Tumor Suppressor Proteins | 2012 |
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyrazines; Treatment Outcome; Validation Studies as Topic | 2012 |
A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction | 2012 |
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Choice Behavior; Cytarabine; Decision Making; Decitabine; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neutropenia; Palliative Care; Patient Participation; Remission Induction; Risk Assessment; Risk Factors; Thrombocytopenia; Treatment Outcome | 2012 |
A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Remission Induction; Thalidomide; Young Adult | 2013 |
Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Cytarabine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Tumor Cells, Cultured; Young Adult | 2012 |
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Feasibility Studies; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Survival Analysis; Treatment Outcome | 2012 |
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Transplantation; Combined Modality Therapy; Female; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous | 2013 |
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2013 |
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Valproic Acid | 2006 |
The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; CCAAT-Enhancer-Binding Protein-delta; Chromatin Assembly and Disassembly; Decitabine; DNA Methylation; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Myeloid, Acute; Male; Methyl-CpG-Binding Protein 2; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Tumor Suppressor Proteins; U937 Cells | 2007 |
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk; Treatment Outcome | 2007 |
Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Azacitidine; Bone Marrow; Chromatography, High Pressure Liquid; Decitabine; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Mass Spectrometry; Middle Aged; Myelodysplastic Syndromes; Sepsis; Tissue Distribution | 2008 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA Methylation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation; Histones; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; RNA, Messenger; Tretinoin; Valproic Acid | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain Diseases; Decitabine; Fatigue; Humans; Infections; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Neutropenia; Remission Induction; Treatment Failure; Valproic Acid | 2007 |
Low response rate to 5 aza-cytidine, vincristine, and prednisone therapy in previously treated childhood acute nonlymphocytic leukemia: a Southwest Oncology Group Study.
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Prednisone; Vincristine | 1981 |
[Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)].
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Leukemia, Myeloid, Acute; Mitoguazone; Recurrence | 1981 |
Continuous infusion of 5-azacytidine as induction for acute nonlymphocytic leukemia in patients with previous exposure to 5-azacytidine.
Topics: Adolescent; Azacitidine; Child; Child, Preschool; Clinical Trials as Topic; Female; Humans; Infant; Infusions, Parenteral; Leukemia, Myeloid, Acute; Male | 1983 |
A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; BCG Vaccine; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Deoxyguanosine; Female; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Thioguanine; Thionucleosides; United States | 1984 |
[Clinical pharmacology of 5-azacytidine].
Topics: Adult; Animals; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as Topic; Dogs; Drug Evaluation, Preclinical; Hepatitis, Animal; Humans; Leukemia, Myeloid, Acute; Mice | 1984 |
Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Selection; Remission Induction; Thioguanine | 1995 |
Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.
Topics: Adult; Azacitidine; Biopsy; Blast Crisis; Bone Marrow; Cell Cycle; DNA, Neoplasm; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Outcome Assessment, Health Care; Recurrence | 1993 |
Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local | 1996 |
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
Topics: Adolescent; Adult; Aged; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Time Factors | 1997 |
Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Daunorubicin; Decitabine; Drug Administration Schedule; Female; Humans; Immunophenotyping; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged | 1997 |
Studies of decitabine with allogeneic progenitor cell transplantation.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Patient Selection; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pseudomonas Infections; Recurrence; Time Factors; Transplantation, Homologous | 1997 |
Decitabine studies in chronic and acute myelogenous leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Female; Fever; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged | 1997 |
[Possibilities for the clinical use of 5-azacytidine].
Topics: Adult; Animals; Azacitidine; Biopharmaceutics; Chemical Phenomena; Chemistry; Child; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; Humans; In Vitro Techniques; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mice; Mice, Inbred AKR; Molecular Conformation | 1977 |
Feasibility and efficacy of 5-azacytidine used early in the therapy of adult acute nonlymphocytic leukemia: an ECOG pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors | 1979 |
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Deoxyadenosines; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Remission Induction | 1992 |
Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Prednisolone; Survival Analysis; Vincristine | 1992 |
Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Drug Combinations; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Nimustine; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Thioguanine; United Kingdom; Vincristine | 1990 |
A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Belgium; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; France; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Vincristine | 1990 |
Preliminary results of intensive therapy of children and adolescents with acute nonlymphocytic leukemia--a Childrens Cancer Study Group report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Pilot Projects; Randomized Controlled Trials as Topic; Remission Induction; Thioguanine; Vincristine | 1990 |
Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Germany, West; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate | 1990 |
Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sex Factors; Survival Analysis | 1990 |
Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Pilot Projects | 1991 |
Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Random Allocation; Remission Induction; Risk; Thioguanine; United Kingdom | 1987 |
The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; England; Etoposide; Humans; Leukemia, Myeloid, Acute; Prednisone; Remission Induction; Thioguanine; Vincristine | 1987 |
Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Prednisolone; Prognosis; Remission Induction; Thioguanine; Vincristine | 1989 |
[AML-6 study of the value of cyclic alternating chemotherapy during remission in acute myelocytic leukemia].
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged; Vincristine | 1985 |
5-Azacytidine: a new active agent for the treatment of acute leukemia.
Topics: Adolescent; Azacitidine; Bone Marrow Examination; Child; Child, Preschool; Chlorpromazine; Clinical Trials as Topic; Cytidine; Digestive System; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Nausea; Remission, Spontaneous; Triazines | 1973 |
693 other study(ies) available for azacitidine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytogenetic Analysis; Decitabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Sulfonamides | 2021 |
Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia.
Topics: Azacitidine; Cost-Benefit Analysis; Humans; Leukemia, Myeloid, Acute | 2021 |
Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy.
Topics: Azacitidine; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Humans; Leukemia, Myeloid, Acute; Proteomics | 2021 |
Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Sulfonamides; Transplantation, Homologous; Treatment Outcome; Young Adult | 2022 |
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Sulfonamides; Young Adult | 2021 |
Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study
Topics: Azacitidine; Belgium; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Lymphocytes; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Retrospective Studies | 2022 |
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Sulfonamides; Transplantation Conditioning; Transplantation, Homologous | 2022 |
Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Arthritis; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2022 |
Exciting times ahead for older patients with acute myeloid leukemia: azacitidine and venetoclax followed by allogeneic hematopoietic cell transplantation.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sulfonamides | 2022 |
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
Topics: Aged; Aged, 80 and over; Azacitidine; Bone Marrow; CD8-Positive T-Lymphocytes; Chromosome Deletion; Chromosomes, Human, Pair 7; Drug Resistance, Neoplasm; Granzymes; Humans; Immune Checkpoint Inhibitors; Leukemia, Myeloid, Acute; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Receptors, Antigen, T-Cell; Single-Cell Analysis; T-Lymphocyte Subsets; T-Lymphocytes; Transcriptome | 2021 |
Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Remission Induction; Sulfonamides | 2021 |
RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Decitabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Sulfonamides; Survival Rate | 2021 |
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Registries; Treatment Outcome | 2022 |
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
[Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.
Topics: Animals; Azacitidine; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Leukemia, Myeloid, Acute; Mice | 2021 |
Infectious Complications Among Patients With AML Treated With Immune Checkpoint Inhibitors.
Topics: Adult; Azacitidine; Humans; Immune Checkpoint Inhibitors; Leukemia, Myeloid, Acute; Nivolumab; Retrospective Studies | 2022 |
Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia.
Topics: Azacitidine; Chemokine CXCL12; Combined Modality Therapy; Cyclopentanes; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; NEDD8 Protein; Pre-B-Cell Leukemia Transcription Factor 1; Pyrimidines; RNA Interference; Signal Transduction | 2021 |
Whom should we treat with novel agents? Specific indications for specific and challenging populations.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Female; Humans; Leukemia, Myeloid, Acute; Male; Prognosis; Sulfonamides | 2021 |
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Dyspnea; Fatigue; Hemoglobins; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life | 2022 |
Decitabine Enhances Acute Myeloid Leukemia Cell Apoptosis through SH3BGRL Upregulation.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Glutamic Acid; Humans; Leukemia, Myeloid, Acute; Proteins; RNA, Messenger; U937 Cells; Up-Regulation | 2022 |
Azacitidine to Consolidate and Deepen the Therapeutic Response Achieved by Intensive Induction Treatment in a Young Patient Affected by NPM1mut-AML Who Has Become Ineligible for High-Dose Consolidation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Remission Induction | 2022 |
Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia.
Topics: Animals; Azacitidine; Cytarabine; Leukemia, Myeloid, Acute; Mice; Myelodysplastic Syndromes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-hck | 2022 |
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dancing; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Sulfonamides | 2022 |
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dancing; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Sulfonamides | 2022 |
Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells
Topics: Aminopyridines; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzamides; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Synergism; Epigenomics; Humans; Leukemia, Myeloid, Acute; U937 Cells; Up-Regulation | 2022 |
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response.
Topics: Animals; Azacitidine; Clonal Hematopoiesis; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Hematopoietic Stem Cells; Leukemia, Myeloid, Acute; Mice; Mutation | 2021 |
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Acute monocytic leukemia with histiocytic morphology in hematological remission after azacytidine and venetoclax therapy.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Safety Concerns Prompt Pause of Magrolimab Trials.
Topics: Antibodies, Monoclonal, Humanized; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sulfonamides | 2022 |
Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Core Binding Factor Alpha 2 Subunit; Fatal Outcome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immune Checkpoint Inhibitors; Leukemia, Myeloid, Acute; Male; Recurrence; RUNX1 Translocation Partner 1 Protein; Transplantation, Homologous | 2022 |
Durable response of therapy-related MDS/AML with concomitant Waldenström's macroglobulinemia treated with venetoclax and azacitidine.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides; Waldenstrom Macroglobulinemia | 2022 |
Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine.
Topics: Abnormal Karyotype; Aged; Antimetabolites, Antineoplastic; Azacitidine; Erythroblasts; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis | 2022 |
Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials.
Topics: Azacitidine; Bias; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
The Clinical Tumor Lysis Syndrome in a Patient with Mixed Phenotype Acute Leukemia Undergoing Induction with Venetoclax and Azacitidine: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Phenotype; Sulfonamides; Tumor Lysis Syndrome | 2022 |
Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Central Nervous System; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Recurrence; Remission Induction; Sulfonamides | 2022 |
Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
Topics: Azacitidine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myeloproliferative Disorders; Neoplasms; Prospective Studies; Recurrence; Retrospective Studies; Transplantation Conditioning | 2022 |
Ex vivo drug sensitivity profiling-guided treatment of a relapsed pediatric mixed-phenotype acute leukemia with venetoclax and azacitidine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia; Leukemia, Myeloid, Acute; Phenotype; Sulfonamides | 2022 |
Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Sulfonamides | 2022 |
[Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Nuclear Proteins; Sulfonamides | 2022 |
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Japan; Leukemia, Myeloid, Acute; Retrospective Studies; Treatment Outcome | 2022 |
Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia.
Topics: Azacitidine; Cost-Benefit Analysis; Humans; Leukemia, Myeloid, Acute; Quality-Adjusted Life Years; Remission Induction; United States | 2022 |
Shall We Dance: Evolving Partnerships of Targeted Therapies for AML.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dancing; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Sulfonamides | 2022 |
Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Febrile Neutropenia; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sulfonamides; Tumor Lysis Syndrome | 2022 |
Erythema nodosum after azacitidine in a patient with acute myeloid leukemia.
Topics: Adult; Azacitidine; Erythema Nodosum; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Sorafenib | 2023 |
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2022 |
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Quality of Life; Retrospective Studies; Sulfonamides | 2022 |
Ivosidenib Boosts OS with Azacitidine in AML.
Topics: Azacitidine; Glycine; Humans; Leukemia, Myeloid, Acute; Pyridines | 2022 |
A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sulfonamides; Treatment Outcome | 2022 |
Epigenetic Silencing of
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Proto-Oncogene Proteins c-mdm2; PTEN Phosphohydrolase | 2022 |
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine.
Topics: Azacitidine; Humans; Leukemia; Leukemia, Myeloid, Acute; Oxazoles; Pyridines; Pyrroles; Skin Neoplasms | 2022 |
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Hospitalization; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Ivosidenib and Azacitidine in IDH1-Mutated AML.
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines | 2022 |
Ivosidenib and Azacitidine in IDH1-Mutated AML.
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines | 2022 |
Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines | 2022 |
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.
Topics: Azacitidine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein | 2022 |
Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Prospective Studies | 2023 |
Predictors of the Overall Survival with Azacitidine Monotherapy in Untreated Acute Myeloid Leukemia Patients Ineligible for Intensive Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Treatment Outcome | 2023 |
Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: a real-world clinical experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Treatment Outcome | 2023 |
Spontaneous Remission of Acute Myeloid Leukemia: A Case Report.
Topics: Aged; Azacitidine; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Remission, Spontaneous; Thrombocythemia, Essential | 2022 |
Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
Topics: Adult; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies; Sulfonamides | 2022 |
Discontinuation of azacitidine in acute myeloid leukemia: a feasible option?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute | 2022 |
Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells.
Topics: Animals; Azacitidine; Enzyme Inhibitors; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mice; Mutation; Stem Cells | 2022 |
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Cytogenetic Analysis; Humans; Leukemia, Myeloid, Acute; Mutation; Treatment Outcome; Tumor Suppressor Protein p53 | 2022 |
[Acute Myeloid Leukemia - Update 2022].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Tretinoin | 2022 |
Megakaryopoiesis impairment through acute innate immune signaling activation by azacitidine.
Topics: Azacitidine; Humans; Immunity, Innate; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thrombocytopenia | 2022 |
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Sulfonamides | 2022 |
Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia.
Topics: Animals; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Leukemia, Myeloid, Acute; Mice; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sulfonamides | 2022 |
Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line.
Topics: Azacitidine; Cell Line; Decitabine; DNA; DNA Methylation; Humans; Leukemia, Myeloid, Acute | 2022 |
Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Renal Dialysis | 2022 |
SARS-CoV-2 Infection in Patients Treated with Azacitidine and Venetoclax for Acute Leukemia: A Report of a Case Series Treated in a Single Institution.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; COVID-19; Female; Humans; Leukemia, Myeloid, Acute; Male; Pandemics; SARS-CoV-2 | 2023 |
Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia.
Topics: Antilymphocyte Serum; Azacitidine; Busulfan; Epstein-Barr Virus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; HLA Antigens; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Positron Emission Tomography Computed Tomography; Tacrolimus; Transplantation Conditioning | 2022 |
[Updated treatment strategies for myelodysplastic syndromes].
Topics: Antineoplastic Agents; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decision Support Systems, Clinical; Humans; Leukemia, Myeloid, Acute; Machine Learning; Sulfonamides; Treatment Outcome | 2022 |
TP53 or Not TP53: That Is the Question.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytogenetic Analysis; Humans; Leukemia, Myeloid, Acute; Mutation; Tumor Suppressor Protein p53 | 2022 |
Diagnostic challenge in mixed phenotype acute leukemia with T/megakaryocyte or T/myeloid lineages accompanied by t(3;3).
Topics: Acute Disease; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cell Lineage; Female; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Megakaryocytes; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sulfonamides | 2022 |
Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Monitoring; Humans; Itraconazole; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Myelodysplastic Syndromes | 2022 |
Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Canada; Cost-Benefit Analysis; Humans; Leukemia, Myeloid, Acute | 2022 |
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Topics: Azacitidine; Decitabine; Humans; Ipilimumab; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Topics: Azacitidine; Decitabine; Humans; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2 | 2023 |
Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; East Asian People; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2023 |
Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Tumor Suppressor Protein p53 | 2023 |
Successful Haploidentical Hematopoietic Stem Cell Transplantation with Azacitidine and Venetoclax Maintenance Therapy for Acute Myeloid Leukemia with
Topics: Azacitidine; Gene Fusion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Nuclear Pore Complex Proteins | 2023 |
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Retinoic Acid Receptor alpha | 2023 |
Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.
Topics: Animals; Azacitidine; Dioxygenases; DNA-Binding Proteins; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Mice; Mutation | 2023 |
All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex.
Topics: Aged; Animals; Antineoplastic Agents; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Mice; Myelodysplastic Syndromes; NF-E2-Related Factor 2; Reactive Oxygen Species; Tretinoin | 2023 |
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
New investigational combinations for higher-risk MDS.
Topics: Aged; Azacitidine; Bone Marrow; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Stem Cell Transplantation | 2022 |
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with
Topics: Azacitidine; Cost-Benefit Analysis; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines; Quality-Adjusted Life Years; United States | 2023 |
Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridines | 2023 |
15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies | 2023 |
CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine.
Topics: Azacitidine; Cell Line; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Propensity Score; Treatment Outcome | 2022 |
High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia.
Topics: Antifungal Agents; Azacitidine; Humans; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Neutropenia; Retrospective Studies | 2022 |
Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Octogenarians | 2023 |
Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies | 2022 |
A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Myeloid, Acute; Male; Neutropenia; Retrospective Studies | 2023 |
Azacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation in Poor-Risk Acute Myeloid Leukemia.
Topics: Adult; Azacitidine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Retrospective Studies | 2023 |
Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Prospective Studies | 2023 |
[Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytogenetic Analysis; Humans; Leukemia, Myeloid, Acute; Male | 2022 |
CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine
Topics: Animals; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Humans; Leukemia, Myeloid, Acute; Mice | 2023 |
[Analysis of the efficacy of azacitidine combined with homoharringtonine and cytarabine in induction and salvage therapy of acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Salvage Therapy; Treatment Outcome | 2022 |
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Electronic Health Records; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; United States | 2023 |
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Retrospective Studies; Sulfonamides | 2023 |
Incidence and predisposing factors of infection in patients treated with hypomethylating agents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Causality; Female; Humans; Incidence; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2023 |
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
Topics: Azacitidine; DNA Methylation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; MicroRNAs; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2 | 2023 |
Efficacy of Azacitidine and Prophylactic Donor Lymphocyte Infusion after HSCT in Pediatric Patients with Acute Myelogenous Leukemia: A Retrospective Pre-Post Study.
Topics: Azacitidine; Child; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Retrospective Studies | 2023 |
High susceptibility of febrile neutropenia in Japanese patients receiving venetoclax plus azacitidine therapy for acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; East Asian People; Febrile Neutropenia; Humans; Leukemia, Myeloid, Acute | 2023 |
Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines.
Topics: Azacitidine; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Humans; Leukemia, Myeloid, Acute | 2023 |
Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2023 |
Determination of 5-azacitidine in human plasma by LC-MS/MS: application to pharmacokinetics pilot study in MDS/AML patients.
Topics: Azacitidine; Chromatography, Liquid; Cytidine Deaminase; Humans; Leukemia, Myeloid, Acute; Pilot Projects; Reproducibility of Results; Tandem Mass Spectrometry | 2023 |
Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.
Topics: Aged; Animals; Antineoplastic Agents; Azacitidine; Humans; Leukemia, Myeloid, Acute; Mice; Quality of Life | 2023 |
Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2023 |
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting.
Topics: Azacitidine; Congresses as Topic; Humans; Leukemia, Myeloid, Acute | 2023 |
Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Proteomics; Proto-Oncogene Proteins c-bcl-2; Stem Cells | 2023 |
Characterization of a multidisciplinary team's role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Patient Care Team; Patient Discharge; Treatment Outcome; Tumor Lysis Syndrome | 2023 |
Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Topics: Antigens, CD34; Azacitidine; Chimerism; Chronic Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nuclear Proteins; Recurrence | 2023 |
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
Topics: Antigens, CD34; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Tumor Microenvironment | 2023 |
Real-world treatment patterns of venetoclax and azacytidine therapy in Japanese patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; East Asian People; Humans; Leukemia, Myeloid, Acute | 2023 |
Subcutaneous azacitidine maintenance in transplantineligible patients with acute myeloid leukemia: a single-center retrospective study.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2023 |
Successful Bridging to Allogeneic Hematopoietic Stem Cell Transplantation by Azacitidine and Venetoclax in a Case of Acute Myeloid Leukemia With t(3;3)(q21.3;q26.2) Developed Early After Orthotopic Heart Transplantation.
Topics: Azacitidine; Female; Heart Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation, Homologous | 2023 |
Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Humans; Leukemia; Leukemia, Myeloid, Acute; Sulfonamides | 2023 |
Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Cell Line, Tumor; Eukaryotic Initiation Factor-4E; Humans; Karyopherins; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-myc; Signal Transduction | 2023 |
Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t(8;21) acute myeloid leukemia.
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies; Transplantation, Homologous | 2023 |
Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; East Asian People; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2023 |
Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia.
Topics: Azacitidine; Cell Line, Tumor; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute; Receptors, Chimeric Antigen; T-Lymphocytes | 2023 |
Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Prognosis | 2023 |
Acute Myeloid Leukemia with NPM1 Mutation and Disseminated Leukemia Cutis: Achievement of Molecular Complete Remission by Venetoclax/Azacitidine Combination in a Very Old Patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins | 2023 |
Treatment in patients with acute myeloid leukemia/high-risk myelodysplastic syndrome with hypomethylating agents: Day-hospital management compared to home care setting.
Topics: Azacitidine; Hospitals; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2023 |
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Topics: Adult; Azacitidine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Myelodysplastic Syndromes; Recurrence; T-Lymphocytes; Transplantation, Homologous | 2023 |
Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase I as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2023 |
Azacitidine as a rare cause of reactive arthritis in a patient with acute myeloid leukemia.
Topics: Aged; Arthritis, Reactive; Azacitidine; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Retrospective Studies | 2023 |
Venetoclax and Azacitidine Treatment in Relapsed Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation: A Cohort Study in the Real-World Setting of a Tertiary Center
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute | 2023 |
Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2023 |
The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Ribosomal Protein S6 Kinases; Ribosomal Protein S6 Kinases, 90-kDa; RNA, Guide, CRISPR-Cas Systems | 2023 |
Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia.
Topics: Adult; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 2023 |
Case report: Positive response to venetoclax and azacitidine in the treatment of acute myeloid leukemia with myelodysplasia-related changes and blasts of the mixed T/myeloid phenotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Phenotype | 2023 |
[Prompt cytogenetic response by venetoclax plus azacitidine regimen in a patient with AML harboring double-minute chromosomes with MYC gene amplification].
Topics: Aged, 80 and over; Azacitidine; Chromosome Aberrations; Chromosomes; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute | 2023 |
[Multicenter Prospective Study of Different Induction Regimens of Azacytidine in Treatment of Elderly Patients with Acute Myeloid Leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Treatment Outcome | 2023 |
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle Proteins; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nuclear Proteins; Proto-Oncogene Proteins c-bcl-2; Recurrence; RNA-Binding Proteins; Transcription Factors | 2023 |
Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.
Topics: Azacitidine; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Fatty Acids; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein | 2023 |
Evaluation of Expression Profile of Patients with Acute Myeloid Leukemia in Response to Azacitidine with Biological System Approach.
Topics: Azacitidine; Computational Biology; Gene Expression Profiling; Gene Regulatory Networks; Humans; Leukemia, Myeloid, Acute; MicroRNAs | 2023 |
Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute | 2023 |
Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Cytidine Deaminase; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Treatment Outcome | 2023 |
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.
Topics: Antineoplastic Agents; Azacitidine; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2 | 2023 |
Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA; DNA Methylation; Humans; Leukemia, Myeloid, Acute | 2023 |
[Current state of treatment for myelodysplastic syndromes].
Topics: Azacitidine; Genome-Wide Association Study; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis | 2023 |
[Ivosidenib-azacitidine in acute myeloid leukemia with IDH1R132 mutation].
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Mutation; Pyridines | 2023 |
Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2023 |
Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen.
Topics: Azacitidine; Bone Marrow; CpG Islands; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute | 2023 |
The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Cell Survival; Child; Humans; Leukemia, Myeloid, Acute | 2023 |
Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Danazol; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Thalidomide; Young Adult | 2023 |
[Recent findings in myelodysplastic syndrome].
Topics: Anemia; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis | 2023 |
Venetoclax-based therapy in treatment-naïve and relapsed/refractory acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
[How did the survival of acute myeloid leukemia change over the last ten years in our unit?]
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
[Comparison of induction protocols for VEN+AZA and HAG+AZA in single-center elderly acute myeloid leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2023 |
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Dendritic Cells; DNA Methylation; Drug Delivery Systems; Female; Hematologic Neoplasms; Humans; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Male; Mice; Mice, Nude; Minor Histocompatibility Antigens; Neoplasm Proteins; Recombinant Fusion Proteins; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2019 |
Post-Myelofibrosis Acute Myeloid Leukemia Effectively Treated with a Combination of Ruxolitinib and 5-Azacytidine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
[Impact of time to hematological response on survival in patients treated with azacytidine: a single-center retrospective study].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2019 |
Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia - results from a retrospective Belgian registry study.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Belgium; Decitabine; Humans; Leukemia, Myeloid, Acute; Registries; Retrospective Studies; Treatment Outcome | 2021 |
Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Follow-Up Studies; Genetic Testing; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Sulfonamides; Treatment Outcome | 2019 |
The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Cesarean Section; Female; Humans; Induction Chemotherapy; Infant, Newborn; Leukemia, Myeloid, Acute; Live Birth; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third | 2019 |
Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies.
Topics: Animals; Antineoplastic Agents; Autophagy; Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Hydroxychloroquine; Kidney Neoplasms; Leukemia, Myeloid, Acute; Lysosomes; Mice | 2019 |
Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways.
Topics: Aged; Apoptosis; Azacitidine; Baculoviral IAP Repeat-Containing 3 Protein; Cell Line, Tumor; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Morpholines; Piperazines; Pyrroles; Ubiquitin-Protein Ligases | 2020 |
Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression.
Topics: Aged; Alternative Splicing; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Carrier Proteins; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Differentiation; GTPase-Activating Proteins; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Mannosyltransferases; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retroelements; Transcriptome; Treatment Failure; Tumor Suppressor Proteins | 2019 |
Deubiquitinase USP28 inhibits ubiquitin ligase KLHL2-mediated uridine-cytidine kinase 1 degradation and confers sensitivity to 5'-azacytidine-resistant human leukemia cells.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; HEK293 Cells; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Microfilament Proteins; Nerve Tissue Proteins; Ubiquitin Thiolesterase; Uridine Kinase | 2020 |
Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow.
Topics: Animals; Apoptosis; Azacitidine; Bone Marrow; Cell Count; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Monocytes; Myeloid Cells; Neoplastic Stem Cells; Oncogenes; Promoter Regions, Genetic; Receptors, Calcitriol; Signal Transduction; Survival Analysis; Tumor Stem Cell Assay | 2020 |
Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Clonal Evolution; Female; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes; Treatment Outcome | 2020 |
[Therapeatic Efficacy of Decitabine on Low and Moderate-Risk MDS Patients and the Prognostic Factors].
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Treatment Outcome | 2020 |
Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Delivery of Health Care; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Ontario | 2020 |
5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Disease Models, Animal; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Leukemia, Myeloid, Acute; Mice; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2020 |
Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Sulfonamides; Survival Analysis; Treatment Outcome | 2020 |
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate | 2020 |
The Application of Next-generation Sequencing Tumor Molecular Profiling in the Diagnosis and Management of a Case of Acute Myelogenous Leukemia With MLL-PTD in a Pediatric Heart Transplant Recipient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Combined Modality Therapy; Disease Management; Female; Gene Duplication; Heart Transplantation; Hematopoietic Stem Cell Transplantation; High-Throughput Nucleotide Sequencing; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myeloid-Lymphoid Leukemia Protein; Prognosis; Sorafenib; Tandem Repeat Sequences | 2021 |
Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair 7; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Shwachman-Diamond Syndrome | 2020 |
AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding.
Topics: Azacitidine; CCCTC-Binding Factor; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplasm Proteins; Response Elements | 2020 |
Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.
Topics: Aged; Aniline Compounds; Animals; Azacitidine; Benzimidazoles; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mice | 2021 |
Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nausea; Oncogene Proteins, Fusion; Sulfonamides; Transplantation, Haploidentical; Treatment Outcome; Vomiting | 2020 |
Continuity and efficacy of real-world use of azacitidine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Continuity of Patient Care; Female; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Topics: Azacitidine; beta-Globins; beta-Thalassemia; DNA Mutational Analysis; Female; Heterozygote; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Phenotype; Pregnancy; Retrospective Studies; Risk Factors; Silent Mutation; Treatment Outcome | 2020 |
[Treatment of secondary acute myeloid leukemia with azacitidine : Maintenance of quality of life and independence in advanced age].
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Maintenance; Neoplasms, Second Primary; Quality of Life; Treatment Outcome | 2020 |
Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
Topics: Abnormal Karyotype; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Diseases; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Febrile Neutropenia; Female; France; Hospitalization; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome | 2020 |
IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
Topics: Azacitidine; Disease Progression; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pharmaceutical Preparations; Prognosis | 2020 |
To target the untargetable: elucidation of synergy of APR-246 and azacitidine in
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quinuclidines; Tumor Suppressor Protein p53 | 2020 |
The geriatric nutritional risk index predicts the early death and survival in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Azacitidine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Nutritional Status; Survival Rate | 2020 |
Sustained Complete Remission with Incomplete Hematologic Recovery (CRi) in a Patient with Relapsed AML and Concurrent BCR-ABL1 and CBFB Rearrangement Treated with a Combination of Venetoclax and 5-Azacytidine.
Topics: Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Remission Induction; Sulfonamides | 2020 |
Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.
Topics: Acetylation; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cell Line, Tumor; Cytidine; Decitabine; DNA Methylation; Histones; Humans; Leukemia, Myeloid, Acute; Sirtuins | 2020 |
Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Creatinine; Cytochrome P-450 Enzyme Inhibitors; Drug Administration Schedule; Drug Synergism; Female; Humans; Hyperuricemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Sulfonamides; Triazoles; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Young Adult | 2020 |
Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
Topics: Azacitidine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous | 2020 |
The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia related changes treated with azacitidine.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nutritional Status; Prognosis | 2020 |
Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute | 2020 |
Dose-Reduced Decitabine Might Bring Benefits for Elderly AML Patients with Complex Karyotype: a Case Report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Karyotype; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2020 |
Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Risk Factors; Sulfonamides; Tumor Lysis Syndrome | 2021 |
Eat and be healthy: nutritional status in myelodysplastic syndromes.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nutritional Status; Prognosis | 2020 |
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Cause of Death; Cell Count; Decitabine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA, Neoplasm; Female; Hemoglobins; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2020 |
Venetoclax in AML: efficacy confirmed.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Child; Clinical Trials, Phase III as Topic; Cytarabine; Datasets as Topic; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenetic Repression; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Organic Cation Transport Proteins; Progression-Free Survival; Randomized Controlled Trials as Topic; Symporters; Young Adult | 2021 |
Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Ontario | 2021 |
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Female; France; Genes, p53; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Registries; Tumor Suppressor Protein p53 | 2020 |
Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine.
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nuclear Proteins; Twist-Related Protein 1 | 2020 |
[European approvals: Glasdegib for Acute myeloid leukemia].
Topics: Antineoplastic Agents; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Drug Approval; Europe; Gemtuzumab; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sulfonamides | 2020 |
Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Transplantation Conditioning | 2021 |
Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sulfonamides | 2021 |
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Decitabine; DNA Methylation; Drug Evaluation; Febrile Neutropenia; Germany; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukocyte Count; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Salvage Therapy; Sulfonamides; Thrombocytopenia; Transplantation Conditioning; Tumor Lysis Syndrome | 2021 |
Azacitidine and Venetoclax in AML.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Azacitidine and Venetoclax in AML.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Azacitidine and Venetoclax in AML.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Azacitidine and Venetoclax in AML. Reply.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Drug Combinations; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sulfonamides; Young Adult | 2020 |
Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; COVID-19; Cytarabine; Extracorporeal Membrane Oxygenation; Female; Humans; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; SARS-CoV-2; Treatment Outcome | 2020 |
Minimal Residual Disease Eradication by Azacitidine Maintenance in a Patient with Core-Binding Factor Acute Myeloid Leukemia.
Topics: Adult; Azacitidine; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Oncogene Proteins, Fusion; Remission Induction | 2020 |
Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Hypoxia-Inducible Factor 1; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Risk Factors; Up-Regulation | 2021 |
The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Assessment; Spain | 2021 |
Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Developing Countries; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
New maintenance option for AML.
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute | 2021 |
The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Fibrinogen; Follow-Up Studies; Humans; Inflammation; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Retrospective Studies; ROC Curve; Serum Albumin, Human | 2021 |
Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia.
Topics: Aniline Compounds; Azacitidine; Benzimidazoles; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Methyltransferases | 2021 |
Case of neutrophilic eccrine hidradenitis resembling acanthosis nigricans in a patient with acute myeloid leukemia associated with azacitidine and sorafenib.
Topics: Acanthosis Nigricans; Azacitidine; Hidradenitis; Humans; Leukemia, Myeloid, Acute; Sorafenib | 2021 |
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Hypomethylating agents and venetoclax in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Recurrence; Salvage Therapy; Sulfonamides; Treatment Outcome | 2021 |
Synchronous detection of multiple myeloma and acute myeloid leukemia: A diagnostic and therapeutic challenge.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Arm; Azacitidine; Biopsy; Bone Marrow; Bortezomib; Dexamethasone; Fatal Outcome; Granulocyte Precursor Cells; Humans; Leukemia, Myeloid, Acute; Male; Multiple Myeloma; Myeloma Proteins; Necrosis | 2021 |
Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival.
Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Impatiens; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Outpatients; Retrospective Studies; Survival Rate | 2021 |
Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations.
Topics: Azacitidine; Decitabine; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Receptors, Chimeric Antigen; Tumor Suppressor Protein p53 | 2021 |
Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Blood Cell Count; Bone Marrow; Cancer Survivors; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Diagnosis, Differential; Eosinophilia; Hemorrhagic Disorders; Humans; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pancytopenia; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Staurosporine; Tryptases | 2021 |
[A monocentric study on the management of patients with myelodysplastic syndromes in Morocco].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Bone Marrow Transplantation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Morocco; Myelodysplastic Syndromes; Retrospective Studies; Time Factors; Treatment Outcome | 2020 |
Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML.
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Transplantation, Homologous | 2021 |
Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Cytoskeletal Proteins; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Endogenous Retroviruses; Female; Gene Expression Regulation, Leukemic; Gene Knockout Techniques; HCT116 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Progression-Free Survival; RNA Stability; RNA-Binding Proteins; RNA-Seq; RNA, Double-Stranded; RNA, Long Noncoding; RNA, Viral | 2021 |
Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis.
Topics: Adolescent; Adult; Aged; Azacitidine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2021 |
The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; Clinical Trials, Phase III as Topic; Decitabine; DNA Methylation; Drug Approval; Drug Combinations; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Uridine | 2021 |
Minimal Residual Disease in Acute Myelogenous Leukemia Is Predictive, Unless You Are Over Age 60 and Treated with Decitabine.
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual | 2021 |
Oral Azacitidine Maintenance for Acute Myeloid Leukemia.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute | 2021 |
Oral Azacitidine Maintenance for Acute Myeloid Leukemia. Reply.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute | 2021 |
Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA.
Topics: Aminopyridines; Azacitidine; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Triazines | 2021 |
Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Azacitidine; Disease Susceptibility; Female; Humans; Incidence; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2021 |
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cyclopentanes; Humans; Leukemia, Myeloid, Acute; Pyrimidines; Sulfonamides | 2022 |
The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 2021 |
Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation, Homologous | 2021 |
In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quinuclidines; Treatment Outcome; Tumor Cells, Cultured | 2021 |
Durable Remission of Chemotherapy-Refractory Myeloid Sarcoma by Azacitidine.
Topics: Aged, 80 and over; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Sarcoma, Myeloid | 2021 |
Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation, Homologous | 2021 |
Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome.
Topics: Azacitidine; Clinical Trials, Phase II as Topic; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Lymphocytes; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Transplantation, Homologous | 2021 |
Azacitidine and venetoclax for post-transplant relapse in a case of CBFA2T3/GLIS2 childhood acute myeloid leukaemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Humans; Kruppel-Like Transcription Factors; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Repressor Proteins; Sulfonamides | 2021 |
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Sulfonamides; T-Lymphocytes | 2021 |
The Real-Life Efficacy of Fixed-Dose Hypomethylating Agents in Older Patients With Acute Myeloid Leukemia: A 10-Year Experience.
Topics: Aged; Azacitidine; Cohort Studies; Humans; Leukemia, Myeloid, Acute; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2021 |
Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Sulfonamides | 2021 |
A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Comorbidity; Decitabine; Female; Humans; Kidney Diseases; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2018 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT.
Topics: Adolescent; Adult; Aged; Allografts; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence | 2017 |
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Topics: Aged; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms, Second Primary; Proportional Hazards Models; Remission Induction; Retrospective Studies; Treatment Outcome | 2017 |
Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Topics: ADAM17 Protein; Adult; Aged; Azacitidine; Cell Line, Tumor; Chromosome Aberrations; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Leukemic; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Leukemia, Myeloid, Acute; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Prognosis; Tissue Inhibitor of Metalloproteinase-3 | 2017 |
Hypomethylation agent decitabine restores drug sensitivity by depressing P-glycoprotein activity through MAPK signaling pathway.
Topics: ATP Binding Cassette Transporter, Subfamily B; Azacitidine; Decitabine; Female; Humans; K562 Cells; Leukemia, Myeloid, Acute; Male; MAP Kinase Signaling System; MCF-7 Cells; Neoplasm Proteins | 2017 |
Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous | 2017 |
Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Case-Control Studies; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; HL-60 Cells; Humans; Inhibitor of Differentiation Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Signal Transduction; Survival Analysis | 2017 |
Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience.
Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Failure | 2017 |
Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Computational Biology; Cytarabine; Databases, Genetic; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Ontology; Gene Regulatory Networks; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Annotation | 2017 |
Successful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation.
Topics: Adult; Antimetabolites, Antineoplastic; Asian People; Azacitidine; Behcet Syndrome; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Remission Induction; Tacrolimus; Transplantation, Homologous; Treatment Outcome | 2017 |
Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Child; Drug Synergism; Epigenesis, Genetic; Flow Cytometry; Gene Expression Profiling; Humans; Hydroxamic Acids; Immunoblotting; Indoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Mice; Oligonucleotide Array Sequence Analysis; Panobinostat; Remission Induction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Bone Marrow Cells; Female; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins c-bcl-2; Treatment Outcome | 2017 |
Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Erythrocyte Transfusion; Erythrocytes; Female; Humans; Isoantibodies; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transfusion Reaction | 2017 |
Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
Topics: Adolescent; Antineoplastic Agents; Azacitidine; Decitabine; Drug Therapy, Combination; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Palliative Care; Quality of Life; Vorinostat | 2017 |
Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.
Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; In Situ Hybridization, Fluorescence; Janus Kinase 2; Leukemia, Myeloid, Acute; Multiple Myeloma; Mutation, Missense; Neoplasms, Multiple Primary; Remission Induction; Translocation, Genetic | 2017 |
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2017 |
Feasibility and cost-effectiveness of at home azacitidine administration.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cost-Benefit Analysis; Feasibility Studies; Health Care Costs; Home Care Services, Hospital-Based; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies; Spain; Treatment Outcome | 2017 |
Targeted therapy-induced differentiation of acute myeloid leukemia blasts.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Bone Marrow; Cell Differentiation; Enzyme Inhibitors; Female; Flow Cytometry; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Neoplastic Stem Cells | 2017 |
Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Clinical Trials, Phase I as Topic; Female; Fetal Hemoglobin; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Pyridines | 2018 |
Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia.
Topics: Azacitidine; Cell Differentiation; Computational Biology; DNA Demethylation; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Demethylases; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Models, Molecular; Promoter Regions, Genetic | 2017 |
[The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Patients; Remission Induction; Retrospective Studies; Treatment Outcome | 2017 |
The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Azacitidine; Ciprofloxacin; Communicable Diseases; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Morbidity; Retrospective Studies; Treatment Outcome | 2017 |
Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Decision-Making; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Survival Rate; Treatment Outcome | 2017 |
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomedical Research; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Predictive Value of Tests; Remission Induction; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2018 |
Time to response and survival in hypomethylating agent-treated acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sex Factors; Survival Analysis; Time Factors; Treatment Outcome | 2018 |
Guadecitabine: a new therapeutic option for acute myeloid leukaemia?
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute | 2017 |
MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML.
Topics: Adolescent; Azacitidine; Carcinogenesis; Cell Line, Tumor; Child; Child, Preschool; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Epigenesis, Genetic; Exons; Female; Gene Expression Regulation, Leukemic; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Trans-Activators; Tumor Suppressor Proteins | 2018 |
Fulminant
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bacillus cereus; Fatal Outcome; Hemorrhagic Septicemia; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Male; Multiple Organ Failure | 2017 |
Azacitidine-induced Sweet syndrome: Two unusual clinical presentations.
Topics: Abdominal Wall; Antimetabolites, Antineoplastic; Azacitidine; Biopsy, Needle; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Risk Assessment; Sampling Studies; Severity of Illness Index; Sweet Syndrome; Treatment Outcome | 2018 |
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Administration Schedule; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Missouri; Mycoses; Myelodysplastic Syndromes; Neutropenia; Opportunistic Infections; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Virus Diseases | 2017 |
[Clinical Observation of Therapeutic Regimen Consisted of Decitabine Combined with Low-Dose IA Regimen for Myelodysplastic Syndrome-EB].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Retrospective Studies; Treatment Outcome | 2017 |
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Risk Factors; Survival Rate | 2017 |
Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation.
Topics: Antimetabolites, Antineoplastic; Autophagy; Azacitidine; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Decitabine; Epigenetic Repression; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Monocytes; Myelodysplastic Syndromes; Phosphorylation | 2017 |
Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2018 |
Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; Caco-2 Cells; Cell Line, Tumor; Decitabine; Drug Carriers; Drug Liberation; Drug Resistance, Neoplasm; Drug Stability; Ethylene Glycols; Humans; Leukemia, Myeloid, Acute; Lipids; Nanocapsules; Polysorbates | 2017 |
"Epigenetic" modification as therapy for acute myeloid leukemia.
Topics: Azacitidine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute | 2018 |
[Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia].
Topics: Alzheimer Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2017 |
A new option for remission induction in acute myeloid leukaemia.
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Sulfonamides | 2018 |
Octasomy 21 in a patient with secondary AML after CMML: the role of acquired NRAS mutations in triggering aneuploidy.
Topics: Aged; Aneuploidy; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 21; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; GTP Phosphohydrolases; Humans; Karyotyping; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Membrane Proteins; Neoplasms, Second Primary | 2018 |
Treatment With Azacitidine in the Context of Palliative Care for a Patient With Acute Myeloid Leukemia Complicating Fanconi Anemia With Biallelic FANCD1/BRCA 2 Mutations.
Topics: Antimetabolites, Antineoplastic; Azacitidine; BRCA2 Protein; Fanconi Anemia; Female; Humans; Infant; Leukemia, Myeloid, Acute; Mutation; Palliative Care | 2018 |
[Clinical Efficacy of Decitabine Combined with or without Cytarabine-based Low Dose Regimen for Senile patients with Acute Myeloid Leukemia].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Retrospective Studies; Treatment Outcome | 2018 |
Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Gene Expression Regulation, Neoplastic; Granulocytes; Hematopoietic Stem Cells; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Acute; Multipotent Stem Cells; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Prospective Studies | 2018 |
Major response of PNH to an AML chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cytarabine; Daunorubicin; Hemoglobinuria, Paroxysmal; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 2018 |
Pevonedistat, a new partner for 5-azacitidine.
Topics: Azacitidine; Cyclopentanes; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; NEDD8 Protein; Pyrimidines | 2018 |
Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cross-Sectional Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Palliative Care; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2018 |
Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Case-Control Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2018 |
MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Myelodysplastic Syndromes | 2018 |
Azacitidine effectively reduces
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cord Blood Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Prognosis; Salvage Therapy; Tumor Suppressor Protein p53 | 2018 |
The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Transformation, Neoplastic; Female; Greece; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Topics: Azacitidine; Biopsy; Diagnosis, Differential; Female; Fusariosis; Fusarium; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Middle Aged; Mycelium; Myelodysplastic Syndromes; Sarcoma, Myeloid; Sequence Analysis, DNA; Skin | 2018 |
Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Bone Marrow; Clonal Evolution; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Philadelphia Chromosome; Treatment Outcome | 2018 |
Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada.
Topics: Aged; Aged, 80 and over; Azacitidine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Ontario; Risk Factors; Survival Rate | 2018 |
Activity of decitabine in pericardial myeloid sarcoma.
Topics: Allografts; Antimetabolites, Antineoplastic; Azacitidine; Consolidation Chemotherapy; Decitabine; Drug Administration Schedule; Female; Heart Neoplasms; Humans; Leukemia, Myeloid, Acute; Pericardium; Positron Emission Tomography Computed Tomography; Remission Induction; Sarcoma, Myeloid; Stem Cell Transplantation; Treatment Outcome | 2018 |
Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies | 2018 |
[Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Treatment Outcome | 2018 |
Acute liver failure due to liver parenchymal infiltration with acute myelogenous leukaemia in a patient with myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Liver; Liver Failure, Acute; Myelodysplastic Syndromes | 2018 |
Glycemic dysregulation in a patient with type 2 diabetes treated with 5-azacitidine: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Diabetes Mellitus, Type 2; Epigenesis, Genetic; Glucose; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes | 2018 |
Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2018 |
[All-Trans Retinoic Acid and Decitabine Synergistically Induce Anti-Leukemia Effect on U937 Cell Line and Newly Diagnosed Elder AML Patients].
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Tretinoin; U937 Cells | 2018 |
Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplasm, Residual; Primary Myelofibrosis; Retrospective Studies; Transplantation, Homologous; Young Adult | 2018 |
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytogenetics; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation | 2018 |
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cytarabine; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Case-Control Studies; DNA Methylation; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Humans; Integrin beta1; K562 Cells; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Prognosis; Promoter Regions, Genetic; Survival Analysis; Young Adult | 2019 |
Venetoclax with decitabine or azacitidine for AML.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Sulfonamides; Time Factors; Treatment Outcome | 2018 |
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Apoptosis; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Electron Transport Complex II; Energy Metabolism; Female; Humans; Ketoglutaric Acids; Leukemia, Myeloid, Acute; Male; Neoplastic Stem Cells; Oxidative Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Succinate Dehydrogenase; Sulfonamides; Tricarboxylic Acids | 2018 |
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.
Topics: Amino Acids; Animals; Antineoplastic Agents; Azacitidine; Biological Transport; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Fatty Acids; Female; Glycolysis; Humans; Leukemia, Myeloid, Acute; Lipid Metabolism; Metabolome; Mice; Neoplastic Stem Cells; Oxidative Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2018 |
Pre-emptive azacitidine for relapse prevention in acute myeloid leukaemia.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Secondary Prevention | 2018 |
Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies | 2018 |
Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion.
Topics: Azacitidine; Cell Adhesion; Cell Line, Tumor; Cell Survival; Female; Humans; Integrin alpha2; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Mesenchymal Stem Cells; Middle Aged; Myelodysplastic Syndromes; Neoplastic Stem Cells; Tumor Microenvironment | 2019 |
10-day decitabine schedule in acute myeloid leukaemia: no extra bang for the buck.
Topics: Aged; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute | 2019 |
Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome.
Topics: Azacitidine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Leukemic; Genomics; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Neoplasm Proteins; Proteome; Up-Regulation | 2019 |
Venetoclax in AML: aiming for "just right".
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2019 |
Venetolax with Azacitidine Drains Fuel from AML Stem Cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Energy Metabolism; Humans; Leukemia, Myeloid, Acute; Stem Cells; Sulfonamides | 2019 |
Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Safety; Survival Rate; Treatment Outcome | 2019 |
Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 2019 |
Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Biomarkers, Tumor; Bone Marrow; Cell Transformation, Neoplastic; Disease Progression; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Proto-Oncogene Proteins; Repressor Proteins; Trans-Activators; Up-Regulation | 2019 |
Azacitidine resistance caused by LAMP2 deficiency: a therapeutic window for the use of autophagy inhibitors in MDS/AML patients?
Topics: Autophagy; Azacitidine; Humans; Leukemia, Myeloid, Acute; Lysosomal-Associated Membrane Protein 2; Lysosomes; Molecular Chaperones | 2019 |
Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.
Topics: Animals; Antineoplastic Agents, Immunological; Azacitidine; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; DNA Methylation; Down-Regulation; Humans; Immunity, Cellular; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Neoplasm Transplantation; Programmed Cell Death 1 Receptor; Retroviridae; Tumor Microenvironment; Virus Activation | 2019 |
Maintenance therapy for AML: are we there yet?
Topics: Aged; Azacitidine; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy | 2019 |
10-day vs 5-day decitabine: equivalence cannot be concluded.
Topics: Aged; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute | 2019 |
Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine.
Topics: Aged; Aged, 80 and over; Azacitidine; Biomarkers; Cell Line, Tumor; Cytotoxicity, Immunologic; Female; Humans; Killer Cells, Natural; Leukemia, Myeloid, Acute; Lymphocyte Subsets; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; ROC Curve | 2019 |
Low-dose azacitidine for relapse prevention after allogeneic hematopoietic cell transplantation in children with myeloid malignancies.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Secondary Prevention; Tacrolimus; Transplantation, Homologous; Treatment Outcome; Young Adult | 2019 |
Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Homologous | 2019 |
Healthcare expenditures of older patients with AML are similar between HMA and intensive induction chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Female; Follow-Up Studies; Health Care Costs; Health Expenditures; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Natural killer cell activity and survival after azacitidine treatment in high-risk MDS.
Topics: Azacitidine; Hematologic Tests; Humans; Killer Cells, Natural; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2019 |
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Chemotherapy-Induced Febrile Neutropenia; Decitabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Sulfonamides; Survival Analysis; Transplantation, Homologous | 2019 |
Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Transplantation, Homologous; Treatment Outcome; WT1 Proteins | 2019 |
One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic
Topics: Antigens, CD; Azacitidine; CD8-Positive T-Lymphocytes; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Lymphocyte Activation Gene 3 Protein; Male; Middle Aged; Myelodysplastic Syndromes; Programmed Cell Death 1 Receptor; Recurrence; Transplantation, Homologous | 2019 |
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase I as Topic; Cytarabine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Remission Induction; Sulfonamides; Treatment Outcome | 2019 |
Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease.
Topics: Aged; Antineoplastic Agents; Azacitidine; Diagnosis, Differential; DNA; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Female; Glucocorticoids; Humans; Leukemia, Myeloid, Acute; Male; Methyltransferases; Middle Aged; Neutrophils; Panniculitis; Prednisone; Skin Diseases; Treatment Outcome | 2019 |
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Decitabine; Disease-Free Survival; DNA, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Remission Induction; Retrospective Studies; Risk Assessment; Sulfonamides; Treatment Outcome; Young Adult | 2019 |
Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Topics: Aged; Azacitidine; Greece; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies | 2020 |
The wolf of hypomethylating agent failure: what comes next?
Topics: Animals; Azacitidine; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vorinostat; Wolves | 2019 |
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Bone Marrow; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mice; Patient Selection; Primary Cell Culture; Retrospective Studies; SAM Domain and HD Domain-Containing Protein 1; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Child; Child, Preschool; Combined Modality Therapy; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Neoplasm Proteins; Neutropenia; Remission Induction; RNA, Neoplasm; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2013 |
Myelodysplasia: new approaches.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Stem Cell Transplantation | 2013 |
Demethylation demystification.
Topics: Animals; Azacitidine; Decitabine; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute | 2013 |
[Curative effect of decitabine combined with cytokine-induced killer cells in two elderly patients with acute myeloid leukemia].
Topics: Aged, 80 and over; Azacitidine; Cytokine-Induced Killer Cells; Decitabine; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Male; Treatment Outcome | 2013 |
[Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Combined Modality Therapy; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Gene Expression; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Gene Transfer Techniques; Humans; Leukemia, Myeloid, Acute; Linoleic Acid; Male; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Nanoparticles; Phosphatidylethanolamines; Polyethylene Glycols; RNA Interference; Transferrin; Xenograft Model Antitumor Assays | 2013 |
Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation.
Topics: Aged; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation, Autologous | 2013 |
Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Count; Myelodysplastic Syndromes; Recurrence; Salvage Therapy; T-Lymphocytes, Regulatory; Transplantation, Homologous | 2013 |
Decitabine in older adults with acute myeloid leukemia: why was the dream broken?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Drug Approval; Humans; Leukemia, Myeloid, Acute | 2013 |
Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome | 2013 |
[Interpretation of decitabine treatment for elderly patients with acute myeloid leukemia: the multicenter, open-label, phase III clinical trial (registered trial DACO-016)].
Topics: Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Humans; Leukemia, Myeloid, Acute; Multicenter Studies as Topic | 2013 |
5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Cells; Chromosome Aberrations; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nuclear Proteins; Nucleophosmin; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2013 |
Acute graft-versus-host disease in a nonhematopoietic stem cell transplantation candidate treated with decitabine followed by granulocyte colony-stimulating factor-primed peripheral blood stem cells infusion: a special entity of the disease?
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Combined Modality Therapy; Decitabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning | 2014 |
Concise drug review: azacitidine and decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Drug Approval; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 2013 |
Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia.
Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Administration Schedule; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thrombocythemia, Essential; Treatment Outcome | 2013 |
Case of azacitidine-induced maculopapular erythematous eruption.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Drug Eruptions; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 2013 |
Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytogenetic Analysis; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Rate; Treatment Outcome | 2013 |
Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Karyotype; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome | 2013 |
Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide | 2013 |
[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzoates; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Deferasirox; Disease Progression; Drug Resistance; Epoetin Alfa; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Triazoles | 2014 |
Reply to H. Kantarjian et al.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Drug Approval; Humans; Leukemia, Myeloid, Acute | 2013 |
The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Biological Transport; Cell Line, Tumor; DNA Methylation; DNA Modification Methylases; Dogs; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Humans; Leukemia; Leukemia, Myeloid, Acute; Madin Darby Canine Kidney Cells | 2013 |
[Clinical efficacy of decitabine plus improved CAG chemotherapy and haplo-identical donor peripheral lymphocyte infusion regimen on elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Haploidy; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Lymphocytes; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2013 |
[5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2013 |
The different faces of myelodysplasia in peripheral blood granulocytes.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chemotherapy, Adjuvant; Decitabine; Female; Granulocytes; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Ovarian Neoplasms; Remission Induction | 2014 |
Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Case-Control Studies; Cell Differentiation; Deferasirox; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Cells; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Triazoles; Vitamin D | 2013 |
The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML).
Topics: Adolescent; Azacitidine; Bone Marrow; Cell Line, Tumor; Child; Child, Preschool; China; Decitabine; DNA Methylation; Female; Genes, Tumor Suppressor; Humans; Infant; Leukemia, Myeloid, Acute; Male; MicroRNAs; Promoter Regions, Genetic; Sequence Analysis, DNA; Transcription, Genetic | 2013 |
Simultaneous occurrence of large B-cell non-Hodgkin lymphoma and acute myeloid leukaemia in an elderly patient: complete remissions of both diseases by rituximab-bendamustine regimen combined to hypomethylating therapy.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Female; Frail Elderly; Humans; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Nitrogen Mustard Compounds; Remission Induction; Rituximab | 2013 |
Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
Topics: Aminopyridines; Antigens, Neoplasm; Apoptosis; Azacitidine; Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Decitabine; Flow Cytometry; Histone Deacetylase Inhibitors; HLA-A Antigens; Humans; Leukemia, Myeloid, Acute; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic | 2013 |
The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Case-Control Studies; CpG Islands; Decitabine; DNA Methylation; Female; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Nucleocytoplasmic Transport Proteins; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.
Topics: Apoptosis; Autocrine Communication; Azacitidine; Caspases; Cell Line, Tumor; Decitabine; DNA Fragmentation; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Leukemia, Myeloid, Acute; Mitochondria; Mitochondrial Proteins; Necrosis; Oligopeptides; Paracrine Communication; Tumor Necrosis Factor-alpha | 2013 |
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Prognosis; Treatment Outcome | 2014 |
Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Comorbidity; Consolidation Chemotherapy; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Methylation; DNA, Neoplasm; Drug Evaluation; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate | 2014 |
[Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Azacitidine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Hepatomegaly; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Serositis | 2014 |
Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antimetabolites, Antineoplastic; Azacitidine; Humans; Incidence; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Salvage Therapy | 2014 |
Successful management of acute myeloid leukemia transformed from myelodysplastic syndromes in an elderly patient aged over 80 years old by ultralow dose decitabine combined with amifostine and autologous CIK cells.
Topics: Aged, 80 and over; Amifostine; Azacitidine; Cells, Cultured; Combined Modality Therapy; Cytokine-Induced Killer Cells; Decitabine; Disease Management; Disease Progression; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Transplantation, Autologous | 2014 |
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; B7-H1 Antigen; Biomarkers, Tumor; Cohort Studies; CTLA-4 Antigen; Decitabine; DNA Methylation; Female; Flow Cytometry; Humans; Immunoenzyme Techniques; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukocytes, Mononuclear; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Programmed Cell Death 1 Ligand 2 Protein; Programmed Cell Death 1 Receptor; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured | 2014 |
Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.
Topics: Acetylation; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Survival; Chromatin Assembly and Disassembly; Core Binding Factor Alpha 2 Subunit; Decitabine; DNA Modification Methylases; Gene Silencing; Histones; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Methylation; Promoter Regions, Genetic; Proto-Oncogene Proteins; RUNX1 Translocation Partner 1 Protein; Transcription Factors | 2014 |
inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Inversion; Chromosomes, Human, Pair 2; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Molecular Chaperones; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2014 |
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
Topics: AC133 Antigen; Antibodies; Antibodies, Bispecific; Antigens, CD; Azacitidine; CD3 Complex; Cell Line, Tumor; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Glycoproteins; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; O(6)-Methylguanine-DNA Methyltransferase; Panobinostat; Peptides; Polymorphism, Single Nucleotide; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes | 2014 |
Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Compassionate Use Trials; Febrile Neutropenia; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Sepsis; Treatment Outcome | 2014 |
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Chemotherapy, Adjuvant; Cladribine; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Failure; Young Adult | 2014 |
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; bcl-X Protein; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myeloid Cell Leukemia Sequence 1 Protein; Myeloproliferative Disorders; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Sulfonamides | 2014 |
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Pharmacological; Bone Marrow Cells; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloid Progenitor Cells; Prognosis; Research Design; Retrospective Studies; Risk Factors | 2014 |
miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle; Cell Proliferation; CpG Islands; Decitabine; Gene Expression Regulation, Leukemic; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; MicroRNAs; Oncogene Proteins v-erbB; Signal Transduction | 2014 |
Cladribine in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins | 2014 |
Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Azacitidine; Blotting, Western; Caspase 8; Dipeptides; DNA Methylation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitochondrial Proteins; Neoplastic Stem Cells; Protein Array Analysis | 2014 |
A 5-day outpatient regimen of azacitidine is effective and well tolerated in patients with acute myeloid leukemia unsuitable for intensive chemotherapy.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Frail Elderly; Humans; Leukemia, Myeloid, Acute; Male | 2014 |
Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cytarabine; Drug Administration Schedule; Female; Hemorrhage; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Palliative Care; Pneumonia; Retrospective Studies; Survival Analysis | 2014 |
HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Graft Survival; Graft vs Leukemia Effect; Histocompatibility; HLA Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Male; Middle Aged; Remission Induction; Tissue Donors | 2014 |
[Identification of myelodysplastic syndromes patients].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Quality of Life; Risk Factors; Survival | 2014 |
Leukemic pleural effusion: diagnostic approach and controversies in pleurodesis.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Bleomycin; Clone Cells; Combined Modality Therapy; Drainage; Fatal Outcome; Granulocyte Precursor Cells; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Pleural Effusion, Malignant; Pleurodesis; Sclerosing Solutions | 2014 |
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Retrospective Studies | 2014 |
TP53 mutations and azacitidine treatment: to be or not to be related?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Genes, p53; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes | 2014 |
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Genes, p53; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis | 2014 |
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly].
Topics: Aged, 80 and over; Anemia, Aplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Diagnosis, Differential; Disease Progression; Hematopoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2014 |
Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Remission Induction; Retrospective Studies; Treatment Outcome | 2014 |
Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Cells, Cultured; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA-Binding Proteins; Drug Administration Schedule; Female; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Promoter Regions, Genetic; RNA, Messenger; Survival Analysis | 2014 |
Acute basophilic leukemia.
Topics: Aged; Antibiotics, Antineoplastic; Antigens, CD; Antimetabolites, Antineoplastic; Asthenia; Azacitidine; Basophils; Bone Marrow; Cytarabine; Female; Humans; Idarubicin; Leukemia, Basophilic, Acute; Leukemia, Myeloid, Acute | 2014 |
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Gene Expression; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
[Comparative analysis of decitabine combined with DAG regimen and other regimens in treatment of refractory/relapsed acute myeloid leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Ultra-low-dose decitabine combined with autologous cytokine-induced killer cells for elderly patients with acute myeloid leukemia transformed from myelodysplastic syndrome.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Combined Modality Therapy; Cytokine-Induced Killer Cells; Decitabine; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Transplantation, Autologous; Treatment Outcome | 2014 |
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Prognosis; Retrospective Studies; Treatment Outcome | 2014 |
Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Epigenesis, Genetic; Female; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Panobinostat; Treatment Outcome | 2014 |
[Myelodysplastic syndrome with rapid disease progression after withdrawal of treatment with azacitidine].
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation, Homologous; Treatment Failure | 2015 |
MLL5 expression as a biomarker for DNA hypermethylation and sensitivity to epigenetic therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA-Binding Proteins; Female; Humans; Leukemia, Myeloid, Acute; Male; RNA, Messenger | 2014 |
Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; France; Humans; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Lymphocyte Count; Male; Middle Aged; Multivariate Analysis; Palliative Care; Prognosis; Prospective Studies; Regional Medical Programs; Survival Analysis | 2014 |
SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Azacitidine; Bone Marrow; Cell Line, Tumor; Decitabine; DNA Methylation; DNA, Neoplasm; Down-Regulation; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; RNA Interference; RNA, Messenger; RNA, Neoplasm; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Young Adult | 2014 |
Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.
Topics: Animals; Azacitidine; Cell Line, Tumor; DNA Methylation; Female; Humans; Immunologic Factors; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2014 |
Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Pioglitazone; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Thiazolidinediones; Tretinoin | 2015 |
Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Failure | 2015 |
DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Acute; Promoter Regions, Genetic; Sequence Analysis, RNA | 2014 |
A WIMSical approach to decoding DNA methylation in myeloid leukemia.
Topics: Azacitidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Gene Silencing; Humans; Leukemia, Myeloid, Acute; Promoter Regions, Genetic | 2014 |
Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Belgium; Female; Health Services Accessibility; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Reimbursement Mechanisms | 2015 |
Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Treatment Failure; Valproic Acid | 2015 |
[Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Core Binding Factor Alpha 2 Subunit; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; Recurrence; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Treatment Outcome; Young Adult | 2014 |
[Effect of decitabine on immune regulation in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Quality of Life; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Transplantation, Homologous | 2014 |
[The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Belgium; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Product Surveillance, Postmarketing; Treatment Outcome | 2015 |
Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Gene Expression; Gene Expression Profiling; Genes, myc; Glycogen Synthase; Humans; Hypoxia; Intramolecular Oxidoreductases; Leukemia, Myeloid, Acute; Macrophage Migration-Inhibitory Factors; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Treatment Outcome | 2015 |
5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Non-Small-Cell Lung; CpG Islands; DNA Methylation; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Tumor Cells, Cultured; U937 Cells | 2015 |
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
Topics: Animals; Azacitidine; Benzodioxoles; Blotting, Western; Colony-Forming Units Assay; Decitabine; Exome; Flow Cytometry; Hematologic Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Mice; Mutation, Missense; Myeloproliferative Disorders; Nitriles; Purines; Pyrazoles; Pyrimidines; Tumor Suppressor Protein p53 | 2014 |
Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Treatment Outcome | 2015 |
Leukemic transformation in essential thrombocythemia.
Topics: Azacitidine; Cell Transformation, Neoplastic; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Mutation; Prognosis; Risk Factors; Stem Cell Transplantation; Thrombocythemia, Essential; Transplantation, Homologous | 2014 |
Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Female; Follow-Up Studies; Hospitalization; Humans; Idarubicin; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Silencing HO-1 sensitizes SKM-1 cells to apoptosis induced by low concentration 5-azacytidine through enhancing p16 demethylation.
Topics: Adult; Aged; Animals; Apoptosis; Azacitidine; Cells, Cultured; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Silencing; Genes, p16; HEK293 Cells; Heme Oxygenase-1; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; RNA, Small Interfering; U937 Cells; Xenograft Model Antitumor Assays | 2015 |
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; Validation Studies as Topic | 2015 |
RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype.
Topics: Adult; Aged; Azacitidine; Cell Line, Tumor; Chromosome Inversion; Core Binding Factor Alpha 3 Subunit; Decitabine; DNA Methylation; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Middle Aged; Promoter Regions, Genetic; Transcriptional Activation | 2015 |
Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2015 |
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Female; Genotype; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Mutation; Odds Ratio; Prognosis; Remission Induction; Retrospective Studies; Sex Factors | 2015 |
The DNA methylation inhibitor induces telomere dysfunction and apoptosis of leukemia cells that is attenuated by telomerase over-expression.
Topics: Adult; Aged; Apoptosis; Azacitidine; Cell Line, Tumor; DNA Damage; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Telomerase; Telomere; Young Adult | 2015 |
[Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; DNA Modification Methylases; Exportin 1 Protein; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Cells, Cultured; Up-Regulation | 2015 |
5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft.
Topics: Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Stem Cell Transplantation | 2015 |
Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Epigenesis, Genetic; Female; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mycoses; Myelodysplastic Syndromes; Platelet Count; Risk Factors; Virus Diseases | 2015 |
Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Line, Tumor; Drug Administration Schedule; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Leukemia, Myeloid, Acute; Mice; Monocytes; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
Topics: Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Blood Cells; DNA Methylation; Drug Resistance; Female; Gene Expression Regulation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Activation; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Programmed Cell Death 1 Receptor; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm; T-Lymphocyte Subsets | 2015 |
Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Nucleophosmin; Transplantation Conditioning; Treatment Outcome; Young Adult | 2015 |
Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytidine Deaminase; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide | 2015 |
The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells.
Topics: 5-Methylcytosine; Azacitidine; Catalytic Domain; Chromatography, High Pressure Liquid; CpG Islands; Cytosine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA-Binding Proteins; Enzyme-Linked Immunosorbent Assay; HL-60 Cells; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; MCF-7 Cells; Microscopy, Fluorescence; Mixed Function Oxygenases; Protein Binding; Proto-Oncogene Proteins; Spectrometry, Fluorescence; Tandem Mass Spectrometry | 2015 |
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease Progression; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Registries; Spain; Treatment Outcome | 2015 |
Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aquaporins; Arsenic Trioxide; Arsenicals; Azacitidine; Blotting, Western; Cell Line, Tumor; Cells, Cultured; Drug Synergism; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Oxides; Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Up-Regulation | 2015 |
Acute myeloid leukemia cells MOLM-13 and SKM-1 established for resistance by azacytidine are crossresistant to P-glycoprotein substrates.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Azacitidine; bcl-2-Associated X Protein; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Glutathione Transferase; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; NF-kappa B p50 Subunit; NF-kappa B p52 Subunit; Proto-Oncogene Proteins c-bcl-2; Transcription Factor RelA; Tumor Suppressor Protein p53; Vincristine | 2015 |
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Count; Disease Management; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
[Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia].
Topics: Azacitidine; Decitabine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous | 2015 |
Differentiation syndrome in acute myeloid leukemia after treatment with azacitidine.
Topics: Aged; Azacitidine; Female; Fever; Humans; Hypotension; Leukemia, Myeloid, Acute; Pericardial Effusion; Syndrome | 2015 |
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Chromosome Aberrations; Chromosomes, Human, Pair 3; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate | 2015 |
Azacitidine in AML: a treatment option?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Female; Humans; Leukemia, Myeloid, Acute; Male | 2015 |
The 5' flanking region of miR-378 is hypomethylated in acute myeloid leukemia.
Topics: 5' Flanking Region; Adult; Aged; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Prognosis; Real-Time Polymerase Chain Reaction | 2015 |
Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Lineage; Female; Flow Cytometry; Gene Expression; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Receptors, Antigen, T-Cell; Treatment Outcome | 2015 |
Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Administration Schedule; Female; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
5-Azacytidine in the Treatment of Intermediate-2 and High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia. A Five-year Experience with 44 Consecutive Patients.
Topics: Aged; Aged, 80 and over; Azacitidine; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Treatment Outcome | 2015 |
Infection Rate and Risk Factors in Patients Treated With Azacitidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Virus Diseases | 2015 |
First Steps Towards Successful Post-Transplantation Therapy for Myeloid Malignancies after Allogeneic Blood Stem Cell Transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Myelodysplastic Syndromes | 2015 |
Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Female; Humans; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Thalidomide; Tumor Suppressor Protein p53 | 2015 |
Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).
Topics: Aged; Alternative Splicing; Anthracyclines; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Exons; Gene Expression Profiling; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Oncogene Proteins; Oncogenes; Poly-ADP-Ribose Binding Proteins; RNA Interference; RNA, Small Interfering; WT1 Proteins | 2016 |
Guadecitabine for AML and MDS: hype or hope?
Topics: Azacitidine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes | 2015 |
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis | 2015 |
[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Karyotype; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancytopenia; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
[Successful Hematopoietic Cell Transplantation Following Azacitidine Treatment in an Acute Myeloid Leukemia Patient with t(3;3)(q21;q26.2) Translocation and Marked Thrombocythemia].
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Translocation, Genetic | 2015 |
Response and survival in acute myeloid leukemia patients not candidates to transplantation treated with azacitidine versus palliative treatment: a retrospective study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Palliative Care; Quality of Life; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.
Topics: Adult; Aged; Allografts; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous | 2016 |
Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine.
Topics: Azacitidine; Cell Line, Tumor; Cyclopentanes; Humans; Leukemia, Myeloid, Acute; Neoplasm Proteins; Proteomics; Pyrimidines | 2016 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.
Topics: Aclarubicin; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cytarabine; Decitabine; Disease-Free Survival; Female; Harringtonines; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Young Adult | 2015 |
Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Topics: Abnormal Karyotype; Aclarubicin; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Humans; Induction Chemotherapy; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Treatment Outcome | 2015 |
Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair 7; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Sorafenib; Stem Cell Transplantation | 2016 |
Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytidine Deaminase; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Design; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Epigenesis, Genetic; Half-Life; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2015 |
Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Topics: Apoptosis; Azacitidine; Carbazoles; Cell Line, Tumor; Cells, Cultured; DNA Methylation; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Gene Duplication; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Protein Tyrosine Phosphatase, Non-Receptor Type 6; STAT3 Transcription Factor | 2015 |
Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Survival Rate | 2016 |
The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Modification Methylases; Drug Synergism; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 2016 |
The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Cluster Analysis; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplastic Stem Cells; Phenotype; Prognosis; Proteome; Signal Transduction; STAT3 Transcription Factor; STAT5 Transcription Factor; Survival Analysis; Treatment Outcome | 2016 |
[Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Remission Induction; Retrospective Studies | 2015 |
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Middle Aged; Randomized Controlled Trials as Topic | 2016 |
Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia.
Topics: Adult; Aged; Azacitidine; Case-Control Studies; CpG Islands; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitochondrial Proton-Translocating ATPases; Promoter Regions, Genetic; Recurrence; Remission Induction; Young Adult | 2016 |
Impact of Global and Gene-Specific DNA Methylation in de Novo or Relapsed Acute Myeloid Leukemia Patients Treated with Decitabine.
Topics: Adult; Aged; Azacitidine; CpG Islands; Decitabine; Disease-Free Survival; DNA; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Octamer Transcription Factor-3; Prognosis; SOXB1 Transcription Factors; Young Adult | 2016 |
Synergisitic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycitidine and 1-h-D-Arabinofuranoside.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Survival; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Time Factors | 2016 |
The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Comorbidity; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; ROC Curve; Young Adult | 2016 |
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; CD8-Positive T-Lymphocytes; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2016 |
Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Virus Diseases | 2016 |
Autoimmune diseases and myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Comorbidity; Disease Progression; Disease Susceptibility; Female; Follow-Up Studies; Hashimoto Disease; Humans; Immunocompromised Host; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prevalence; Proportional Hazards Models; Retrospective Studies; Thalidomide; Thyroiditis, Autoimmune; Young Adult | 2016 |
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Middle Aged | 2016 |
Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Calcitriol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome; Vitamin D | 2017 |
[Effect of Decitabine on DKK1 Gene Demethylation in Leukemia Cells].
Topics: Apoptosis; Azacitidine; beta Catenin; Decitabine; DNA Methylation; Gene Expression Regulation, Bacterial; Genes, myc; HL-60 Cells; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; RNA, Messenger; Wnt Signaling Pathway | 2016 |
Azacitidine-Induced Pericarditis: A Case Series.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chest Pain; Combined Modality Therapy; Diagnosis, Differential; DNA Modification Methylases; Drug Monitoring; Enzyme Inhibitors; Female; Glucocorticoids; Humans; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Pericarditis; Prednisone; Treatment Outcome | 2016 |
Pre- and post-treatment serum ferritin levels in patients with higher risk myelodysplastic syndromes receiving azacitidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Ferritins; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2016 |
Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Proliferation; Decitabine; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2016 |
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cells, Cultured; Combined Modality Therapy; Cytotoxicity, Immunologic; Decitabine; Drug Synergism; HL-60 Cells; Humans; Immunoglobulin Fc Fragments; Killer Cells, Natural; Leukemia, Myeloid, Acute; Recombinant Proteins; Sialic Acid Binding Ig-like Lectin 3 | 2016 |
Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Topics: Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antifungal Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic-Myeloproliferative Diseases; Neutropenia; Numbers Needed To Treat; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed; Triazoles | 2016 |
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2016 |
The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male | 2016 |
The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Bone Marrow; Comorbidity; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Blood Component Transfusion; Cell Transformation, Neoplastic; Decitabine; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Propensity Score; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Tretinoin | 2016 |
MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.
Topics: ADP-ribosyl Cyclase 1; Antigens, CD; Antigens, CD34; Azacitidine; Cadherins; Cell Line, Tumor; Cell Survival; Computational Biology; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Synergism; Gene Expression Regulation, Leukemic; Gene Silencing; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid, Acute; Mucin-1; NF-kappa B p50 Subunit; Promoter Regions, Genetic; RNA, Small Interfering; Transcription Factor RelA | 2016 |
Methylation status of the promoter region of the human frizzled 9 gene in acute myeloid leukemia.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Frizzled Receptors; Gene Expression Regulation, Leukemic; Gene Silencing; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid, Acute; Promoter Regions, Genetic | 2016 |
Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.
Topics: Azacitidine; Bone Marrow Cells; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Ribosomal Proteins; Transcriptome; Treatment Failure; Up-Regulation | 2016 |
BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Case-Control Studies; Cell Line; Decitabine; DNA Methylation; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Myelodysplastic Syndromes; Proto-Oncogene Proteins; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2016 |
Severe phototoxic reaction secondary to subcutaneous 5-azacitidine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Dermatitis, Phototoxic; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2017 |
Azacitidine Use After Allogeneic Stem Cell Transplantation-Results From the Polish Adult Leukemia Group.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Poland; Retrospective Studies; Transplantation, Homologous; Young Adult | 2016 |
Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Risk; Thrombocytopenia; Thrombopoietin | 2017 |
Decitabine prior to salvaged unrelated cord blood transplantation for refractory or relapsed childhood acute leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Child; Child, Preschool; Cohort Studies; Cord Blood Stem Cell Transplantation; Decitabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prevalence; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Treatment Outcome | 2016 |
Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Case-Control Studies; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Exons; Female; Gene Expression Regulation, Leukemic; Gene Silencing; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, Steroid; Receptors, Thyroid Hormone | 2016 |
Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug-Related Side Effects and Adverse Reactions; Female; Health Resources; Hospitalization; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Mortality | 2017 |
Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pregnancy; Pregnancy Complications, Neoplastic; Sorafenib; Treatment Outcome | 2018 |
[Clinical Comparation of Two Kinds of Chemotherapy Regimen in the Treatment of Elderly MDS Patients with AML Transformed by Abnormal Proliferation of Bone Marrow].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cell Proliferation; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neutropenia; Quality of Life; Treatment Outcome | 2016 |
Evidence for a role of decitabine in the treatment of myeloid sarcoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Sarcoma, Myeloid; Treatment Outcome | 2017 |
Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Republic of Korea; Retrospective Studies; Treatment Outcome | 2017 |
An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Azacitidine; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferase 1; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Myelodysplastic Syndromes; Prognosis; Signal Transduction | 2017 |
Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine.
Topics: Antibodies, Monoclonal; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Myositis; Neoplasms, Second Primary; Nivolumab; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2017 |
Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia.
Topics: Adolescent; Azacitidine; Cytotoxins; DNA Damage; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2017 |
TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
Topics: Azacitidine; Cell Transformation, Neoplastic; Chromosome Aberrations; Decitabine; Humans; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Predictive Value of Tests; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Case-Control Studies; Erythroblasts; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2017 |
Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.
Topics: Azacitidine; Cell Line, Tumor; Cytogenetics; Decitabine; DNA Methylation; Humans; Leukemia, Myeloid, Acute; Prognosis | 2017 |
Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Israel; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation, Homologous | 2017 |
Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Agents; Azacitidine; Biomarkers; Bone Marrow Cells; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Synergism; Female; GATA2 Transcription Factor; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Mice; Molecular Targeted Therapy; Xenograft Model Antitumor Assays | 2017 |
Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2017 |
A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male | 2017 |
Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Histocompatibility; HLA Antigens; Humans; Karyotype; Leukemia, Myeloid, Acute; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation | 2017 |
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mice; Mice, Mutant Strains; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins; Signal Transduction; Triazines | 2017 |
Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Postoperative Care; Recurrence; Retreatment; Sorafenib; Treatment Outcome | 2017 |
Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Bone Marrow; Bone Marrow Cells; DNA Mutational Analysis; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Postoperative Care; Prognosis | 2017 |
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Austria; Azacitidine; Bone Marrow; Clinical Trials, Phase III as Topic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Treatment Outcome | 2017 |
Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Humans; Incidence; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Time Factors | 2017 |
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Comorbidity; Decitabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genes, Tumor Suppressor; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Transcriptome; Treatment Outcome | 2017 |
A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts.
Topics: Azacitidine; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferases; Enzyme Inhibitors; Female; Granulocyte Precursor Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; I-kappa B Kinase; Leukemia, Myeloid, Acute; Male; Middle Aged; NF-kappa B; Valproic Acid | 2008 |
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Benzoquinones; Cell Differentiation; Cell Proliferation; Decitabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Heat Shock Transcription Factors; Histone Deacetylase Inhibitors; HL-60 Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Indoles; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Neoplasm Proteins; Panobinostat; S Phase; Transcription Factors; Tubulin; Vorinostat | 2008 |
A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Topics: Aged; Aged, 80 and over; Azacitidine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15INK4b gene methylation and high global DNA methylation.
Topics: Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Cytogenetics; Decitabine; DNA Methylation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2009 |
Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Cells; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Pilot Projects; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Follow-Up Studies; Histocompatibility Testing; Humans; Leukemia, Myeloid, Acute; Living Donors; Middle Aged; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome | 2008 |
p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; G1 Phase; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Ribonucleotide Reductases; Tumor Suppressor Protein p53 | 2008 |
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cytidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute | 2009 |
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Blotting, Western; Bone Marrow; Case-Control Studies; Child; Child, Preschool; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Sequence Data; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid; Survival Rate; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Young Adult | 2009 |
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells.
Topics: Azacitidine; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA-Binding Proteins; Drug Combinations; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; K562 Cells; Leukemia, Myeloid, Acute; Panobinostat; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Repressor Proteins; Transcription Factors | 2009 |
Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia.
Topics: Adult; Aged; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Genes, bcl-1; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Middle Aged; Prognosis; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Signal Transduction; Wnt Proteins | 2009 |
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Drug Administration Schedule; Epigenesis, Genetic; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2010 |
Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Diagnosis, Differential; Fatal Outcome; Female; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Sweet Syndrome; Treatment Outcome | 2009 |
Activation of HLA-G expression by 5-aza-2 - deoxycytidine in malignant hematopoetic cells isolated from leukemia patients.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stem Cell Transplantation | 2009 |
Case records of the Massachusetts General Hospital. Case 28-2009. A 68-year-old man with fatigue, cough, and peripheral-blood monocytosis.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Combined Modality Therapy; Cough; Decitabine; Diagnosis, Differential; Fatigue; Humans; Leukemia, Myeloid, Acute; Leukocytosis; Male; Monocytes; Stem Cell Transplantation | 2009 |
Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Proto-Oncogene Proteins c-abl; Recurrence | 2010 |
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 5; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2009 |
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.
Topics: Aged; Aged, 80 and over; Azacitidine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Phosphoinositide Phospholipase C; Phospholipase C beta; Promoter Regions, Genetic; RNA, Messenger | 2009 |
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.
Topics: Adult; Aged; Azacitidine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous | 2010 |
Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.
Topics: Azacitidine; Cell Adhesion Molecule-1; Cell Adhesion Molecules; Cell Line, Tumor; DNA Methylation; Gene Expression Regulation, Leukemic; Histones; Humans; Hydroxamic Acids; Immunoglobulins; Leukemia, Myeloid, Acute; Membrane Proteins; Mutation; Myeloid-Lymphoid Leukemia Protein; Nerve Tissue Proteins; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Receptors, Retinoic Acid; Sequence Analysis, DNA; Tissue Inhibitor of Metalloproteinase-3; Transcription, Genetic; Translocation, Genetic; Tumor Suppressor Proteins | 2009 |
Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.
Topics: Apoptosis; Azacitidine; Cadherins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid, Acute; Methyltransferases; Promoter Regions, Genetic; Repressor Proteins; RNA Interference | 2010 |
Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chemotherapy, Adjuvant; Female; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Middle Aged; Myelodysplastic Syndromes; Recurrence; Salvage Therapy | 2010 |
The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Chromosomes, Human, X; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Leukemic; Genes, X-Linked; HL-60 Cells; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Melanoma-Specific Antigens; Membrane Proteins; Multiple Myeloma; Neoplasm Proteins; RNA, Messenger; RNA, Neoplasm; U937 Cells | 2010 |
Advances in the management of acute myeloid leukemia in older adult patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Education as Topic; Practice Guidelines as Topic; Prognosis; Quality of Life; Social Support; Stem Cell Transplantation | 2010 |
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Kaplan-Meier Estimate; Kidney; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Renal Insufficiency | 2010 |
Screening for methylation-silenced genes in acute myeloid leukemia HL-60 cell line by a quantitative proteomic approach.
Topics: Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; Gene Silencing; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Proteome; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cells, Cultured; Decitabine; DNA Methylation; Epigenomics; Female; Gene Expression Regulation, Leukemic; Gene Frequency; Genome, Human; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Young Adult | 2010 |
Successful resolution of acute myelogenous leukemia-associated hemophagocytic lymphohistiocytosis with decitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Lymphohistiocytosis, Hemophagocytic; Male; Treatment Outcome | 2011 |
Hypomethylating agents for the treatment of acute myeloid leukemia in the elderly: for all, none, or which patients?
Topics: Aged; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute; Middle Aged; Treatment Outcome | 2011 |
Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Decitabine; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Humans; Leukemia, Myeloid, Acute; Markov Chains; Models, Economic; Myelodysplastic Syndromes; Patient Care; Randomized Controlled Trials as Topic; Risk; United States | 2010 |
Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies | 2012 |
Novel agents for the treatment of acute myeloid leukemia in the older patient.
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide | 2011 |
MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Azacitidine; Bone Marrow Cells; Cell Line, Tumor; Cells, Cultured; CpG Islands; DNA Methylation; Female; Gene Silencing; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Monocytes; Promoter Regions, Genetic; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Young Adult | 2011 |
Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Young Adult | 2011 |
Acute myeloblastic leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Dose-Response Relationship, Drug; Drug Hypersensitivity; Erythema Nodosum; Female; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Lung Diseases, Fungal; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 2011 |
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Dioxygenases; Disease-Free Survival; DNA Methylation; DNA-Binding Proteins; DNA, Neoplasm; Female; Hemoglobins; Humans; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Neoplasm Proteins; Proto-Oncogene Proteins; Sequence Analysis, DNA; Treatment Outcome | 2011 |
Epigenetic inactivation of the miR-124-1 in haematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase 6; Epigenesis, Genetic; Female; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methylation; MicroRNAs; Middle Aged; Multiple Myeloma; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2011 |
Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
Topics: Apoptosis; Azacitidine; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Modification Methylases; Drug Therapy, Combination; Enzyme Inhibitors; Epigenomics; Flow Cytometry; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Mutation, Missense; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cost-Benefit Analysis; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Practice Guidelines as Topic; Quality-Adjusted Life Years | 2011 |
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Bcl-2-Like Protein 11; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Decitabine; DNA Methylation; DNA Repair; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Histones; Humans; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Middle Aged; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins | 2011 |
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Cell Differentiation; Cytarabine; Decitabine; DNA Damage; Electrophoresis, Polyacrylamide Gel; Epigenesis, Genetic; Genes, p53; Humans; Leukemia, Myeloid, Acute; Mice; Phosphorylation; Transplantation, Heterologous | 2011 |
[Promoter methylation status of hPer3 gene in AML patients and the in vitro effect of decitabine on the status].
Topics: Adolescent; Adult; Aged; Azacitidine; Cell Proliferation; Decitabine; DNA Methylation; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Period Circadian Proteins; Promoter Regions, Genetic; U937 Cells; Young Adult | 2011 |
Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Recurrence; Treatment Outcome | 2011 |
Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Italy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Longitudinal Studies; Male; Middle Aged; Registries; Retrospective Studies; Treatment Outcome | 2012 |
CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors.
Topics: Antineoplastic Agents; Azacitidine; Base Sequence; Cell Lineage; CpG Islands; Decitabine; DNA Methylation; DNA Primers; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Polymerase Chain Reaction; Promoter Regions, Genetic | 2012 |
Impact of the hypomethylating agent 5-azacytidine on dendritic cells function.
Topics: Aged; Aged, 80 and over; Azacitidine; Cells, Cultured; Dendritic Cells; DNA Methylation; Epigenomics; Female; Humans; Immunity; Immunotherapy; Interleukins; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Th17 Cells | 2011 |
Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Topics: Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Bone Marrow Cells; Case-Control Studies; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenomics; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2011 |
News on hypomethylating agents: chasing the FOX.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Forkhead Transcription Factors; Humans; Leukemia, Myeloid, Acute; Male | 2011 |
Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Thalidomide | 2012 |
Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous | 2012 |
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation | 2012 |
Azacitidine in a patient with newly diagnosed acute myeloid leukemia and poor risk cytogenetics: outcomes of prolonged therapy.
Topics: Abnormal Karyotype; Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Risk; Treatment Outcome | 2012 |
Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine.
Topics: Azacitidine; Core Binding Factor Alpha 2 Subunit; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; Proteomics; RUNX1 Translocation Partner 1 Protein | 2012 |
Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate | 2012 |
Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment.
Topics: Antigens, CD34; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Blood Donors; Bone Marrow Cells; Cells, Cultured; CpG Islands; Cytogenetic Analysis; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Health; Humans; Leukemia, Myeloid, Acute; Stem Cells | 2012 |
Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Death; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Promoter Regions, Genetic; Telomerase; Telomere; U937 Cells | 2012 |
Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Arabinonucleosides; Azacitidine; Child; Child, Preschool; Clofarabine; Cytotoxins; Decitabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Middle Aged; Models, Biological; Signal Transduction; Tumor Cells, Cultured | 2012 |
BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.
Topics: Azacitidine; Biomarkers, Pharmacological; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Survival Analysis; Transgenes | 2012 |
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Retrospective Studies; Risk; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2012 |
[The comparison of short-term efficacies between decitabine and HA regimen for MDS/AML patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Treatment Outcome | 2012 |
Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; CpG Islands; DNA Methylation; fas Receptor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Promoter Regions, Genetic; Proportional Hazards Models; Risk | 2012 |
Transplantation for MDS in the elderly: more evidence, or more bias?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Transplantation Conditioning | 2012 |
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Profiling; Genome, Human; Humans; Leukemia, Myeloid, Acute; Male; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Promoter Regions, Genetic | 2012 |
Outcome of therapy-related myeloid neoplasms treated with azacitidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2012 |
Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Treatment Outcome | 2012 |
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Biphenyl Compounds; Cell Line, Tumor; DNA Modification Methylases; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mitochondria; Neoplasm Proteins; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Improving the outlook for myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Disease Progression; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Myelodysplastic Syndromes; Phosphoproteins; Point Mutation; Prognosis; Ribonucleoprotein, U2 Small Nuclear; Risk Assessment; RNA Splicing; RNA Splicing Factors; Spliceosomes; Thalidomide | 2012 |
The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Down-Regulation; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression Regulation, Leukemic; Genes, Tumor Suppressor; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Young Adult | 2012 |
The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; bcl-Associated Death Protein; Blotting, Western; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; Female; Flow Cytometry; Hematopoietic Stem Cells; Humans; Immunoprecipitation; Indoles; Leukemia, Myeloid, Acute; Male; Mechanistic Target of Rapamycin Complex 1; Middle Aged; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Sulfonamides; TOR Serine-Threonine Kinases; Young Adult | 2013 |
Case report of isochromosome 17q in acute myeloid leukemia with myelodysplasia-related changes after treatment with a hypomethylating agent.
Topics: Azacitidine; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 17; Decitabine; DNA Methylation; Fatal Outcome; Humans; Isochromosomes; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2012 |
Necrotizing fasciitis in myelodysplastic syndrome: an exceptionally rare occurrence.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chemoprevention; Fasciitis, Necrotizing; Fatal Outcome; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Stem Cell Transplantation | 2013 |
Cp-jeez! Aza-natomy!
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; DNA Methylation; Female; Gene Expression Profiling; Genome, Human; Humans; Leukemia, Myeloid, Acute; Male | 2012 |
Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Drug Approval; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2012 |
Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Cluster Analysis; CREB-Binding Protein; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Rearrangement; Histone Acetyltransferases; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Translocation, Genetic; Tumor Cells, Cultured; Young Adult | 2013 |
The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Promoter Regions, Genetic; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2013 |
All-trans retinoic acid combined with 5-Aza-2'-deoxycitidine induces C/EBPα expression and growth inhibition in MLL-AF9-positive leukemic cells.
Topics: Animals; Azacitidine; CCAAT-Enhancer-Binding Protein-alpha; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Mice; Myeloid-Lymphoid Leukemia Protein; Nuclear Proteins; Oncogene Proteins, Fusion; Tretinoin | 2012 |
Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; DNA Damage; Drug Synergism; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines | 2013 |
Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Topics: Azacitidine; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chemotherapy, Adjuvant; Cohort Studies; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Transplantation, Homologous; Young Adult | 2013 |
What is better for older patients with acute myeloid leukemia?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Choice Behavior; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Palliative Care; Patient Participation | 2013 |
When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome/acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Choice Behavior; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Palliative Care; Patient Participation | 2013 |
Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cluster Analysis; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male | 2013 |
C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia.
Topics: Animals; Azacitidine; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cells, Cultured; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Genes, Reporter; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Leukemia, Myeloid, Acute; Luciferases, Renilla; Mice; Mice, Inbred C57BL; Mice, Knockout; Myeloid Cells; Neutrophils; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Protein Binding; Stem Cells; Up-Regulation | 2012 |
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
Topics: Animals; Azacitidine; Blotting, Western; Cell Line, Tumor; Decitabine; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Phenylbutyrates; Up-Regulation | 2013 |
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Polyphosphates | 2013 |
Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Immunophenotyping; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplastic Stem Cells; Prognosis | 2013 |
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Odds Ratio; Prognosis; Retrospective Studies; Risk Factors; Treatment Outcome | 2013 |
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome | 2013 |
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Topics: Animals; Azacitidine; Cytarabine; Cytidine; Cytidine Deaminase; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Mice; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Survival Analysis; Treatment Outcome | 2013 |
Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mouth Neoplasms; Recurrence; Skin Neoplasms | 2013 |
Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia.
Topics: Aged; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Recurrence; Remission Induction; Treatment Outcome | 2013 |
Genomic impact of transient low-dose decitabine treatment on primary AML cells.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genome, Human; Humans; Leukemia, Myeloid, Acute; Mice; Microarray Analysis; Primary Cell Culture; Time Factors | 2013 |
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antimetabolites; Azacitidine; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Follow-Up Studies; Genes, p53; Humans; Incidence; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Prognosis; Risk; Treatment Outcome; Young Adult | 2013 |
Successful azacitidine treatment with increase of regulatory T cells for relapsed acute myeloid leukemia after allogeneic stem cell transplant.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; T-Lymphocytes, Regulatory; Transplantation, Homologous; Treatment Outcome | 2013 |
Scedosporium apiospermum soft tissue infection as the initial presentation of acute myeloid leukemia: a case report.
Topics: Aged, 80 and over; Amputation, Surgical; Antifungal Agents; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Diagnosis, Differential; Disease Progression; Fatal Outcome; Female; Humans; Leg Ulcer; Leukemia, Myeloid, Acute; Mycoses; Pancytopenia; Pyrimidines; Scedosporium; Soft Tissue Infections; Triazoles; Voriconazole | 2013 |
Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cytotoxicity, Immunologic; Decitabine; DNA Methylation; Humans; K562 Cells; Killer Cells, Natural; Leukemia, Myeloid, Acute; Natural Cytotoxicity Triggering Receptor 2; Phenotype; Receptors, KIR; Receptors, Natural Killer Cell; RNA, Messenger; Transcription, Genetic | 2013 |
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Disease Susceptibility; Female; Humans; Incidence; Infections; Israel; Leukemia, Myeloid, Acute; Male; Methylation; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Risk Factors; Severity of Illness Index; Thrombocytopenia | 2013 |
On the use of DNA methylation inhibitors and the reversal of transcriptional silencing.
Topics: Azacitidine; Decitabine; DNA Methylation; DNA-Cytosine Methylases; Enzyme Inhibitors; Gene Silencing; Humans; Leukemia, Myeloid, Acute; Transcription, Genetic | 2003 |
Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-deficient mice.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Southern; Blotting, Western; Cell Cycle Proteins; CpG Islands; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Exons; Gene Deletion; Genotype; Introns; Leukemia, Myeloid, Acute; Mice; Mice, Transgenic; Phenotype; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Suppressor Proteins | 2003 |
5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
Topics: Apoptosis; Azacitidine; Blotting, Western; Caspase 3; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; CpG Islands; Cyclin-Dependent Kinase Inhibitor p21; Cytochromes c; Decitabine; DNA Methylation; DNA-Binding Proteins; Epithelial Cells; Flow Cytometry; G1 Phase; Genes, Tumor Suppressor; HeLa Cells; HL-60 Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Membrane Potentials; Microscopy, Fluorescence; Mitochondria; Myelodysplastic Syndromes; Nuclear Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Sulfites; Time Factors; Transfection; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; U937 Cells; Up-Regulation | 2005 |
Methylation silencing of the Apaf-1 gene in acute leukemia.
Topics: 5' Untranslated Regions; Antimetabolites, Antineoplastic; Apoptotic Protease-Activating Factor 1; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Leukemia, Myeloid, Acute; Promoter Regions, Genetic; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; U937 Cells | 2005 |
5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Topics: Acylation; Azacitidine; Chromatin Assembly and Disassembly; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; Enzyme Inhibitors; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; K562 Cells; Leukemia, Myeloid, Acute; Neoplasm Proteins; Promoter Regions, Genetic; Protein Processing, Post-Translational; Tumor Suppressor Protein p53 | 2006 |
Decitabine activates specific caspases downstream of p73 in myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; DNA-Binding Proteins; Enzyme Activation; Humans; Leukemia, Myeloid, Acute; Nuclear Proteins; Promoter Regions, Genetic; Tumor Protein p73; Tumor Suppressor Proteins | 2005 |
Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Aphidicolin; Azacitidine; Child; Cyclin-Dependent Kinases; Cytarabine; Decitabine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Nucleic Acid Synthesis Inhibitors; Ribonucleotide Reductases | 2005 |
Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Butyrates; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Gene Silencing; Granulocytes; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Mannose; Translocation, Genetic | 2005 |
A single nucleotide polymorphism chip-based method for combined genetic and epigenetic profiling: validation in decitabine therapy and tumor/normal comparisons.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Southern; Decitabine; DNA Methylation; DNA, Neoplasm; Epigenesis, Genetic; Gene Dosage; Humans; Kidney Neoplasms; Leukemia, Myeloid, Acute; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Reproducibility of Results; Sulfites; Wilms Tumor | 2006 |
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Female; Genes, p53; Homeodomain Proteins; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; RNA, Long Noncoding; RNA, Untranslated | 2006 |
Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Time Factors | 2006 |
Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Gemtuzumab; Humans; Immunotoxins; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Protein-Tyrosine Kinases; RNA, Small Interfering; Sialic Acid Binding Ig-like Lectin 3; Syk Kinase | 2006 |
Discovery of epigenetically silenced genes in acute myeloid leukemias.
Topics: alpha Catenin; Azacitidine; Carrier Proteins; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Reverse Transcriptase Polymerase Chain Reaction; Vorinostat | 2007 |
Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
Topics: Adult; Azacitidine; Biomarkers, Tumor; Chromatin Assembly and Disassembly; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Mutation; Oligonucleotide Array Sequence Analysis; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; Tumor Cells, Cultured; U937 Cells | 2008 |
Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor Proteins; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Epigenesis, Genetic; Genomic Imprinting; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Neoplasms, Experimental; Tumor Stem Cell Assay | 2008 |
Altered 5-azacytidine metabolism following 3-deazauridine treatment of L5178Y and human myeloblasts.
Topics: 3-Deazauridine; Animals; Azacitidine; Biological Transport; Clone Cells; DNA, Neoplasm; Humans; Leukemia L5178; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice; Neoplasm Proteins; Ribonucleotides; RNA, Neoplasm; Uridine | 1980 |
5-azacytidine.
Topics: Animals; Azacitidine; Carcinogens; Chemical Phenomena; Chemistry; Female; Fetal Death; Humans; Lethal Dose 50; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mutagens; Pregnancy; Reproduction; Teratogens | 1981 |
Dose- and schedule-dependent activation and drug synergism between thymidine and 5-aza-2'-deoxycytidine in a human promyelocytic leukemia cell line.
Topics: Animals; Antineoplastic Agents; Azacitidine; Biological Transport; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Decitabine; DNA; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Leukemia L1210; Leukemia, Myeloid, Acute; Mice; Thymidine; Time Factors | 1982 |
Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213.
Topics: Adult; Aged; Azacitidine; Drug Evaluation; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Podophyllotoxin | 1982 |
The Hickman catheter: sending your patient home safely.
Topics: Adult; Azacitidine; Catheters, Indwelling; Female; Humans; Leukemia, Myeloid, Acute; Patient Discharge; Patient Education as Topic; Self Care | 1982 |
Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60).
Topics: Azacitidine; Cell Differentiation; Cell Line; Clone Cells; DNA (Cytosine-5-)-Methyltransferases; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Methylation; Methyltransferases; Superoxides; Tetradecanoylphorbol Acetate | 1983 |
Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Thioguanine; Time Factors | 1984 |
5-aza-2'-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation.
Topics: Azacitidine; Cell Line; Decitabine; DNA, Neoplasm; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methylation | 1984 |
Hemopoietic stem cells: their roles in human leukemia and certain continuous cell lines.
Topics: Azacitidine; Cell Differentiation; Cell Line; Clone Cells; Colony-Forming Units Assay; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute | 1984 |
5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias.
Topics: Azacitidine; Cell Differentiation; Cells, Cultured; Decitabine; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Neoplastic Stem Cells | 1984 |
Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2'-deoxycytidine.
Topics: Azacitidine; Cells, Cultured; Cytarabine; Cytidine Triphosphate; Cytosine Nucleotides; Gene Expression Regulation; Histocompatibility Antigens Class II; HLA-DR Antigens; Humans; Leukemia, Myeloid, Acute | 1984 |
Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to inhibitors of de novo pyrimidine synthesis.
Topics: Azacitidine; Cell Line; Drug Resistance; Humans; Kinetics; Leukemia, Myeloid, Acute; Pyrimidine Nucleotides; Pyrimidines; Structure-Activity Relationship; Uridine | 1984 |
In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Topics: Animals; Antineoplastic Agents; Azacitidine; Base Sequence; Chromosome Aberrations; Cytarabine; Decitabine; Deoxycytidine Kinase; Drug Resistance; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Molecular Sequence Data; Point Mutation; Polymorphism, Single-Stranded Conformational; Rats; Translocation, Genetic; Tumor Cells, Cultured | 1995 |
Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results.
Topics: Aged; Antineoplastic Agents; Azacitidine; Decitabine; Female; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Prognosis; Remission Induction | 1993 |
[Mechanism of cystostatic effect of 5-azacytidine and its usefulness in clinic].
Topics: Adult; Animals; Azacitidine; Child; Humans; Immunosuppressive Agents; Leukemia; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mice | 1975 |
Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes.
Topics: Azacitidine; Blood Proteins; Cell Separation; Cell-Free System; Cytarabine; Cytidine Deaminase; Deoxycytidine; Granulocytes; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Molecular Weight; Phosphates; Phosphotransferases; Tissue Extracts; Uridine Kinase | 1975 |
5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia.
Topics: Agranulocytosis; Azacitidine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Nausea; Neoplasm Metastasis; Vomiting | 1976 |
Symptomatic hypophosphatemia secondary to 5-azacytidine therapy of acute nonlymphocytic leukemia.
Topics: Adult; Azacitidine; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Phosphates; Prednisone; Pregnancy; Pregnancy Complications; Thioguanine; Vincristine | 1976 |
Separation of leukemic cells into proliferative and quiescent subpopulations by centrifugal elutriation.
Topics: Azacitidine; Bone Marrow; Cell Division; Cell Separation; Centrifugation; Cytarabine; Humans; In Vitro Techniques; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Thymidine | 1977 |
Vinblastine, 5-azacytidine, and VP-16-213 therapy for previously treated patients with acute nonlymphocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Azacitidine; Drug Evaluation; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Vinblastine | 1977 |
5-azacytidine in acute leukemia.
Topics: Acute Disease; Adult; Azacitidine; Bone Marrow; Central Nervous System; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Remission, Spontaneous; Time Factors | 1978 |
Treatment of refractory adult acute leukemia with 5-azacytidine plus beta-2'-deoxythioguanosine.
Topics: Adolescent; Adult; Azacitidine; Deoxyguanosine; Drug Resistance; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous; Thionucleosides; Time Factors | 1979 |
Reversible renal dysfunction due to 5-azacytidine.
Topics: Aged; Azacitidine; Female; Humans; Kidney Diseases; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1979 |
Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia.
Topics: Adult; Aged; Azacitidine; Bone Marrow; Cell Differentiation; Drug Evaluation; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1990 |
Synergistic interactions between differentiation-inducing agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic micro assays.
Topics: Acetamides; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Differentiation; Cell Division; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Tretinoin; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1991 |
Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine.
Topics: Antineoplastic Agents; Azacitidine; Cell Differentiation; Cell Line; Decitabine; Dimethyl Sulfoxide; DNA; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Methylation; Superoxides | 1985 |
Enhancement of phorbol diester-induced HL-60-mediated cytotoxicity by retinoic acid, dimethyl sulfoxide, and 5-azacytidine.
Topics: Azacitidine; Cell Differentiation; Cell Line; Cytotoxicity, Immunologic; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Leukemia, Myeloid, Acute; Macrophages; Monocytes; Phorbol 12,13-Dibutyrate; Phorbol Esters; Tetradecanoylphorbol Acetate; Tretinoin | 1986 |
Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells.
Topics: Azacitidine; Cell Division; Cell Line; Colony-Forming Units Assay; Cytarabine; Decitabine; Deoxycytidine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute | 1986 |
Gamma interferon and 5-azacytidine cause transcriptional elevation of class I major histocompatibility complex gene expression in K562 leukemia cells in the absence of differentiation.
Topics: Azacitidine; Cell Cycle; Cell Differentiation; Cell Division; Cell Line; Genes; Humans; Interferon-gamma; Leukemia, Myeloid, Acute; Major Histocompatibility Complex; Poly A; RNA; RNA, Messenger; Transcription, Genetic | 1986 |
Sensitivity to 5-azacytidine of blast progenitors in acute myeloblastic leukemia.
Topics: Azacitidine; Cell Survival; Cells, Cultured; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Tumor Stem Cell Assay | 1987 |
Treatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Whole-Body Irradiation | 1987 |
In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine.
Topics: Adult; Azacitidine; Cells, Cultured; Child; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine Kinase; DNA Replication; DNA, Neoplasm; Drug Resistance; Humans; In Vitro Techniques; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Thymidine Kinase | 1987 |
Resistance of HL-60 promyelocytic leukemia cells to induction of differentiation and its reversal by combination treatment.
Topics: Antineoplastic Agents; Azacitidine; Cell Differentiation; Cell Line; Decitabine; Dimethyl Sulfoxide; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Tretinoin | 1987 |
Response to 5-azacytidine of leukemic blast cells in suspension: a biological parameter associated with response to chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Division; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid, Acute; Methylcellulose; Middle Aged | 1987 |
5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Bone Marrow; Cell Differentiation; Decitabine; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplastic Stem Cells | 1989 |
The antileukaemic activity of 5-Aza-2-deoxycytidine (Aza-dC) in patients with relapsed acute leukaemia.
Topics: Antineoplastic Agents; Azacitidine; Bone Marrow; Decitabine; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1989 |
The effect of 5-azacytidine and its analogues on blast cell renewal in acute myeloblastic leukemia.
Topics: Azacitidine; Cell Division; Culture Media; Decitabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Phenotype; Stem Cells | 1985 |
[Antimetabolites in the treatment of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. II].
Topics: Antimetabolites; Azacitidine; Azaguanine; Azauridine; Cell Membrane Permeability; Cytarabine; DNA, Neoplasm; Fluorouracil; Humans; Immunity, Cellular; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Purines; Pyrimidines | 1974 |